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Foreword 
Why Paul Ricœur? The question kept coming up, throughout my PhD journey, so I have 
decided to use this foreword to explain the reasons behind my choice. Ricœur’s philosophy is 
too often dismissed as dense and difficult to understand. Whilst his oeuvre is certainly 
intense, and richly detailed, this is owing to the perpetual justification, revision and 
development of his arguments, in consideration of philosophical trends, past and present. I 
see him as a philosopher with a clear vision of justice, who cared for each individual, and for 
humanity as a whole. 
Regarding the digital revolution of health information. I begin with an ontological view of 
health-related data, originating from the patient, i.e. patient data. However, there is a 
potential tension between individual rights and public interest, as the management of this data 
could benefit either patients as donors, or the population as a whole. 
Randomised control trials in clinical research provide the classical example of this tension, as 
the patient gives up some of their rights, without directly benefiting, whilst society gains 
from the research. Traditionally, this tension is addressed by legal norms and bioethics 
principles. However, this approach is under increasing scrutiny, as patient data is required for 
more sophisticated processing and secondary uses, in the new era of genomics and big data. 
Although traditional frameworks can address ethical issues with patient data in the individual 
context of clinical research, public health or clinical care, no single set of principles can 
address the whole field of the production and use of patient data. Moreover, there is no 
coherent normative justification for combining these frameworks. In contrast, Ricœur’s ‘little 
ethics’ would provide an overarching framework capable of overcoming this potential tension 
and incoherence.1  Early on, Ricœur foresaw the “colonisation” of the medical act, following 
genetic and biologic advances and the subsequent risk of objectifying the patient. He 
grounded his ethical reflection through his work on narrative identity and the concept of 
agency as the “homme capable” of suffering, acting and having concerns for others.2 
The management of patient data can thus be considered as a narration with character-
stakeholders as agents being accountable and capable of self-reflection. The reflection would 
start from the patients (data donors) in relation to other stakeholders (receivers). The 
1 Ricœur, P. 1992. Oneself As Another (trans: Blamey, K.). Chicago and London: The University of Chicago 
Press, ch 7,8,9. Originally published as Soi-Même Comme un Autre. 1990. Paris: Editions du Seuil. 
2 Ricœur, P. 2007. Reflections on The Just (trans: Pellauer, D.). Chicago and London: The University of Chicago
Press, pp. 45-57. Originally published as Le Juste 2. 2001.Paris: Editions Esprit. 
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production of patient data and its subsequent use should not be dissociated in ethical analysis. 
Nor should patients be separated into biological, psychological and social parts. Furthermore, 
stakeholders are worth more than just their actions, as their capability covers acting and 
“speaking”, by translating the Ricœur’s ethical aim of a “good life, with and for others, in just 
institutions” into practice. The negative side of capability is vulnerability. Vulnerability 
impedes the possibility to translate capability into practice, creating distance from others, 
with incommunicability and hostility. 3 It is interesting to note that Ricœur did not take the 
level of competence as the starting point, to define a patient’s decision-making capacity with 
vulnerability as the limitation of this competency. Ricœur’s notion of vulnerability and 
distance allows respect and intimacy to be reconciled. In other words, (and this applies to the 
management of patient data), an appropriate distance between the donor and the receiver 
reconciles the responsibility for oneself and the accountability for others, whilst introducing 
the supremacy of justice: “the move from narrative identity to justification resolves the 
seeming paradox that effects one’s encounter with global justice.” 4  
The translation of philosophy into political action and practice was a central theme for 
Ricœur. His ‘little ethics’ must not be understood as “little” in terms of philosophical depth. 
“Little” refers to translation in opposition to metaphysical philosophy. Ricœur has himself 
applied ‘little ethics’ to the medical domain, showing the way towards a wise management of 
patient data. 5 His approach combines an ethics of care with an ethics of justice. This is 
essential for the fair governance of patient data, as it allows for wider social benefits, whilst 
strengthening the patient’s capability to act and speak i.e. the patient’s voice should be 
listened to. 
I hope that I have “translated” my appreciation for Ricœur, and that you can take note of his 
approach as you read this dissertation. 
3 Jervolino, D. 2008. Rethinking Ricœur: The unity of his work and the paradigm of translation. In Reading 
Ricœur. David M. Kaplan ed. Albany: State University of New York Press, ch 13, pp. 230-234. 
4 Rasmussen, D.M. 2008. Justice and interpretation. In Reading Ricœur. David M. Kaplan ed. Albany: State 
University of New York Press, ch 12, p. 220. 
5 Ibid note 1, pp. 198-212. 
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EXECUTIVE SUMMARY 
The starting point for this dissertation is the development in the healthcare system of large 
patient data sets that are changing biomedical research and medical practice thanks to 
scientific and technological advances. The management of this flourishing health information 
is expected to lead to important benefits in cure and care for the patients. There is therefore a 
public interest to develop large patient data sets, but also a public duty to respect patient 
rights. This raises fundamental ethical issues, as it is necessary to find an adequate balance 
between the gain from public interest and any morally acceptable overriding of patient rights. 
The situation is complex and an overly simplistic approach to the competing framework of 
public interest and patient rights can create difficulties and doubt.  This PhD dissertation thus 
poses and addresses the following question:  
How to appraise the issues raised from the tension between patient rights and public interest 
in the management of large patient data sets? 
The dissertation examines different experiences on how patient data are produced and used in 
the domain of clinical registries. It also reports on a qualitative study seeking at a better 
understanding of the ethical awareness of healthcare providers, health administrators and 
policy makers with regard to the patient data they contribute to collect and use. Based on the 
results of this empirical material, it is my assertion that neither public interest nor patient 
rights are optimally respected. A traditional framework balancing principles and ethical 
theories of utilitarianism and Kantian-deontology is not appropriate to handle the 
multidisciplinary, technological and changing context of patient data. An overarching 
perspective that could ensure social benefits while strengthening patient rights would be 
preferable. Using a narrative approach, it is possible to consider the plurality of stakeholders’ 
needs in different contexts and for various purposes with patient data. The resulting mattering 
map would allow a common harmony to emerge under appropriate ethical governance.  
In order to facilitate the transition from narration to ethics, the report draws upon the passage 
by interpretation and the concept of narrative identity as defined by Paul Ricœur. Narrative 
identity transforms a passive character into an active one, an agent capable of acting and of 
being accountable for his or her own actions. Agency expresses itself through the narrative 
individual and collective identities. Therefore, narrative theory serves as mediation between 
the theory of action and the theory of ethics. Ethics is not about the identity of things (data) 
but about moral agents (healthcare stakeholders). With regard to patient data, individual, 
2 
collective and historical narrations are reconciled around agents’ common ethical aim. 
Thereafter, appropriate governance for patient data can be developed at the medical, 
biomedical and public health levels, following the norms of autonomy, respect for others and 
justice. Conflicting norms are resolved by recourse to the common ethical aim.   
The conclusion explains the new framework, and the importance of the “Ricœurian” 
principles of imputability and intentionality for a wise management of large patient data sets 
in practice. The dissertation then provides some recommendations for enhancing the 
stakeholders’ ethical awareness and accountability, and for opening up governance of 
healthcare information to representatives of society as a whole.  
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PART I. INTRODUCTION 
1. Stating the problem
The production and use of patient data provide social benefits 
 A wide range of stakeholders uses patient healthcare data for a variety of different purposes, 
and this picture is continuously evolving. It is claimed that big data will improve healthcare 
quality and efficiency.6 Following advances in knowledge generation and dissemination, 
health-related data has increased in volume, velocity and also variety with medical text-based 
documents and non-medical social data. To keep pace with the digitalisation of the health 
system, healthcare information needs the expertise of professionals from bioinformatics and 
the biomedical sciences, as well as the possibility to develop public-private partnerships. 
These transformations lead to changes in health professionals’ practices and in the 
relationships of healthcare providers to patients and healthcare consumers.  
Managing patient data raises fundamental ethical issues 
Healthcare stakeholders may experience difficulties addressing the ethical, legal and social 
implications (ELSI) of evolving healthcare information, and the literature reports on this. 7 
From the start, my research identified some inconsistencies. First, patients could take on a 
more active role regarding their health-related data and corresponding rights as their 
awareness and understanding of medical information increases. Yet, their capacity to 
intervene and claim rights in the healthcare system could de facto be limited by the 
development of data linkages able to deliver patient data without having to involve patients 
directly. Second, healthcare professionals and policy-makers are confronted with the 
challenge of understanding and contributing to the utility and meaning of large patient data 
sets whilst appraising their obligations towards patient rights. To sum up, all healthcare 
stakeholders are faced with the urgent need to find an adequate balance between the expected 
social benefits and any morally acceptable infringement8 of patient rights.  
6 Murdoch,T.B., Detsky, A.S. 2013. The inevitable application of big data to health care. Journal of American 
Medical Association, 309(13):1351-1352. 
7 Morrison, M., Dickinson, D. and Lee S. S-J. 2016. Introduction to the article collection ‘Translation in 
healthcare: ethical, legal, and social implications’. BMC Medical Ethics, 17:74.  
8 I used the word infringement as defined by Beauchamp and Childress, i.e. «a justified action overriding a right» 
in opposition to violation. This was a point of divergence between American authors and Swiss bioethicists. I will 
use from now on the word overriding instead of infringement for this work for the University of Zürich, (see p.22). 
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Showing the social value of research to justify clinical trials has already been recognised.9 
With the expansion of the concept of research towards the activities of quality improvement, 
evaluation of health services and secondary uses of stored patient data and samples, some 
authors have also stressed the importance of social benefits in most of these new research 
circumstances, and acknowledged that it was often justified to waive informed consent 
because obtaining consent was impractical or because they judged that overriding patient 
rights had no moral gravity.10  The WMA (World Medical Association) in re-examining the 
case of large health data sets and biobanks, has further widened the perimeter of research 
with commercial, administrative or political activities related to health databases, and stated 
that all these projects should be governed by the ethical principles of biomedical research. 
This includes in particular their contribution to the benefit to society (article 8) and the 
respect of the dignity, autonomy, privacy and confidentiality of individuals (article 9).11  
All these developments represent a growing body of evidence suggesting that healthcare 
stakeholders need to be aware of their moral obligations in balancing public interest and 
patient rights when they decide to collect, use or store patient data. Figure 1 illustrates the 
dilemma with the risk that patient rights could be disregarded, following an exaggerated 
weight on public interest. This suggestion does not exclude other risks, such as the case 
where public interest might be neglected despite patients’ consent. The model of balancing is 
by definition in search of equilibrium, namely unstable.  
Figure 1: Competing framework12 
9 Emanuel, E.J., Wendler, D., Grady, C.. 2000. What makes clinical research ethical? JAMA 283(20):2701-2711.  
10 Gelinas, L., Wertheimer, A., Miller, F.G. 2016. When and why is research without consent permissible? The 
Hastings Center report 46(2):35-43. 
11 WMA, World Medical Association. 2016. Declaration of Taipei on Ethical Considerations Regarding Health 
Databases and Biobanks. https://www.wma.net/policies-post/wma-declaration-of-taipei-on-ethical-considerations-
regarding-health-databases-and-biobanks/.  Accessed 20 January 2017. 
12 I used the word competing for the framework based on the traditional model of balancing interests or 
principles. Competing does not describe the process of balancing. It illustrates rather the result of balancing, as 
one side of the balance will get more weight and gain from decision-making in its favour. 
Public Interest 
Patient Rights 
?Production and use of patient data 
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Issues raised under a competing framework between patient rights and 
public interest   
Beauchamp and Childress insist on the necessity to reduce intuition, partiality and 
arbitrariness in applying the model of balancing. They thus propose a set of constraining 
conditions to justify the act of overriding a prima facie norm.13 The statement of the dilemma 
seems clear, as public interest should deliver expected benefits, and overriding rights should 
be justified.14 However, establishing the equilibrium in Figure 1 remains complex, as there 
are neither clear-cut definitions nor easy measurements of public interest and patient rights. 
Patients also have stakes on both side of the balance. They are both individual right-bearers 
and citizens who are part of the public. Moreover, ethical reflection may also be disturbed by 
the sense of urgency induced by the booming rhythm of technological progress and the 
significant human and financial investments attached to their developments. Initiatives in 
favour of big data health networks and precision medicine projects have expanded 
worldwide15,16. Following Jonas on the technological age, the question of the force of the 
future in the present needs to be raised.17 The emphasis put on the weight of public interest 
would need legal and ethical evaluations.  
On the legal side, each country has strict criteria for judging the permissibility of restricting 
fundamental patient rights. For instance, the fundamental right of privacy could be restricted 
by the use of quarantine for serious infectious diseases. However, public interest is rarely so 
obvious or immediate. Additionally, patient rights can be interpreted differently depending on 
the national legal context or institutional rules.  
On the moral side, the justification of public interest may involve controversial theories of 
justice. Moreover, patient rights entail loosely defined concepts such as those of autonomy, 
privacy, functioning, agency or human dignity. This heterogeneity renders more complex the 
deliberation on a consensual ethical guidance for healthcare stakeholders. Traditional 
principle-oriented approach to ethical decision-making may be subject to bias following 
partial evaluation of social benefit, autonomy, potential harm or justice. 
13 Beauchamp, T.L. and Childress, J.F. 2009. Principles of biomedical ethics, 6th ed. New York: Oxford 
University Press, p. 23. 
14 Ibid, p. 352. 
15 Collins, F.S., Varmus, H. 2015. A new initiative on precision medicine. New England Journal of Medicine, 
372(9):793-795. 
16 European Alliance for Personalised Medicine. 2014. 
http://euapm.eu/pdf/EAPM_A_Europe_wide_data_ecosystem_for_personalised_medicine_A_proposal_for_a_Lig
hthouse_Initiative.pdf.  Accessed 20 January, 2016. 
17 Jonas, H. 1984. The Imperative of Responsibility. In Search of an Ethics for the Technological Age. Chicago & 
London: The University of Chicago Press. Paperback Edition.1985. pp. 21-22. 
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Reframing the issue through Ricœur’s approach 
Applying the model of balancing is therefore difficult. It relies on the principle of 
proportionality to assess the permissible level of overriding patient rights in order to obtain 
public interest. This means choosing the minimal restriction of patient rights to reach the goal 
of public interest. Proportionality on the legal side corresponds to the moral justification of 
overriding prima facie norms, as presented above. Legal and ethical aspects are linked in the 
concept of proportionality. The pressing issue of balancing is therefore pushed to the question 
of how proportionality could be judged fairly and what governance would be appropriate to 
make this judgement. The question to pose and address is:  
How to appraise the issues raised from the tension between patient rights and public interest 
in the management of large patient data sets? 
I think that the issue with proportionality reveals the difficulties and doubts behind a solution 
based on a traditional perspective of the production and use of patient data in the healthcare 
system. I argue that it is necessary to move away from the tension of a model based on 
facilitating the gain of public interest whilst trading off some patient rights. Ideally, the 
production and use of patient data should benefit public interest and strengthen patient rights. 
In the long term, such a perspective could promote the development of more and safer social 
benefits. Consequently, I propose to base our ethical reflection on Paul Ricœur’s ‘little 
ethics’. This leading French philosopher himself developed an ethical approach to medical 
and judicial judgements.18 I consider that his ethics established on his specific concept of 
narrative identity, facilitates a reframing of the ethical guidance for patient data management, 
shifting from a competing framework towards an ethics of justice and reconciliation between 
individual and public interests.  
In the following I shall explain how I use the terms patient data, public interest and patient 
rights in this PhD dissertation. 
18 Ricœur, P. 2007. Reflections on the Just (trans: Pellauer, D.). Chicago and London: The University of Chicago 
Press, pp. 213-222. Originally published as Le Juste 2.2001. Paris: Editions Esprit. 
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2. Defining the main concepts of patient data, public interest and
patient rights
I have chosen the term patient data to distinguish the patients’ health-related data from the 
patient information considered as the information given to patients to help them understand 
their health status in order to make informed decisions. Patient data is included in the concept 
of health information management defined as the “management of the acquisition, 
organization, retrieval, and dissemination of health information” (Medline 2013). Large 
patient data sets result from the aggregation of patient data. The data is measured, collected, 
stored, protected and used by healthcare stakeholders who have roles and responsibilities 
regarding the creation and management of health data. These healthcare stakeholders regroup 
patients, healthcare providers (physicians, nurses, pharmacists, other care givers in primary or 
stationary care, private or public institutions), researchers, and experts in bioinformatics, 
policy-makers, lawyers and decision-makers. Healthcare providers refer to physicians, 
healthcare professionals in primary care and stationary care, and also hospitals, private and 
public institutions providing health services to patients and citizens. In this dissertation, 
different stakeholders’ perspectives have been considered, and the term health(care) 
professional has been used for simplification when patients were not concerned. 
Additionally, depending on the context, the term physician potentially covers different 
situations, such as being the treating physician of the patient, a first-line clinician collecting 
patient data, a physician with multiple responsibilities of investigator, researcher or scientific 
advisor.  
All the stakeholders have rights and obligations towards each other in order to leverage 
benefits and reduce burdens and harm when dealing with patient data. Traditional medical 
judgement has evaluated the benefit-risk ratio of patient data management in a well-delimited 
clinical context. With the development of large patient data sets integrating data from routine 
clinical care, research and other databases, the medical judgement develops beyond the 
context of the patient–physician relationship, taking into account the interventions of 
researchers, sponsors, IT experts, funders, and policy-makers. The management of patient 
data has therefore broadened its clinical scope with biomedical research combined with 
observational research, clinical trials, biobanking and epidemiological studies, as well as with 
more administrative and economical evaluation of the healthcare system.  
8 
Patient data 
Importance of health information and patient data 
Van Rensselaer Potter, who first used the term bioethics in 1971, indicated the necessity to 
bridge science and philosophy with wisdom in order to acquire the “knowledge of how to use 
knowledge”.19 In practice, it is difficult to have complete knowledge in health. The WHO 
definition of health “a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity” is so large that the required information to serve 
better health appears almost without limit. The WHO definition of health was contemporary 
to the Universal Declaration of Human Rights after the Second World War. Legal and ethical 
considerations were thus influencing scientific and political statements. Callahan at an early 
stage challenged the wideness of this definition, especially its mental and social attributes. 20 
His quote about the “fervent faith in the possibilities of medical science to achieve world 
health, enhanced by the development of powerful antibiotics and pesticides during the war” 
seems comparable to the current fervent faith in medical sciences, genomics and 
bioinformatics to achieve better health. In the healthcare domain, the increased dissemination 
of information has also revealed the dark side of medicine in terms of safety21 and the need 
for better quality22. Modern information technology offers tools that could fill the gap in our 
ignorance. As the bibliometric curves in Figures 2 and 3 show, health-related data, patient 
data and health big data have gained in importance in the recent years, and especially since 
the years 2012-2013. The increasing volume and variety of health-related data, potential data 
linkages and data uses was, and is, obviously changing the healthcare system. 
19 Henk A.M.J. ten Have, 2012. Potter’s notion of bioethics, Kennedy Institute of Ethics Journal, 22(1):59-82. 
20 Callahan, D. 1973. The WHO definition of “health”. The Hastings Center Studies, 1(3):77-87.  
21 IOM (Institute of Medicine).1999. To Err is Human: Building a Safer Health System. Washington, DC: The 
National Academies Press. 
22 IOM (Institute of Medicine). 2001. Crossing the Quality Chasm, A New Health System for the 21st Century. 
Washington, DC: The National Academies Press. 
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Figure 2: Pubmed bibliometrics (accessed March 30, 2017) 
Health-related data 
Health big data 
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The patient-physician relationship is impacted by the development of patient data, as 
information technology appears as a third “partner” in the medical judgement. For instance, 
the IBM’s Watson computer is able to analyse patient data better than physicians23. In 
neurology, brain-computing interfaces are challenging the concepts of agency and 
accountability for patients and physicians.24 Therefore, the necessity to bridge science and 
philosophy with wisdom applies to the management of patient data in clinical care and 
research, i.e. and paraphrasing Potter, there is a necessity to develop “information about how 
to use information”.  
Definition of patient data 
Patient data are health-related data coming from healthcare and biomedical research settings. 
In its report on healthcare and biomedical data, the Nuffield Council on Bioethics has 
included the following categories of data25: 
- Clinical care data (e.g. primary care and hospital records)
- Data from clinical trials and observational studies
- Patient-generated data (e.g. from ‘life logging’ or consumer genetic testing)
- Laboratory data (e.g. from imaging, biobanking, genome sequencing and other
‘omics’)
- Administrative data or metadata
The Nuffield Council distinguishes between the data produced by observation or 
measurement (raw materials) and the data used in different contexts (information value).26 It 
23 Doyle-Lindrud, S.2015. Watson will see you now: A supercomputer to help clinicians make informed treatment 
decisions. Clinical Journal of Oncology Nursing, 19(1):31-32. 
24 Kellmeyer, P., Cochrane, T., Müller, O., Mitchell, C., Ball, T., Fins, J. J., Biller-Andorno, N. 2016. The effects 
of closed-loop medical devices on the autonomy and accountability of persons and systems. Cambridge Quarterly 
of Healthcare Ethics, 25(4):623-633. 
25 Nuffield Council on Bioethics. 2015. Biological and health data: The collection, linking and use of data in 
biomedical research and health care: ethical issues, p. 4. http://nuffieldbioethics.org/report/collection-linking-
use-data-biomedical-research-health-care/chapter-downloads-2/.  Accessed 17 April 2017. 
26 Ibid, p. 5. 
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also recognises that its task “was complicated by the fact that we built on shifting sands.”27 
This sentence confirms the fast-evolving field of health-related data and the importance of 
explaining each working definition.  
 
In this dissertation, the concept of patient data regroups the two aspects of production and use 
of patient data. On the production side, technological progress in data processing, storage, 
retrieval and linking of datasets is building health big data sets, characterised by high volume, 
variety, velocity and value. Unstructured sources of patient data, e.g. text forms, can be 
translated and integrated into patient datasets. On the usage side, secondary uses of 
recombined patient data are susceptible to endless exploitation in the absence of legal and 
ethical limitations. This PhD research concentrates on the patient data produced and used in 
the healthcare system, usually generated in the patient-physician relationship, and used for 
medical, research, commercial, administrative or political purposes. Patient data produced 
and used independently from this system, such as most life-logged data, might require a 
specific, different reflection. Patient data that is the subject of this dissertation includes data 
from the (electronic) patient record but is not restricted to it, as patient data could be collected 
and used outside the patient record following a legal mandatory data collection, or specific 
clinical trials.  
 
Patients and their first–line clinicians are directly involved in the production and use of 
patient data, but new healthcare incumbents are increasingly involved too, in particular 
experts in non-clinical areas such as electronic health records, bioinformatics or genomics. 
The resulting “data-based medicine” is different from the traditional empirical medicine 
based on observation and from the evidence-based medicine based on hypothesis testing. 
There is a data mining approach to research, precision medicine and healthcare comparative 
effectiveness assessment that is transforming the health model into a continuously learning 
system focusing on value and the benefit-cost ratio. Consequently, sharing and combining 
diverse sources of patient data can become a source of benefits for society.  
Data ownership 
An important question is therefore what the just distribution of benefits could be, and the 
corollary question is to whom does the data belong. Data ownership is understood as the 
possibility to collect and use the data, i.e. in terms of privacy rights and not of property rights. 
International law does not directly consider patient data ownership. Neither does Swiss law. 
What is considered is rather the patient right to decide without constraint what could be the 
destiny of her/his personal data (see section on patient rights). Therefore, laws concentrate on 
                                                      
27 Ibid, Nuffield report’s foreword, p. VII. 
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data protection and not data ownership. For instance, Swiss cantonal laws regulate data 
protection in the relationship between patient and physicians working in the public cantonal 
institutions, whilst the Federal Data Protection Act regulates data between relationships 
between patient and physician in the private sector, and between patient and social insurances 
in the public sector.  
Moreover, it is difficult to use a concept of individual patient data property as patient data 
does not carry the usual features of property for things. To be medically relevant for a patient, 
her/his data needs to be compared and aggregated with health-related data from several 
patients. The value of patient data comes from its collection, interpretation, storage and 
usage, and from the obligations that this data management generates. Therefore, a concept of 
stewardship by health professionals rather than a typical form of data ownership is 
appropriate.  
However, data ownership is regularly discussed in biomedical literature and conferences, 
following the onset of new possibilities of commercial and intellectual property advantages. 
Patient privacy rights may no longer protect patient data. In practice, it is difficult to 
guarantee anonymity and confidentiality of patient data when it includes genetic information 
or linkage with other data sets. Patient data related to genomic information would indeed be 
preferably considered under a common regulated ownership. Nevertheless, new genomic 
sequencing may grant some private ownership rights to professional groups and private 
companies. 28  Kaplan also reports examples where the U.S. constitutional free speech 
protections have allowed the sale and use of patient prescription data. 29 Furthermore, data 
mining developments include the creation of innovative algorithms for processing patient 
data, and these algorithms may benefit from intellectual property rights, with patent 
protection. As a result, a feeling of despoliation may rise in patients, and also in first-line 
physicians collecting the patient data.   
All these changes with patient data may redefine a new approach to data ownership that not 
only protects patient with privacy rights, but also develops positive claims to have full and 
transparent information about their data destiny, as well as the possibility to intervene. This 
assumes a sufficient level of literacy on health-related data and data processing methods. 
Therefore, similar to the concept of common data ownership mentioned above, a common 
ethical governance of patient data would be necessary. 
This promise of social benefits thus necessitates a better understanding of the public interest 
attached to patient data management. 
28 Montgomery, J. 2017. Data sharing and the idea of ownership. The New Bioethics, 23(1):81-86.  
29 Kaplan B. 2015. Selling health data: de-identification, privacy, and speech. Cambridge Quarterly of Healthcare 
Ethics, 24(3):256-71.  
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 Public interest 
The concept of public interest 
In this dissertation, the term social benefits is used in the sense of a better society to live in 
with regard to health issues, and not in its narrow economical definition of social transfers 
received by households. Social benefits are an expression of public interest. There is no 
absolute definition of public interest, but rather reasons for public interest and, consequently, 
potential justifications to limit individual and private rights. Political systems and political 
choices are used as reasons to justify public demands on other individuals and groups. In my 
interviews with Swiss national parliamentary representatives (empirical research of the 
dissertation, part III), I identified a political divide regarding the public interest reasons 
allegedly to be upheld. The political party on the right was limiting the public interest reason 
to a minimum of obligations insisting on liberty and privacy issues, whilst the socialist party 
preferred to expand social interventions and health agencies in the interest of public health 
and biomedical research. Political sciences as well as theories of economics, justice and 
ethics, influence public interest, the sphere of common good and the role of the state. It is 
acknowledged, therefore, that the public interest reasons rely not so much on a kind of 
absolute “truth”, but rather on a consensual, shared commitment of public representatives, 
private groups and citizens to accept some degree of coercion over rights.30 
Concerning the production and use of patient data, public and private interests are sometimes 
combined to leverage competencies and funding of large integrated data sets. In this 
dissertation, I have sometimes used the term public interests with an “s” to show the different 
interests able to benefit society. I have preferentially used public interest (singular) for the 
legal approach as indicated in the European Convention on Human Rights (CEDH): Article 8 
on the right to respect for private and family life justifies a public authority’s interference 
with this right when it is necessary in “the interests of national security, public safety or the 
economic well-being of the country, for the prevention of disorder or crime, for the 
protection of health or morals, or for the protection of the rights and freedoms of others.”  
Additionally, the word “public” not only refers to populations, but also indicates collective 
interventions by government (or other public institutions).31 Public interests can thus indicate 
not only the benefits for society, but also beneficial returns on state interventions. For 
instance, using patient data to compare healthcare cost-effectiveness could be in the interest 
30 Quong, J. 2013. Public Reason. In The Stanford Encyclopedia of Philosophy. Edward N. Zalta ed. 
https://plato.stanford.edu/archives/sum2013/entries/public-reason/. Accessed 25 April 2017. 
31 Verweij, M., Dawson, A. 2007. The meaning of „public“ in „public health“. In Ethics, Prevention and Public 
Health. Oxford: Oxford University Press, ch  2, pp. 13-29. 
13 
of the government and its aim of ensuring the sustainability of the healthcare system; yet, it 
might not be in the public interest of the society as a whole, with some populations running 
the risk of being stigmatised for their higher health costs, or of having to make increased out-
of-pocket payments for their health in the absence of any consensual commitment or consent. 
However, the sum of individual interests is not equivalent to public interest. It is therefore 
important to understand the competing interests in patient data to evaluate the weight of 
public interest compared to patient rights. 
Public interest reasons for sharing and using patient data 
Sharing and using patient information can serve public health interests, but the extended 
development of scientific, commercial, administrative and political uses of patient data 
demonstrates the possibilities of larger social benefits. State government, health 
administration and public institutions want to stay in the competitive health information field 
for two main reasons. The first reason is to develop a modern and sustainable health system. 
To this end, programs have been proposed in most developed countries, for instance in the 
USA with the National Institute of Health (NIH) project of “Better health at lower costs” 32, 
and in Switzerland with the Health2020 project promoting a greater use of e-health and an 
improved availability and analysis of data to manage the health system more efficiently33. 
The second reason is related to the need to build innovation and competitive advantage in the 
flourishing domain of the medical sciences such as precision medicine and the concept of 
modern 4P medicine: preventive, prognostic, predictive and participatory. Generously funded 
projects are being developed. Following former President Obama’s initiative on Precision 
Medicine (PMI), the NIH has started a PMI-cohort programme collecting and analysing 
health information from at least one million American volunteers “thanks to advances in 
genomic technologies, data collection and storage, computational analysis, and mobile 
health applications“ 34. Similarly in Switzerland, a national project of Swiss Personalized 
Health Network (SPHN) has been designed to „create a national infrastructure allowing the 
sharing across Switzerland of patient data for research”.35  
32 IOM (Institute of Medicine).2012. Best Care at Lower Cost: The Path to Continuously Learning Health Care in 
America. Washington, DC: The National Academies Press.  
33 Federal Office of Public Health (FOPH). 2013. The Federal Council’s Health-Policy Priorities, Health2020 
Report. http://www.bag.admin.ch/gesundheit2020/index.html?lang=en.  Accessed 28 November 2016.  
34 Precision Medicine Initiative (PMI) Working Group Report to the Advisory Committee to the Director, NIH. 
2015. The Precision Medicine Initiative Cohort Program. Building a Research Foundation for 21st Century 
Medicine. https://www.nih.gov/sites/default/files/research-training/initiatives/pmi/pmi-working-group-report-
20150917-2.pdf. Accessed 28 November 2016. 
35 SPHN (Swiss Personalized Health Network) project. 2016. https://www.sib.swiss/services-
infrastructure/personalized-health/swiss-personalized-health-network Accessed 28 November 2016. 
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In short, patient data can benefit society in the fields of clinical practice, public health and 
biomedical science. The realisation of these benefits necessitates an evaluation justifying the 
preeminence of public interest over other legitimate interests and rights. 
Evaluation of public interest in patient data 
Once the social benefits of sharing and using patient data have been recognised, it is 
important to reflect on the main factors driving the realisation of public interest. The 
evaluation of public interest is not always straightforward, and may be hindered by potential 
underlying conflicts of interests, such as advantages for academic careers or the 
pharmaceutical industry. When public interest in patient data results from competing reasons, 
it should undergo a fair evaluation of medical, scientific or economics factors, with 
transparency.  
Accelerated by information technology, the social dimensions of scientific knowledge have 
become more complex. It is no longer possible for a single individual to control and evaluate 
the results of other team workers. Each contributor must trust others and have good reason to 
trust them. It has been documented that the power of interdisciplinary science prevails over 
individual lives.36 Acceptance of new products or technologies is justified by the evaluation 
of scientific evidence and social and economic risk (e.g. precautionary principle), potentially 
at the expense of philosophical rationality (e.g. sense of prudence as practical wisdom). 
Consequently, the power to define and judge the value of public interest relies predominantly 
on social institutions, such as state government, legal systems, administrations, hospitals, 
scientific academies, and some private corporations. Hence, policy-makers are directly 
involved in organising the legal and financial frames establishing the basis of public interest. 
As indicated previously, their decision-making process is not neutral. It depends on their 
political engagement, and also on ad hoc reports, consultation with experts, economic value, 
lobbying influences and relations with their electorate support. These diverse criteria make it 
complex to impartially assess and weight the potential interests.  
For instance, the commitment to rare disease programs could have been favoured by 
concerned patient groups, electors, researchers and pharmaceutical industries, although 
results from the perspective of economic sustainability of the health system or distributive 
justice of health primary goods might not have been so positive.37 Investments in genomics 
could also be subject to discussion regarding public interest. The development of genomic 
36 Longino, H. 2016. The social dimensions of scientific knowledge. The Stanford Encyclopedia of Philosophy. 
Edward N. Zalta ed. https://plato.stanford.edu/archives/spr2016/entries/scientific-knowledge-social/.  Accessed 28 
April 2017. 
37 This example is extracted from the interview of a member of the Swiss parliament in the qualitative research 
reported in Part III of the manuscript. 
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medicine and companion diagnostics requires big investments and often public-private 
partnerships in order to aggregate biomedical research data, environmental data and 
phenotype data coming from routine patient medical records. The expected benefits are of 
course medical - with new, safer and targeted treatments- but also scientific and economic 
with the development of profitable high-level technology, know-how and patents. 
Nevertheless, the clinical implementation of these discoveries remains difficult; it 
necessitates the design of more innovative genomics-based trial and sequencing technologies, 
the integration of epigenetic changes, and the aptitude to enhance patient care practice. One 
main limitation is that not all mutations would be “druggable”.38 Furthermore, molecular 
profiling in oncology has disqualified broad treatment for all, in favour of targeted treatment 
to individual genomic drivers of cancer.  This precision medicine cannot produce the same 
economies of scale in the fabrication and distribution of therapeutic products as those of the 
traditional pharmaceutical industry. It would be difficult to guarantee equal access to this 
personalized medicine for all citizens. Justice issues should therefore be appraised to avoid 
limiting personalized medicine to selected groups of people, e.g. those living in big and 
modern cities, close to university hospitals or biomedical experts.  
These examples reveal the importance of justice in the assessment of the reasons justifying 
public interest in the production and use of large patient data sets. This assessment 
encompasses the concepts of distributive justice for a fair allocation of burdens and benefits, 
and also of legitimacy justifying the claim of public interest. The judgement of the value of 
these reasons is influenced by different moral theories proposing how life or actions should 
be. I will briefly cite the main theories invoked in the following chapters, indicating  
succinctly how they can relate to the evaluation of public interest. 
Utilitarianism consecrates public utility. The action producing greatest public interest in the 
greatest number of citizens or patients is considered to be the “right” one.39 Nevertheless, a 
utilitarian perspective is not always synonymous to “just” public interest, as the interests of 
minorities or future generations may be disregarded. The Kantian-deontological theory 
challenges the beneficence of public interest when it results from morally reprehensible 
actions. Moreover, for Kant, with persons being ends in themselves, public interest could not 
justify treating individuals merely as the means to others’ ends.40 Virtue theory focuses on the 
capacity to act according to “excellence” or “virtue”, to be developed through education and 
38 Simon, R., Roychowdhury, S. 2013. Implementing personalized cancer genomics in clinical trials. Nature 
Review. Drug Discovery, 12(5):358-69.  
39 Mill, J.S. 1863. Utilitarianism. In Oxford Philosophical Texts, 1998. Roger Crisp ed. Oxford: Oxford University 
Press. 
40 Kant, I. Groundwork of the Metaphysics of Morals. 1785. Cahn, S.M. ed. 2002. In Classics of Western 
Philosophy, 6th ed. Indianapolis / Cambridge: Hackett Publishing Company, Inc. 
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training. It is the role of the state by means of public law to make citizens virtuous. 41 Virtue 
ethics challenges the top-down system of institutions making the decision on the relevance of 
public interest, by appealing to the bottom-up involvement of virtuous citizens.42 
Combining the theories for an ethical management of patient data would lead to an 
“impossible” recommendation of collecting and using patient data for a right end, with the 
right means, without considering others as means, and with the goal of a good and virtuous 
life and the necessity to involve citizens in the decision-making process around patient data. 
Even taken in isolation, these main three philosophical approaches could be challenged in 
their ability to judge the value of public interest in practice. What, indeed, applies to 
individuals may not be easily transferable to populations and public institutions.  
Other theoretical approaches have been proposed considering liberty and equality in society. 
In his theory of justice based on equal liberties and opportunities, Rawls43 proposed a 
contractual method to identify the principles of justice, and combined it with a method of 
reflective equilibrium to justify the relevance of these principles that should play a 
foundational public role in a society.44 Daniels has adapted Rawls’s political approach to 
justice in the healthcare domain.45  The evaluation of public interest has to take into 
consideration which level of inequalities would matter, and make those who are worst off as 
well off as possible (difference principle). In the case of persistent disagreement, the public 
deliberation should engage a larger public in the decision-making process with adequate and 
relevant information that could come from large patient data sets. Daniels recommends 
establishing the accountability of decision-makers, and a legitimate procedure of valuation of 
public interest. This or similar approaches have been used for a fair allocation of healthcare 
resources. Regarding patient data, patients may have the right to participate in the 
corresponding decision-making process. This raises the issue of rights and obligations for 
healthcare stakeholders. 
Public interest reasons could also be discussed in terms of political rights, and not only in 
terms of goodness and justice. The question is how to choose the right option for public 
interest. The possibility of different options questions the theory’s independence from the 
41 Aristotle. Nicomachean Ethics. From Prof. Dr. Richard Amesbury’s lecture on social ethics. 2013. Theology 
Faculty. Zurich University. 
42 Galston, W.A. 2012. Virtue. In A Companion to Contemporary Political Philosophy, 2nd ed. Godin R.E., Pettit 
P., Pogge T. eds. Washington, DC: Blackwell Publishing Ltd, ch 54, pp. 842-851. 
43 Rawls, J. 2003. Principles of Justice. In Justice as fairness. A restatement. Erin Kelly ed. Cambridge, MA: The 
Belknap Press of Harvard University Press, part 2, pp. 39-79. 
44 Pettit, P. 2012. Analytical Philosophy. In A Companion to Contemporary Political Philosophy, 2nd ed. Godin 
R.E., Pettit P., Pogge, T. eds. Blackwell Publishing Ltd, ch 1, pp. 5-35.
45 Daniels, N. 2001. Justice, Health, and Healthcare. The American Journal of Bioethics, 1(2):2-16.
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institutions’ beliefs.46  In this dissertation, I will consider that rights are correlative to 
obligations, without entering presently into the philosophical debate of the primacy of rights 
or obligations.   
These moral philosophies and justice theories should not be applied directly to judge public 
interest in practice. They help frame different forms of debate between citizens and 
institutions and ideally lead to the best or most appropriate political consensus for the society 
at a given period. The justification of public interest necessitates a careful appraisal 
combining normative reflection and case-based reasoning. Beauchamp and Childress support 
an integrated reflective model based on reflective equilibrium to adjust between the different 
moral theories and principles.47 Nevertheless, they acknowledge that equilibrium is difficult 
to achieve. 
For instance, it would be morally wrong to have accepted overriding patient rights for the 
benefit of a claimed public utility, while fulfilling a secondary goal with no public interest. 
However, such a conflict of interest, “a set of circumstances that creates a risk that 
professional judgement or actions regarding a primary interest will be unduly influenced by 
a secondary interest”48, may also depend on how it is evaluated e.g. effective, potential or 
perceived as possible. 
To overcome conflicting theories, norms and interests, Ricœur’s ethical philosophy could 
provide for a new overarching architecture to public interest. Ricœur differentiated between 
the terms ethics and morality. Ethics is about what is considered to be good (teleological, 
Aristotelian perspective), and morality is about what imposes itself as obligatory 
(deontological, Kantian perspective). He also defined agency as an expression of the narrative 
identity.49 For him, ethics is not about the identity of things or data, but about moral agents 
(in our topic, healthcare stakeholders) with The Just influencing all human actions. As his 
concept of narrative identity concerns the self as well as the others, everyone is a subject of 
rights. Consequently, reasons of public interest depend on the sense of justice and its 
expression in practice through the interpretation of facts and the juridical reasoning about the 
law. 50  Furthermore, Ricœur’s approach has the advantage to take into account the 
46 Beauchamp, T.L. and Childress, J.F. 2009. Principles of Biomedical Ethics, 6th ed. New York: Oxford 
University Press, pp.333-367. 
47 Ibid, pp. 333-367. 
48 IOM (Institute of Medicine).  2009. Conflict of Interest in Medical Research, Education, and Practice. 
Washington, DC: The National Academies Press, p.45. 
49 Ricœur, P. 2000. The Just (trans: Pellauer, D.). Chicago and London: The University of Chicago Press, p. 3. 
Originally published as Le Juste. 1995. Paris: Editions Esprit. 
50 Ricœur, P. 2007. Reflections on The Just (trans: Pellauer, D.). Chicago and London: The University of Chicago 
Press, pp. 58-71. Originally published as Le Juste 2. 2001. Paris: Editions Esprit. 
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contributions of other ethical approaches, such as the Kantian and Rawlsian theories. 
However, it ensures the primacy of the ethical aim where conflicts between different moral 
norms are present (see more on Ricœur, Part IV). 
To sum up, underlying moral judgements influence the reasons for public interest and its 
weight compared to patient rights. Faced with the difficulty of determinating how to evaluate 
what morally wrong means for public interest and the management of patient data, Ricœur’s 
approach to justice and medical judgement could help define just and shared reasons of 
public interest, including the respect for patient rights.  
Patient rights 
The patient-physician relationship was the first domain where a notion close to patient rights 
was considered, although this was rather from the perspective of doctors’ duty than the 
modern perspective of human rights. Since Hippocrates, the professional deontology as self-
regulation has been based on the “do no harm” principle, but also on a medical knowledge 
that physicians were not ready to share with lay people, following a predominantly 
paternalistic approach. Changes arrived with the necessity to obtain informed consent from 
the research subject. Patients’ self-determination was recognised. Thereafter, health law was 
able to challenge and complete the professional code of deontology, especially in complex 
situations created by biomedical scientific progress. Patient rights have essentially developed 
on the normative structure of human rights.  
Patient rights are human rights 
Human rights have been extensively and universally recognised after the Second World War 
with the Universal Declaration of Human Rights (UDHR) of 1948. In the preamble of the 
UDHR, the idea of human rights is linked to the notion of human dignity, which at this time 
was not clearly defined but was able to reconcile the different historical, philosophical, 
religious and cultural values of the members writing the Declaration.  
In respect to healthcare, the UDHR recognises the right to protection against interference 
with privacy and the right to medical care.51 The human right to health or more precisely to 
51 United Nations. Universal Declaration of Human Rights. 1948. Article 12. No one shall be subjected to 
arbitrary interference with his privacy, family, home or correspondence, nor to attacks upon his honour and 
reputation. Everyone has the right to the protection of the law against such interference or attacks. Article 25. 1. 
Everyone has the right to a standard of living adequate for the health and well-being of himself and of his family, 
including food, clothing, housing and medical care and necessary social services, and the right to security in the 
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the “highest attainable standard of health” was later established in the International 
Covenant on Economic, Social and Cultural Rights (art. 12, ICESCR). In 2005, the right to 
benefit from scientific progress was added (art. 15, para. b, ICESCR). Wolff mentions that 
these steps in international law were important, but not enough to define strong obligations to 
fulfil rights; he distinguishes first-generation (or passive) rights of non-interference (e.g. 
privacy right) that are easy and cheap to enforce from second-generation (or active) rights 
(e.g. right to medical care, or access to scientific progress) requiring expensive actions to be 
enforced.52 When it comes to strengthening the obligations to meet patient rights in practice, 
Wolff considers two points which could be applied to large patient data sets: the need to 
collect data and understand them i.e. to be able to disaggregate data, and the need for global 
health governance. 
The European Biomedicine Convention (1997), also known as the Oviedo Convention, is a 
regional binding instrument for the states that signed and ratified it. 53 Its goal is to protect the 
dignity and identity of all human beings with respect to the application of biology and 
medicine. It guarantees every person’s integrity, and other rights and fundamental freedoms 
(article 1). The primacy of the human individual is affirmed in article 2: “the interests and 
welfare of the human being shall prevail over the sole interest of society and science.” Article 
10 on private life and the right to information provides that “everyone has the right to respect 
for private life in relation to information about his or her health (para. 1), that “everyone is 
entitled to know any information collected about his or her health”, and that “the wishes of 
individuals not to be so informed shall be observed” (para. 2). The same provision stipulates 
that “in exceptional cases, restrictions may be placed by law on the exercise of the rights 
contained in paragraph 2 in the interests of the patient.”  
Other articles include norms relating to genetic testing and non-discrimination, scientific 
research and consent issues. Article 28 recognizes the need for a public debate on the ethical, 
legal and social implications (ELSI) of the “fundamental questions raised by the 
developments of biology and medicine”.   
The UNESCO Universal Declaration on Bioethics and Human Rights (2005) provides in 
Article 9 that “the privacy of the persons concerned and the confidentiality of their personal 
information should be respected”. At the same time, it stipulates that “to the greatest extent 
event of unemployment, sickness, disability, widowhood, old age or other lack of livelihood in circumstances 
beyond his control.  
52 Wolff, J.  2012. The Human Right to Health. New York: W.W. Norton & Company, Inc., ch 2. 
53 European Convention on Human Rights and Biomedicine. Convention for the Protection of Human Rights and 
Dignity of the Human Being with regard to the Application of Biology and Medicine. 
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possible, such information should not be used or disclosed for purposes other than those for 
which it was collected or consented to, consistent with international law, in particular 
international human rights law”. Following articles include more general recommendations 
supporting the pluralist context - legal, ethical and political - of the bioethics principles.  
Andorno analysed the main biolaw instruments (the three UNESCO declarations relating to 
bioethics (1997, 2003 and 2005), and the European Biomedicine Convention) and identified 
fourteen core principles with legal and moral imbrication.54 With regard to large-scale 
biobanks (and their related patient data), he stressed that the main challenges regarding 
patients’ rights concern issues relating to “informed consent, confidentiality of data, 
discrimination on genetic grounds, feedback to participants, and property and benefit-
sharing.” 55 
These issues are relevant to patient rights and their health-related data. First-generation 
fundamental rights of non-interference related to privacy and non-discrimination necessitate 
the direct involvement and consent of patients regarding their data. Return of information to 
patients, data ownership and benefits sharing are second-generation positive rights with 
corresponding obligations to be evaluated. 
To sum up this brief review of international biolaw, the application of patient rights to patient 
data are a direct expression of human rights in the healthcare and biomedical domain. Three 
major themes can be identified:  
1. Patient rights around patient data are dependent on principles of human rights and
human dignity.
2. The protection of the fundamental privacy rights relates to the healthcare
professionals’ duty of confidentiality.
3. The context of research requires a special treatment of informed consent.
Local aspects of patient rights 
A few countries have developed national laws dedicated to patient rights (e.g. Belgium) or to 
patient rights and obligations (e.g. Luxemburg). In the USA, the Patient Self-determination 
Federal Act ensures that patients are involved in healthcare decisions concerning themselves. 
Under this act, healthcare providers and health agencies have the obligation to inform patients 
about their rights. There is not such a specific law in Switzerland, but the Swiss Academy of 
Medical Sciences provides medical-ethical guidelines and most healthcare institutions deliver 
information on patient rights based on the Swiss legal and ethical framework. 
54 Andorno, R. 2013. Principles of International Biolaw. Seeking Common Ground at The Intersection of 
Bioethics and Human Rights. Bruxelles: Editions Bruylant, ch 1.  
55 Ibid, ch 7. 
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On July 24, 2008, Switzerland signed and ratified the European Convention on Human 
Rights and Biomedicine which develops in a binding legal way the fundamental rights and 
rules of law in the area of medicine (RS 0810.2). The Swiss constitution guarantees the 
fundamental rights of human dignity (article 7), right to life and personal freedom (article 10) 
and privacy rights (article 13.al 2 “Everyone has the right to be protected against the misuse 
of their personal data”). Subsequent federal health legislation on Data Protection (RS 235.1), 
Human Research (RS 810.30), Human Genetic Testing (RS 810.12), Patient Electronic 
Dossier (RS 816.1), and Medical Professions (RS 811.11) have specified patient rights 
regarding their data at a national level. The Swiss Civil Code (personality rights, mandate 
norms), Penal Code (professional secrecy), health cantonal laws and professional 
deontological rules complete the Swiss frame for patient rights. To sum up, regarding patient 
data the main identified patient rights are as follows:  
- Right to information, which is mandatory to informed consent,  
- Right to control patient’s own patient dossier and to decide who can access it. 
- Right to privacy, in particular right to patient data protection and confidentiality. 
Restrictions on patient rights 
Fundamental human rights and corresponding patient rights are not absolute rights. They can 
be legally limited under strict conditions, i.e.:  
- A legal basis exists,  
- A public interest or another fundamental right predominates, 
- The restriction is proportional to the expected goal.  
Moreover, a few “sacrosanct” rights must always be respected (e.g. prohibition of torture). 
I have already developed the relativity of public interest depending on political, moral and 
societal choices. Some fundamental rights can also compete amongst themselves: e.g. 
freedom of opinion and expression may be restricted by the protection of privacy. The rules 
of proportionality ensure that the pursued goal does not justify all means. A proportional 
restriction must be appropriate to the goal, limited to the minimum intrusion necessary to 
reach the goal, and finally proportional in the narrow sense i.e. not disproportionate to the 
goal. In the legal area of the council of Europe, derogation to the CEDH is possible under 
such strict conditions and following the European Court’s case law.56 The Swiss constitution 
has similar conditions for restrictions stated in article 36 (RS 101). 
56 European Court of Human Rights. Council of Europe. European Convention on Human Rights (CEDH) 
http://www.echr.coe.int/Documents/Convention_ENG.pdf. Accessed 12 April 2017. 
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Some authors have differentiated the violation of a right (an unjustified action against a right) 
from the infringing of a right, a justified action overriding a right.57 As the term infringing 
could lead to confusion because of the possible reference to an illegal action e.g. in the 
locution “patent infringement”, the term overriding was preferentially used in the dissertation 
to describe all cases where rights are or could be limited following a justified or excusable 
action, moral justifiability being the subject of the ethical discussion. Right-bearers can give 
up patient rights if they specifically consent to do so. To legally allow this procedure, 
corresponding obligation-bearers have to inform the patient, and ensure that the patient is 
competent for decision-making regarding the object of consent and that she/he acts 
voluntarily. Information needs to be adapted to the patient and complete. In medical care and 
research, a valid informed consent requires these three distinct and additional components: 
information, voluntariness and competence.58 
So, the case for overriding patient rights seems to be appropriately legally framed. However, 
the moral question remains present, in particular surrounding the justification of the 
superiority of public interest or others’ interest over patient rights regarding their health-
related data. Different arguments can be discussed. The knowledge argument supports the 
benefit of building large patient data sets because isolated patient data does not support 
research and medical advances. Actually, the main issues relate to the governance and 
ownership of decision-making about the superiority of public interest or others’ interests. The 
major role of professionalism and expertise in the decision process could be viewed as a new 
form of paternalism. In the Principles of Biomedical Ethics, paternalism is defined as the 
intentional overriding of patient’s rights to express preferences or actions based on the 
arguments of beneficence or non-maleficence for the patient. 59  The justification of 
paternalism concerning patient data would mainly rely on prospected social benefits. 
Antipaternalists may reject this justification as it imposes others’ conception of good on 
patients, denies patients’ capability to be treated as moral equals, and fails to respect patients’ 
autonomy. The moral conflict between paternalism and autonomy influences the conditions 
of acceptability for overriding patient rights, and consequently the appraisal of the trade-off 
between public interest and patient rights with regard to patient data.   
57 Beauchamp, T.L. and Childress, J.F. 2009. Principles of Biomedical Ethics, 6th ed. New York: Oxford
University Press, p. 352. 
58 Brock, D.W. 2008. Philosophical justifications of informed consent in research. In: The Oxford Textbook of 
Clinical Research Ethics. New York: Oxford University Press Inc., ch 56. 
59 Ibid note 57, pp. 208-216. 
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Patient rights ethics and autonomy 
Patient autonomy is a well-recognized principle in biomedical ethics, but it needs to be 
further examined as the consideration of patient data is continuously evolving. Since the year 
2000, the World Medical Association (WMA) has widened the field of human medical 
research with the notion of identifiable human data,60 and in 2016, as mentioned before, it 
acknowledged the use of health data for commercial, administrative or political purposes. 
Finally, the impact of scientific and technological progress on the norms of privacy, 
confidentiality and data sharing has led to better data security and greater benefit from 
aggregating patient data.  
With regard to patient data, its paper or electronic supports detached from the patient’s body 
and the possibility to use it in a coding fashion, the concept of autonomy may not be 
considered primarily or only in a procedural way based on data protection, patient consent or 
health law. However, the theory of autonomy can be interpreted in various ways depending 
on the social and medical context, the level of permissibility for limiting privacy rights, and 
the link between autonomy, rights and accountability for choice. 
Beauchamp and Childress have concentrated the concept of autonomy on “autonomous 
choice rather than on general capacities for governance and self-management.” They 
justified this choice because they consider that a patient status results in weak governing 
capabilities due to “illness, depression, ignorance, coercion, or other conditions that restrict 
their options.” Concerning patient data, this choice is debatable. Large patient data sets have 
a broader scope than usual clinical settings. Patients with good digital education or acquired 
literacy in the context of chronic diseases or rare diseases are often capable of enhanced 
autonomy, understanding and decision-making regarding health-related data. Therefore, self-
management and shared “participative” governance could increasingly contribute to a wide 
concept of autonomy including patient’s agency freedom.61 
Patient rights remain at the core of the ethical reflection because informed consent for giving 
up rights cannot resolve all issues. The Nuffield Council on Bioethics has already identified 
60  Declaration of Helsinki. 2013.  “Preamble: 1. The World Medical Association (WMA) has developed the 
Declaration of Helsinki as a statement of ethical principles for medical research  involving human subjects, 
including research  on identifiable human material and data.”. 
http://jamanetwork.com/journals/jama/fullarticle/1760318.  Accessed 20 April 2017. 
61 Sen, A. 1985. Well-being, agency and freedom: The Dewey lectures 1984. The Journal of Philosophy, 
82(4):203–204. In this dissertation, I have primarily used the Sen’s wide definition of agency freedom as:  
“the freedom to achieve whatever the person as a responsible agent, decides he or she should achieve”.  
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the problem:62 “…consent does not itself ensure that all of the interests of the person giving 
consent are protected nor does it set aside the moral duty of care owed to that person by 
others who are given access to the information. On its own, consent is not always necessary, 
not always sufficient for ethical extensions of data access.”  
 
For O’Neill, individual autonomy limited to informed consent provides incomplete ethical 
guidance. Inspired by Kant’s writings, she has recommended grounding human rights in 
human obligations. She proposes the concept of principled autonomy as self-legislation to 
make each free individual able to govern ways of thinking and willingness to act.63 Principled 
autonomy applied to the management of large patient data sets necessitates that patients, 
donors and citizens have access to information and trust it in order to judge upon their rights 
and obligations. O’Neill has highlighted the difficulty of trusting others based on status or of 
placing trust in complex institutions.64 Consequently, health professionals should increase 
their accountability for building trust with patients and citizens. They have the obligation to 
be competent, to follow regulated and audited practices and to be engaged in transparent and 
reciprocal communication with patients, peers and institutions. The value of informed 
consent would rely on a commitment to trustworthiness based on principled autonomy and 
the corresponding obligations not to deceive, coerce or harm, as well as the obligation to help 
others and respect their right to decide and act.65  
 
In contrast to utilitarianism, Raz has used the concept of autonomy as linked to the individual 
capacity to choose amongst adequate options, free from manipulation or state coercion. 66 
However, there is a risk of favouring some private and commercial options and disregarding 
the public reason of sharing in an expression of solidarity a maximum of data for the 
common good. Other researchers have challenged the concept of autonomy as a foundation 
for patient rights because of its usage in too broad a fashion.67 Indeed, claims to autonomy 
have been made for Kantian reasons, contractual theories, liberty theories, Aristotelian view 
of the good, and also in opposition to utilitarianism or paternalism.  
 
                                                      
62 Nuffield Council on Bioethics. 2015. Biological and Health Data: The Collection, Linking and Use of Data in 
Biomedical Research and Health Care: Ethical Issues, p. 46. http://nuffieldbioethics.org/report/collection-linking-
use-data-biomedical-research -health-care/ch apter-downloads-2/.  Accessed 10 May 2017.  
63 O’Neill, O. 2002. Autonomy and Trust in Bioethics. Cambridge, UK: Cambridge University Press, ch 4, pp. 83-
86. 
64 Ibid, ch 6, pp. 118-123. 
65 Ibid, ch 7, pp. 141-164. 
66 Vayena, E. 2015. Direct-to-consumer genomics on the scales of autonomy. Journal of Medical Ethics, 41:310-
314. 
67 Dworkin, G. 2012. Autonomy. In A Companion to Contemporary Political Philosophy, 2nd ed. Godin R.E., 
Pettit P., Pogge T. eds. Washington, DC: Blackwell Publishing Ltd, ch 18, pp. 443-451. 
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With regard to patient data, I refer pragmatically to a broad concept of autonomy supporting 
the following claims:  
- Patient rights to be informed and to give or withdraw consent regarding the use of 
their data,  
- Patient rights to participate in decision-making and governance of healthcare projects 
based on patient data, 
- Patient rights to have feedback on the use of their data, and also a right not to know, 
- Healthcare professionals’ rights to be informed and involved in the decision-making 
process and governance of patient data, influencing their work, 
- Healthcare stakeholders’ obligations to respect others’ autonomy (e.g. patients, peers, 
patients’ families, data managers, social workers) 
- Citizens’ rights to be informed and involved in the governance of public and private 
projects associated with patient data that are able to influence their health and the 
healthcare system, or that use healthcare competing resources.  
The definition of autonomy is therefore tied to both autonomous choice and agency freedom 
for individuals and communities concerned about the production and use of patient data.  
3. Thesis structure
In part I, whilst acknowledging the promising benefits arising from the production and use of 
patient data, I stated that it was fundamental to have appropriate governance for the ethical 
management of patient data. In the previous pages, I explained how patient data, public 
interest and patient rights are understood and used in this PhD thesis, as there are no clear-cut 
“true” or “universally harmonised” definitions of these concepts. So, how should we appraise 
the issues raised from the tension between patient rights and public interest in the 
management of large patient data sets? In order to address this question, the rest of this thesis 
will contain the following parts: 
Part  II and III assess the current ethical frame of, on the one hand, facilitating the gain of 
public interest in patient data whilst, on the other hand, partially trading off patient rights. To 
this end, a descriptive approach based on casuistic and qualitative methodologies is used.  
- The casuistic perspective (Part II) reports my experience and personal reflection 
in the field of clinical registries, as well as the difficulties of identifying appropriate 
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uses of patient data in terms of either public interest or patient rights. The first case 
(chapter 4) concerns the use of patient data in the evaluation of a Swiss reform of 
public hospitals. The second case (chapter 5) narrates the importance of patient data 
for adjusting the treatment of epilepsy in pregnant women.  
- The qualitative perspective (Part III) presents empirical research which has explored 
the ethical awareness of Swiss professionals and decision-makers involved in clinical 
registries (chapter 7). They play a central role in the governance of health 
information, and should be aware of their legal as well as moral obligations towards 
patients, peers and society. This empirical material permits us to infer that the ethical 
angle of a competing framework between public interest and patient rights might be 
wrong (chapter 8).  
Part IV then reports a normative approach based on Paul Ricœur’s ‘little ethics’, 
recommending that healthcare stakeholders should manage health information from a 
narrative standpoint. This approach permits us to take into account the multiplicity of 
stakeholders and the complexity of contexts and purposes of large patient data sets. I will 
describe how Ricœur ensures the transition from narration to ethics and proposes an 
overarching ethical approach, able to guide the agents governing the production and use of 
patient data. (chapters 8, 9). 
The overall research flow combines inductive and deductive analysis following the pragmatic 
approach advocated by Ives and Draper.68 As a result, in the conclusion (Part V), chapter 10 
generates the argument which reframes the ethical guidance for patient data. Chapter 11 
applies the new framework to the previous empirical examples. A general implementation 
strategy is then suggested in chapter 13. Subsequently, chapter 14 provides a list of concrete 
recommendations mainly in the Swiss context. 
68 Ives, J., Draper, H. 2009. Appropriate methodologies for empirical bioethics: It’s all relative. Bioethics, 
23(4):249-258. 
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PART II. CASUISTIC APPROACH 
Case analysis has been developed in clinical ethics, starting with a detailed review of a case-
story, drawing upon responses to similar cases, weighing the principles involved and 
subsequently developing an ethical evaluation by analogical thinking. The advantage of 
casuistry is that it permits combination of different ethical principles and theories, depending 
on the context of each particular case. The method is, however, open to criticism, due to bias 
induced by reporting the facts retrospectively, or by applying moral theories in a too 
indeterminate way.69 Casuistry therefore requires prudence, intuition and wisdom.70 I used an 
approach derived from casuistry as a learning process for possible ethical issues with patient 
data management in the context of clinical registries.  
4. Impact of new health care policies on the quality of acute
myocardial infarction treatment in Swiss hospitals:  A before and
after observational study.
Introduction 
This study IDoC 1-D was one of the five sub-projects (A to E) of the overall IDoC project 
“Assessing the Impact of Diagnosis Related Groups (DRGs) on patient care and professional 
practice” performed under the leadership of the Institute of Biomedical Ethics of the 
University of Zürich and funded by the Swiss National Fund. The design and first findings 
were presented as a part of the general IDoC symposium on November 14th, 2013.71 As a 
member of the IDoC group, I also contributed to the joint IDoC publication in the peer-
reviewed journal Swiss Medical Weekly.72  
69 Arras, J.D. 2009. A case approach. In A Companion to Bioethics, 2nd ed. Kuhse, H., Singer, P. eds. Oxford: 
Blackwell Publishing Ltd, ch 12.  
70 Jonsen, A.R. 2010. Casuistry and clinical ethics. In Methods in Medical Ethics. 2nd ed. Sugerman, J. Sulsamy, 
D.P. eds. Washington, DC: Georgetown University Press, ch 7. 
71 IDoC Symposium (PDF). http://www.ibme.uzh.ch/de/ethik/forschung/drg.html.  Accessed 25 April 2017. 
72 Wild, V. Fourie, C., Frouzakis, R., Clarinval, C., Fässler, M., Elger, B., Gächter, T., Leu, A., Spirig, R., 
Kleinknecht, M., Radovanovic, D., Mouton Dorey, C., Burnand, B., Vader, J.P.,  Januel, J.M., Biller-Andorno, N. 
2015. Assessing the impact of DRGs on patient care and professional practice in Switzerland (IDoC) - a potential 
model for monitoring and evaluating healthcare reform. Swiss Medical Weekly, 145:w14034. 
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The case study IDoC 1-D reports an example of the secondary use of patient data from a 
national clinical registry. In this registry, patient data were initially collected to examine 
hospital treatment for patients presenting with an acute myocardial infarction. The registry 
set-up included the possibility of re-using data for other research projects, subject to approval 
by the steering committee. We thus measured the impact of a national hospital reform on the 
quality of treatment delivered to the registry patients. The treatment of acute myocardial 
infarction is based on well-established guidelines from evidence-based medicine, and thus 
any changes in adherence to these guidelines could indicate any clinical impact due to this 
hospital reform. The advantage of such a form of evaluation is that the indicators are 
independent of the public administration responsible for the reform.  
The scientific research of evidence is usually contrary to the philosophical research of 
reasons.73 It was thus interesting to reflect on the use of an evidence-based medicine approach 
to contribute to a project aiming at a reasons-based ethical appraisal of a public hospital 
reform. However, the passage from the facts to the ethical reasoning remains difficult. 
Reasons behind our observations suggesting that the overall maintenance of treatment quality 
could have been associated with some “hidden” moral distress of the hospital healthcare 
professionals remains hypothetical. 
This study was the first step of my PhD research. I wanted to investigate further my intuition 
that something could have been morally questionable in the management of patient data. 
I presented the study results in a poster session at the International Forum on Quality & 
Healthcare, in Gothenburg, Sweden (April 2016). We published the following article 
together with Milo Alan Puhan and Nikola Biller-Andorno, in May 2016, in the peer-
reviewed Journal of Hospital Administration, 5 (3): 10-19.74 
The publication: 
73 Hope, T. 2004. On why medical ethics is exciting. In Medical Ethics, a Very Short Introduction. Oxford: 
Oxford University press, ch 1. 
74 doi:10.5430/jha.v5n3p10. 
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ABSTRACT
Objective: Following a revision of the Swiss Federal Health Insurance Act, the regional hospital planning structure was modified
and the hospital financing organized at a national level with the use of diagnosis related groups (SwissDRGs). The aim of
this observational study was to determine in an independent way the initial impact of these changes on the quality of hospital
treatment, with patients hospitalized for Acute Myocardial Infarction (AMI) being the chosen study group.
Methods: We used prospective data from a Swiss clinical registry for AMI. The quality was measured based on the adherence
to 10 evidence-based performance indicators for AMI treatment, and on the evaluation of in-hospital outcomes (mortality,
complications, length of hospital stay [LOS]) globally and for seven pre-defined vulnerable subgroups. The study compared
patient-based data before (2011) and after (2012) the implementation of the reform.
Results: The study included 33 matched hospitals, and compared the AMI treatment of 2,491 patients in 2011 (before) and 2,544
in 2012 (after the hospital reform). No significant changes in the evidence-based performance indicators were observed, but an on
average one day reduction in the LOS and worse outcomes in one of the pre-defined group of patients were found. The issue of
how the clinical team achieved these results was not directly explored due to the underlying registry’s unalterable structure.
Conclusions: One year after the implementation of a new hospital financing system in Switzerland, the quality of treatment
delivered to patients hospitalized for AMI was maintained overall. The worse in-hospital mortality in one pre-defined vulnerable
subgroup could reflect the emergence of difficulties for clinical teams to cope with patients demanding extra care and time.
Further investigation is warranted.
Key Words: Hospital medicine, Quality measurement, Health policy, Evidence-based medicine, Clinical registries
1. INTRODUCTION
Healthcare systems differ worldwide but they all share the
common aims of high quality and cost containment, which
in turn leads to a need for reforms and for an increased ac-
countability to monitor and evaluate health care changes and
disease management. The recent revision of the Swiss Fed-
eral Health Insurance Act was planned to both contain hos-
pital costs and guarantee hospital healthcare quality, whilst
respecting the three main principles of effectiveness, ade-
quacy and economical efficiency, as laid down by the law.[1]
Switzerland was therefore a good proxy for the evaluation of
healthcare quality under cost constraints.
úCorrespondence: Corine Mouton Dorey; Email: corine.moutondorey@uzh.ch; Address: Institute of Biomedical Ethics and History of Medicine
(IBME), University of Zurich, Zurich, Switzerland.
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Table 1. Reform of hospital financing in Switzerland[1]
 
Common features of Swiss hospital financing before and after the reform implementation  
• Universal basic health insurance (UHI) compulsory for each Swiss resident, federal competence.
• Multiple competitive Swiss health insurers for UHI. 
• Private complementary insurers.
• Cantonal (i.e. regional) competence for healthcare planning.
• No free choice of doctor in hospital.
• Health services not covered by UHI: payments by patients and private insurers.
Main UHI financial aspects before January 2012 Main UHI financial aspects from January 2012 
Cantonal planning 
x Cantonal competence. 
x Establishment of a cantonal list of public and subsidized hospitals
eligible for cost reimbursement.
x Choice of hospital: free choice limited to hospitals enlisted on the 
cantonal list of the resident. 
x Cost allocation: 
○  Cantonal listed hospitals: Minimum of 50% at cantonal level, 
remaining cost paid by UHI.
○ Cantonal non-listed hospitals: payments by patients and private
insurers.
○ Hospitals in other cantons: full payments by patients and private
 insurers (except for extra-cantonal hospitals enlisted in the
 cantonal list and in a few medically justified exceptions). 
• Cantonal competence, but economics, infrastructure and quality
standards for hospital selection are defined at federal level.
• The cantonal list of eligible institutions for cost reimbursement
includes not only public and subsidized hospitals, but also private
hospitals and potentially hospitals from other cantons.
• Choice of hospital under UHI: free choice for the whole of
Switzerland, amongst the list of indexed hospitals. 
• Cost allocation: 
○  Cantonal listed hospitals: Minimum of 55% at cantonal level, 
maximum of 45 % for UHI. 
○  Cantonal non-listed hospitals: payments by patients and private
 insurers or if they have signed a contract with UHI, UHI
 contributes up to 45%.
○ Listed hospitals in other cantons: reimbursement based on the
 residential cantonal prices.  Potential surcharges paid by 
 patients and private insurers. 
Payment model for health services and structure 
x Collectively negotiated between hospitals and health insurers and 
approved by the respective canton at individual cantonal level. 
x Daily price, fee-for-services, AP-DRGs, or mixes of them.
x Infrastructure investments managed separately from health services 
payment.
x Collectively negotiated between hospitals and health insurers and 
approved at national level. 
x Based on Diagnosis Related Groups (SwissDRGs) for somatic 
acute care. 
x SwissDRGs’ national cost-weights applied to hospital basis price. 
x Infrastructure investments included in SwissDRGs.
Challenges 
x Discriminatory cantonal allocation of costs for citizens with 
complementary private insurances compared to citizens with UHI
only (judicial judgment). 
x Outside of a few exceptions, no free country-wide choice of hospital. 
x Limited availability of national standards to compare hospital 
services between cantons. 
x Limited cost transparency reported at insurers’ level. 
x Inadequate dual financing of hospital investment and services at 
cantonal level. 
x Difficulties in containing hospital costs. 
x Who pays the costs in excess of SwissDRGs reimbursement rates?
Not the insurers (max 45%), therefore the institutions’ owner?
Canton? Need to close or restructure hospitals?
x Threat to quality of health services and professional practice due to 
cost pressure from SwissDRGs. 
x Risk of under-investment. 
x Insurers able to challenge SwissDRGs coding and reimbursement 
levels, potentially delaying payment to hospitals. 
x Need to establish evidence of improved hospital economics, access
and quality.
The legal changes in Switzerland were implemented in 2012
and involved two sets of measures: A new cantonal hospital
planning and the introduction of a payment model based
on national diagnosis related groups (SwissDRGs). Table 1
summarizes the main features of the Swiss universal health
insurance (UHI) for hospitals and the modifications due to
the hospital financing reform. Some cantons in Switzer-
land have been working with DRGs (APDRGs) before 2012.
SwissDRGs, however, are based on an adapted version of the
German DRGs, which were considered to be very detailed,
Published by Sciedu Press 
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with a high level of precision for comorbidities and case
severity. Furthermore, as Switzerland is a small country with
German being the most widely spoken language, it was more
cost effective to take over the existing field-tested German
system.
The intent of the national harmonization was to compare and
control costs while guaranteeing health care quality, but to
date no evidence has been provided to support this claim.
There is as yet no national center for health care quality in
Switzerland and no independent program to assess the im-
pact of governmental health care reforms on hospital clinical
pathways. Swiss health care professionals were questioning
the new hospital policies, which could lead to a reduction in
the quantity of care for a standard case, to premature patient
discharges, and a decrease in the quality of hospital treatment.
Furthermore, patients requiring more intensive care could be
the most vulnerable.
The aim of this study was to assess the quality of a routine
hospital treatment, with independently recorded evidence-
based indicators and outcomes, in a comparative study before
and after the introduction of this Swiss national reform. The
results were also contributing to a multi-disciplinary project
assessing the impact of the reform on patient care and pro-
fessional practice.[2]
2. METHODS
The study was performed in order to collect prospectively
the data from the period before the implementation of the
reform, and used comparable indicators before and after the
changes. Moreover, the study design had to integrate the
constraints of the absence of a control group and the funding
period limited to 3 years.
2.1 Research strategy
The first step was to identify the agents concerned by the new
reimbursement policy and to define the types of measure-
ment.[3] Hospitals were the agents, and the measurement was
based on the implementation of evidence-based recommen-
dations for patients for a given disease. There are many ways
of measuring healthcare quality;[4] coded administrative data
and Inpatient Quality Indicators (IQI) are currently used,[5]
but they are linked to the coding guidelines and regulations of
the DRGs themselves,[6] with a possible self-preference bias.
In addition, the importance of an independent evaluation of
government-led reforms has been emphasized.[7] Thus, these
administrative data and IQI were not considered suitable for
this study.
The decision was thus to develop a quality measurement
based on evidence-based recommendations and observational
data in the field of acute myocardial infarction (AMI). First,
coronary artery disease is associated with a high burden
of disease and benefits from long-standing international re-
search and guidelines.[8] These evidence-based recommen-
dations highlight critical clinical care processes to ensure
quality in the treatment of AMI patients.[9] Second, adher-
ence to evidence-based recommendations can be measured
with observational data,[10] and clinical registries are exam-
ples of observational data supporting quality improvement
for a clinical condition, diagnostic, procedure or therapy.[11]
Third, there was an ongoing clinical registry for AMI in
Switzerland, registered at ClinicalTrials.gov and approved
by the Supra-Regional Ethics Committee for Clinical Studies,
the Swiss Board for Data Security, and the Cantonal Ethics
Commissions.[12]
2.2 Access to data and cooperation process
An agreement was signed at the beginning of 2011 with the
registry steering committee for the 3-year research period.
It permitted the secondary use of registry data for the years
2010, 2011 and 2012, but not an alteration of the primary
structure or sampling design of the registry itself. The par-
ticipating hospitals owned the data and data could not be
disclosed to other parties or published without prior consent
of the steering committee. It was agreed that registry data
were strictly confidential and that hospital names had to re-
main anonymous. Patient data were already de-identified in
the registry.
The presence of the study researcher in the registry data cen-
ter allowed an in-depth understanding of the production and
use of the registry data, and has thus facilitated transparency
and trust. The analysis of data developed in the study was
different from the registry’s usual analyses. In the registry,
the analysis took place on the basis of patient cases; matching
hospitals over the years was not required. In our study, the
matching units were the hospitals and as a consequence, pa-
tients from hospitals, which entered or left the registry in one
of the 2-year periods of study, were excluded. Furthermore
our study considered performance indicators with different
appropriate denominators. The registry analysis concerned a
larger and expandable number of variables and could include
data from several previous years. Despite these different
approaches to clinical data, the cooperation process led the
registry’s steering committee to support study disclosure.
2.3 Development of the measurements based on
evidence-based recommendations
Our study drew on international evidence-based recommen-
dations for AMI treatment with predominant class and level
of evidence IA or IB.[13–19] The 2010 retrospective registry
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data were used to adjust the measurement set to the exist-
ing registry structure. In 2010, 2275 AMI patients were
included in the registry by 39 hospitals and amongst them
9 had a round the clock catheter laboratory (CathLab) ser-
vice available. Some possible indicators were not developed
because adequate variables were not at that time collected
in the registry (e.g. initial heparin dose, adult smoking ces-
sation advice) or not systematically controlled (e.g. high
technology interventions for coronary vessels).
Other performance indicators were disregarded because of
missing or implausible data at a rate Ø 5%: these were
mainly time indicators such as time from symptom onset to
hospital admission in patients transferred from/to hospitals
not participating in the registry, or in NSTEMI patients (with-
out ST elevation at the initial ECG) presenting usually with
a less straightforward diagnosis of AMI. For the purpose of
transparency, delays from symptom onset to hospital admis-
sion are shown as baseline characteristics, but not used as
performance indicators.
Vital signs at admission are also reported as baseline charac-
teristics only, because these data were not audited nor linked
to documented clinical shock. Only resuscitation prior to
admission was a controlled reported item. Risk factors were
identified from the anamnesis section of the questionnaire.
For instance a diagnosis of diabetes was identified from the
data reported under the headings Charlson index, risk factors
and regular medical treatment. Missing data exceeded 5%
for some items such as smoking habits, body mass index or
dyslipidemia, and was distributed unequally across hospitals
with no possibility to adjust them with a proper weighting.
These variables are shown as descriptive baseline but cannot
be used for group comparison. For the selected variables
to be reported and used as indicators, the measurement set
retained for the study had to achieve a rate of less than 3%
missing or implausible data from each participating hospital.
2.4 Measurement set description
The set combines ten performance indicators of adherence
to evidence-based recommendations, in-hospital outcomes
and an evaluation of access to care for pre-defined patient
subgroups. Table 2 details the measurement set.
In this study, primary percutaneous coronary intervention
(PPCI) refers to balloon angioplasty, with or without stent-
ing, undertaken as the primary reperfusion strategy for AMI
without previous or concomitant thrombolytic therapy and
performed within 24 hours following hospital admission.
Left ventricular systolic dysfunction was defined as the left
ventricular ejection fraction < 50% measured by angiography
or < 40% measured by cardiac echography.
In hospital outcomes included all-cause mortality, major ad-
verse cerebrovascular and cardiac events (MACCE), and the
length of hospital stay (LOS) measured in days: median,
(IQR 25th and 75th percentiles). Moreover, the following
seven subgroups were defined a priori as vulnerable because
they represent patients, who may have had a less straightfor-
ward diagnosis, required more intensive care or where delays
to hospital admission may have been more frequent. These
are: advanced age over 75 years,[20] female gender,[21] AMI
related cardiac insufficiency at admission defined with Killip
classes 3 or 4,[22] existence of comorbidities measured by the
Charlson comorbidities index (CCI) and more specifically
histories of diabetes or renal insufficiency.[23] We added the
socio-economic factor “basic insurance coverage only” for
patients only covered with the UHI (Universal Health Insur-
ance), additional private and semi-private insurances only
being paid by wealthier patients.
2.5 Implementation of the before and after study
The measurement set was applied to prospectively collected
data to compare the quality of treatment delivered to AMI
patients before (2011) and after (2012) the hospital payment
changes. The study included all patients from the national
clinical registry i.e. AMI patients hospitalized within the
first 24 hours of symptoms onset, and defined as STEMI or
NSTEMI by characteristic symptoms and/or ECG changes,
and cardiac marker elevation. Moreover as we wanted to
match hospitals before and after the reform, only patients
included by the hospitals that participated in the registry in
both years 2011 and 2012 were considered for the analysis.
We considered patient-based data in preference to admission-
based data; patient-based data follow patients across hospi-
tals and exclude double counting the same patient in the case
of hospital transfer.
2.6 Statistical analysis
Data are presented as a proportion of valid cases for discrete
variables, as means ± 1 standard deviation for normally dis-
tributed continuous variables and as medians with IQR (25%
and 75% percentiles) for non-normally distributed continu-
ous variables. Each individual adherence rate to guidelines
was calculated as a performance ratio of valid cases over eligi-
ble patients for the indicator. Comparisons before (2011) and
after (2012) concerned independent patients from matched
hospitals, and were compared using the Student’s two-tailed
unpaired t test for continuous normally distributed variables,
the Mann-Whitney U test for continuous non-normally dis-
tributed variables and the Pearson chi square test for categor-
ical variables. A probability value of < .05 was considered
significant.
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Table 2. Measurement set for patients hospitalized within 24 hours of acute myocardial infarction
Measure Name Eligible patients* Measure type 
A. Adherence rate to evidence-based recommendations in % 
1. Immediate triple therapy (ASA, P2Y12, AC) Alive in the first 24h Treatment 
2. Primary PCI performed: PPCI All Treatment, diagnosis 
3. Evaluation of LVEF (with angiography or 
echography) 
Alive at discharge Intermediate outcome,  diagnosis 
4. DAPT  (ASA, P2Y12) at discharge Alive at discharge Treatment 
5. Beta-blocker at discharge Alive at discharge Treatment 
6. Statins at discharge Alive at discharge Treatment 
7. ACEI or ARB for LVSD, at discharge Alive at discharge and LVSD Treatment 
8. Cardiac rehabilitation patient referral Alive at discharge and no transfer to other hospitals or 
nursing homes 
Patient education 
9. Door-to-balloon time  90 minutes STEMI, PPCI, no symptoms onset in hospital, 
no transfer from/to non participanting registry hospitals 
Treatment, process 
10. Time to reperfusion  12 hours STEMI, PPCI, no symptoms onset in hospital, 
no transfer from/to non participanting registry hospitals 
Treatment, process 
B. In-hospital outcomes
1. All cause mortality, adjusted All  Outcome 
2. MACCE, adjusted All Composite outcome 
3. Length of hospital stay, days (median, IQR) All Process, outcome 
C. Access to care/clinically vulnerable patients
1. Age > 75 years All  Admission rate %. 
In-hospital outcomes.      
Adherence to guidelines when 
relevant. 
2. Female gender All 
3. Killip 3 and 4 at admission All 
4. Charlson Comorbidities Index (CCI)  2 All 
5. Diabetes All 
6. Renal insufficiency moderate & severe All 
7. Basic insurance coverage only All 
* Eligible patients: denominator of the ratio for adherence to guidelines calculation, or for admission rate. AMI: acute myocardial infarction; AC: anticoagulant 
therapies; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ASA: aspirin; CCI: weighted Charlson index for comorbidities; 
DAPT: dual antiplatelet therapy; IQR: interquartile range; LVEF: left ventricular ejection fraction; LVSD: left ventricular systolic dysfunction; MACCE: major 
adverse cardiac- and cerebrovascular events; NSTEMI AMI without ST elevation on the initial electrocardiogram; P2Y12 indirect (thienopyridines) and direct
P2Y12 inhibitors; (P) PCI (primary) percutaneous coronary intervention; STEMI AMI with segment ST-elevation or new left bundle branch block on the initial 
electrocardiogram 
Mortality and MACCE were adjusted for differences in base-
line characteristics known to influence survival and admis-
sion year. We used a logistic regression model with in-
hospital mortality (or MACCE) as a dependent variable and
the following independent variables: year of admission as
the variable of interest, and age, sex, resuscitation before
admission, diagnosis STEMI/NSTEMI, Killip class 3 or 4
at admission and comorbidities as characteristics known for
their strong impact on in-hospital mortality (heart failure,
diabetes, renal insufficiency or metastatic tumors) and thus
acting as potential confounders.[23] The odd ratios (ORs)
were presented with 95% CI. The SPSS software (SPSS Inc.,
Chicago, Illinois; Version 21.0) was used for all statistical
analyses.
3. RESULTS
The clinical registry enrolled 5,935 patients (2,491 in 2011,
2,544 in 2012) whose data were available at the registry data
center at the end of June 2013. The data were accessed and
controlled for our secondary analysis: 5,035 patients met
the study inclusion criteria and the remaining 900 patients
were excluded for the following reasons: double entries
(n = 142 patients transferred and included both in hospi-
tals with and without CathLab for the same AMI); patients
who had PCI before admission in a non-reporting hospital
(n = 92); patients from hospitals that did not participate
in both years of the registry (n = 666 in total, divided in
n = 450 for participation in 2011 only, n = 216 for participa-
tion in 2012 only).
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Table 3. Baseline characteristics of patients admitted with AMI according to year of admission
2011 2012 p-value
N patients (N hospitals) 2,491 (33) 2,544 (33) 
N patients (%) from hospitals with CathLab ( N  = 12) 1,834 (73.6) 1,981 (78.1) 
N patients (%) from hospitals without CathLab ( N = 21) 657 (26.4) 563 (21.9) 
Transfers from non-participating hospitals 610 (24.5) 636 (25.0) 
PPCI 1,760 (70.7) 1,840 (72.3)  .416 
Age (years)  67.1 ± 13.1  66.6 ± 13.0   .231 
Male gender 1,807 (72.5) 1,883 (74.0)  .237 
Delay symptoms onset to admission  1,667 1,808 
• hours: minutes (median, IQR 25, 75 quartiles) 3:30 (1:37, 8:45) 3:06 (1:30, 8:30)  .264 
Diagnosis STEMI 1,295 (52.0) 1,320 (51.9)  .943 
Resuscitation prior admission 123 (4.9) 153 (6.0)  .093 
Symptoms at admission: typical 2,035 (81.7) 2,000 (78.6)  .022 
Vital signs at admission: 
• Systolic blood pressure < 100 mmHg 145 (5.9) 182 (7.3)  .051 
• Heart rate > 100 beats 269 (11.0) 240 (9.6)  .125 
Heart rhythm: 
• Sinus rhythm 2,236 (89.8) 2,303 (90.5)  .666 
• Atrial fibrillation 133 (5.3) 137 (5.4) 
Killip class: 2,483 2,535  .866 
• 1 2,032 (81.8) 2,085 (82.2) 
• 2 238 (9.6) 247 (9.7) 
• 3 83 (3.3) 75 (3.0) 
• 4 130 (5.2) 128 (5.1) 
Risk factors: 
• Current smoker 855 (38.4) 872 (38.5)  .904 
• History of Dyslipidemia 1,195 (54.3) 1,355 (58.9)  .002 
• History of Hypertension 1,518 (64.2) 1,519 (62.2)  .160 
• History of Diabetes 506 (21.4) 501 (20.3)  .341 
• Obesity Body Mass Index > 30 465 (22.4) 477 (21.5)  .465 
History of MI or stable angina 830 (34.3) 812 (32.8)  .275 
Vulnerable sub-groups: 
• Age > 75 years 795 (31.9) 758 (29.8)  .104 
• Female gender 684 (27.5) 661 (26.0)  .237 
• Killip classes 3 and 4 at admission 213 (8.6) 203 (8.0)  .464 
• Diabetes (patient history) 506 (21.4) 501 (20.3)  .341 
• Renal insufficiency 224 (9.2) 230 (9.2)  .990 
• CCI   2 627 (25.2) 645 (25.4)  .881 
• Basic insurance coverage only 1,693 (71.6) 1,859 (75.4)  .003 
Note. Values are mean ± SD (standard deviation), median (IQR), N/total (%), or N. MI: (acute) myocardial infarction; CathLab a round the clock catheter 
laboratory service available; CCI: Charlson index for comorbidities; IQR: interquartile range; PPCI: primary percutaneous coronary intervention; NSTEMI 
AMI without ST elevation on the initial electrocardiogram; STEMI AMI with segment ST-elevation or new left bundle branch block on the initial 
electrocardiogram  
As shown in Table 3, patient baseline characteristics such as
age, gender, AMI diagnosis, hemodynamic status at entry,
major risk factors, and degree of comorbidities measured
by the Charlson index were not statistically significantly dif-
ferent between the 2 years of admission; however, a higher
number of patients with “basic insurance coverage only” was
recorded in 2012.
The results showed no statistically significant differences
in the quality of treatment for eight indicators of adherence
to evidence-based recommendations. The indicators 1 and
4 could not appropriately record the prescription of a new
direct P2Y12 inhibitor treatment introduced onto the market
at the end of 2011; the registry questionnaire was modified in
October 2011 to collect this new item but the changes were
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implemented at an unequal pace amongst hospitals; there-
fore, the observed difference between 2011 and 2012 cannot
be taken into consideration statistically nor clinically (see
Table 4).
Overall, the adjusted rates of mortality (OR 1.061, 95% CI
0.784-1.435) and MACCE (OR 0.915, 95% CI 0.704-1.188)
did not show statistically significant changes in 2012 vs.
2011. There was a statistically significant reduction of 1 day
in the median LOS in 2012 compared to 2011, in all patients
and in STEMI patients (median of 5 days [IQR 2,8] in 2011
to 4 days [IQR 2,7] in 2012, p = .001); vulnerable subgroups
were not discharged earlier.
The analyses of the seven vulnerable subgroups showed that
one subgroup, the patients with Killip class 3 or 4 at admis-
sion, had statistically significant worse in-hospital outcomes.
After adjustment for age and gender, the results confirmed
that year of admission had influenced in-hospital mortality in
these patients (OR 1.60, 95% CI 1.06-2.41) and in-hospital
MACCE (OR 0.658, 95% CI 0.439-0.987).
Table 4. Impact of admission year on adherence rate to evidence-based recommendations in AMI patients
Adherence rate to evidence-based recommendations in % (N) 2011 2012 p-value
1. Immediate triple therapy (ASA, P2Y12, AC) 86.6 (1,774) 75.7 (1,875) < .001* 
2. Primary PCI performed: PPCI 73.2 (1,730) 74.8 (1,797)  .402 
3. Evaluation of LVEF 84.2 (1,991) 85.1 (2,043)  .406 
4. DAPT  (ASA, P2Y12) at discharge 93.7 (2,041) 87.0 (2,079) < .001* 
5. Beta-blocker at discharge 74.2 (1,731) 72.1 (1,730)  .096 
6. Statins at discharge 88.9 (2,079) 89.5 (2,149)  .466 
7. ACEI or ARB for LVSD, at discharge 85.7 (654) 85.9 (639)  .923 
8. Cardiac rehabilitation patient referral 43.7 (750) 45.3 (786)  .330 
9. Door-to-balloon time  90 minutes 62.1 (347) 65.3 (416)  .246 
10. Time to reperfusion  12 hours 83.9 (390) 85.2 (459)  .574 
* The differences in the indicators 1 and 4 are due to the introduction of a new antiplatelet drug at the end of 2011. No weighted adjustment was statistically
possible for the 33 hospitals. AMI: acute myocardial infarction; AC :anticoagulant therapies; ACEI angiotensin-converting enzyme inhibitor; ARB angiotensin 
receptor blocker; ASA: aspirin; DAPT: dual antiplatelet therapy; LVEF left ventricular ejection fraction; LVSD: left ventricular systolic dysfunction; P2Y12 
indirect (thienopyridines) and direct P2Y12 inhibitors; PCI: percutaneous coronary intervention 
 
 
 
4. DISCUSSION
The customized use of clinical registry data enabled a clinical
assessment of hospital treatment quality independent from
administrative data and SwissDRGs. Despite the limited
time available for our research before the introduction of the
reform, it was possible to collect prospective data before the
hospital payment changes and to perform a before and after
observational study.
4.1 Comments on the results
The 33 study hospitals were distributed across Switzerland
and represented about 30% of all AMIs.[24] The higher num-
ber of patients with “basic insurance cover only” in 2012
could be a simple consequence of a reclassification of pa-
tients following the new hospital planning. Baseline charac-
teristics in 2011 and 2012 confirmed the absence of relevant
differences in the clinical profile of the two populations in
comparison.
The results showed that the quality of treatment for AMI
patients was maintained overall after the introduction of new
policies and SwissDRGs. However, this finding needs to be
interpreted cautiously. First, it is not clear how the clinical
team has achieved this preservation of quality and whether
this result will hold over time. Additional studies, which
focus on the behavior of healthcare professionals, would be
useful to help interpret these results because both medical and
non-medical staff are key players for implementing evidence-
based recommendations.[25] Moral distress could develop
following challenging or constraining conditions of work.[26]
This is all the more important, as a recent mixed-method
study emphasized the importance of an integrated approach
to quality management.[27] Concerning the reduction of the
LOS, it is recognized that LOS influences substantially total
hospital expenses.[28] Nevertheless, if this result is confirmed
over time, it still has to be interpreted with prudence as a pos-
itive impact because waste may not have been reduced, rather
it could just represent a shift of activities to the ambulatory
sector without any overall cost reduction. The EuroDRG
group, who identified the difficulty to match AMI clinical
patterns with an appropriate DRGs classification for costs
and performance comparison, has already recognized this
issue.[29]
With regard to the subgroup of patients with Killip class 3 or
4 at admission, their worse in-hospital mortality could reflect
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a stochastic variation, but also the emergence of difficulties
for clinical teams to cope with patients demanding extra care
and time under cost constraints. Even an incorrectly per-
ceived loss of quality by clinical teams has been associated
with an increase of patient mortality.[30]
It is interesting to note that the analysis of specific clusters
for vulnerable patients has detected changes that would have
remained invisible in a solely global quality appraisal. It has
already been demonstrated that global health outcomes can
mask differences between groups and in particular for the
ones vulnerable to inequalities.[31] The DRGs system itself
favors a global approach because variations from a standard
case are regarded as outliers to be solved by a continuous
adjustment. Our study shows that health care quality could
be impaired for one vulnerable group. This quality issue is
also implicitly recognized at the European level as payment
incentives for quality are recommended in order to improve
the DRGs system.[32]
4.2 Comments on the study process
The pioneer aspect in Switzerland of this study is explained
by the following factors. First, the absence of a single health
insurance provider as well as the legislation on privacy and
data protection has limited the development of nationally
publicly funded clinical registries. Second, there is as yet
no single center for quality and safety of the Swiss health
care system; the Swiss Federal Council is currently working
on a federal law for such a center. The Swiss Academy of
Medical Sciences has been consulted and has emphasized the
issues of governance and independence as well as the need
for high quality medical registries and measurements.[33]
On a more general point of view, the governance and inde-
pendence of hospital quality evaluation remain important
issues. This applies not only to the Swiss Bismarck model of
hospital care, but also to countries with a Beveridge model
of national healthcare systems, which may have more exten-
sively developed medical databases for quality evaluation
but are also heavily dependent on public funding. An inde-
pendent evaluation of health care quality would support the
learning process regarding clinical practice under cost pres-
sures, and encourage the “bottom-up” involvement of clinical
teams in discussions pertaining to health care policies.
4.3 Limitations
This study has some limitations. First, the main limit came
from the time-limited funding of the project, which did not
permit pursuing the monitoring after 2013. A prolongation
would increase the chance to detect changes in treatment if
they occur. Second, the advantage of ready-to-use secondary
data was counterbalanced by the dependence on the underly-
ing clinical registry’s unalterable structure. Clinical registries
carry a risk of bias through non-consecutive inclusion and
confounding factors. The quality of the data recording, the
need to include consecutive patients, the necessity of long-
term commitment from the participating hospitals and the
conduct of regular audits are key elements of registry use-
fulness. A further limitation came from the impossibility
to introduce in this short time period the collection of con-
traindications to- or patient refusal of- drug treatment, as
well as the collection of controlled high-technology data (for
instance number and type of stents), patient socio-economic
indicators, or satisfaction scales for patients and clinical
teams. These limitations identify how challenging it can be
to involve clinical registries in quality assessment research.
They also indicate directions for improvement such as the
implementation of recommendations to promote the quality
and social value of clinical registries, and the importance to
maintain a good interdisciplinary dialogue for an indepen-
dent evaluation of hospital quality.
4.4 Ethical perspective
The interface between established clinical registries and qual-
ity assessment research projects also raises some ethical
points of consideration.
Firstly, data ownership and funding can become an issue
in the cooperation process, for instance between publicly
founded academic projects and privately funded registries.
Sustainable funding is a real issue for clinical registries, and
fees for data could stimulate fruitful collaboration on health
care quality improvement projects.[34] However, this could
also lead to moral and legal issues of data ownership, which
need to be further explored.
Secondly, data sharing and trust can be difficult to appropri-
ately manage. Secondary analysis of registry data has been
reported to be useful to improve patient care, but the absence
of a centralized shared repository of data is regarded as a
barrier to its development.[35]
Thirdly, confidentiality, consent and patient information are
important points to be discussed. According to the Swiss
law for human research, ethical review committees waived
patient informed consent for most of the registries dealing
with anonymous data.[36] Consequently, patients are usually
not informed of the possible secondary use of their data for
research projects on health care quality and access to care.
This may not be a problem as long as there is a clear benefit
from the research on health care quality. However, an ethical
issue with patient information would emerge more clearly if
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the quality of health care services worsens, or if some groups
of patients are stigmatized because they demand more care
and thus cost more than the average patient. Better infor-
mation to patients could help improve transparency in the
production and use of data and increase patient’s knowledge
and agency. As a result, the production and use of observa-
tional data could strengthen trustful relationships between
health care providers and patients.[37]
5. CONCLUSION
Sharing of observational clinical data allowed the realization
of this before and after study in order to perform an inde-
pendent assessment of the impact of new hospital financial
policies on the quality of hospital treatment. In the first year
following the introduction of the reform, the study showed
a reduction of the LOS for AMI patients, but no significant
modification of the evidence-based treatment delivered to
them. The specific measurements of outcomes in pre-defined
sub-groups of patients identified one group, namely those
with AMI related cardiac insufficiency at admission, who
demonstrated a higher risk of in-hospital complications and
mortality between the before and after phases. These findings
need to be confirmed over a longer period of time, but can
already contribute to the discussion about hospital costs, pro-
fessional practice constraints, quality of healthcare services
and their concomitant evaluation.
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Lessons learnt 
Three main lessons could be learnt: 
No translation into practice of findings that could be of public interest 
There was a tension between physicians relying on medical indicators from clinical registries 
and policy-makers using hospital quality indicators from national statistics. Our study 
findings promoting the necessity to add dedicated measurement for clusters of high-risk 
patients were challenged by the people involved in the implementation of the new reform at 
the final symposium presentation, while by contrast well received at the International Forum 
on Quality & Healthcare. Swiss state representatives did not seem willing to integrate clinical 
teams’ contribution for the evaluation of public policy. 
Restricted data sharing and private governance 
The steering committee members were prudent about sharing data for external projects such 
as our academic one. They considered that it was important to respect the anonymity of the 
participating hospitals to ensure their continuing participation in the registry. They should 
thus exercise a firm control on data access and use and on collaboration with public or private 
partners, as well as decide on authorships for publication and funding. Representatives from 
patient associations, civil communities or public health agencies were not involved in 
governance. 
Patients’ passivity 
As patient data was coded (“pseudo-anonymised”), it was not necessary to obtain consent for 
its use. Thus, it was not possible to learn how patients were informed about their data being 
used or re-used. Patients whom I re-contacted by telephone 3 months and then one year after 
hospital discharge had no apparent recollection of ever having given their consent for the 
follow-up study.75 Neither did they question the fact that I had access to their data. These 
observations raise the joint issues of the quality of patient information, and a possible passive 
trust in medical institutions. 
75 I was asked to re-contact French-speaking patients for the follow-up study, three months and one year after 
their acute myocardial infarction to obtain information on the rates of morbidity, re-hospitalisation and mortality. 
These patients were contacted only if they had signed an informed consent. 
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5. Ethical considerations concerning the inclusion of pregnant
women in clinical registries
Introduction 
The story started in Bigorio (Tessin) at the Swiss Society of Biomedial Ethics (SSBE), when 
Dr Hasselmann shared with me his ethical concerns about the risk of antiepileptic treatment 
in pregnant women. The following commissioned article went through editorial peer review 
and was published in December 2015, in the Swiss journal Epileptologie 32 (4): 188-193.76 
The article promoted the necessity of gathering more patient data to support the therapeutic 
decision for pregnant women suffering from epilepsy. It has been acknowledged that 
generating more data and evidence on the safety profile of drugs in pregnancy improve drug 
acceptance and reduces patients’ distress.77 As pregnancy registries had already identified the 
serious in utero complications following the use of valproate (a very effective drug for 
treating seizure disorders), they could represent a valid alternative to randomized control 
trials, under appropriate ethical governance.  
Three months after the publication, the health scandal about “DepakineTM” broke out in 
France. Drugs containing the chemical entity valproate had been prescribed in pregnant 
women despite the known risks of teratogenicity, child malformations and long-term 
cognitive disorders. In France, 14 322 mothers may have been afflicted. On April 20, 2017, 
the ASNM (French national public agency for the safety of therapeutic products) published a 
report which estimated that during the period 1967-2016 between 2150 and 4100 congenital 
malformations could be the result of valproate use in pregnancy, i.e. an incidence 2 to 4 times 
higher than usual.78 The information came from the cross-linkage of datasets from the social 
security with datasets on congenital malformations, but was limited by the absence of 
specific registries. Moreover, no precise data on the rate of miscarriage or number of children 
with long-term cognitive disorders was available. 
The article: 
76 http://www.epi.ch/_files/Artikel_Epileptologie/Dorey_4_15.pdf 
77 Wild, V., Biller-Andorno, N. 2016. Pregnant women’s view about participation in clinical research. In Clinical 
Research Involving Pregnant Women. Bayls, F., Ballantine, A. eds. Basel: Springer, pp.119-136. 
78 ASNM. Agence Nationale de Sécurité du Médicament et des Produits de Santé.  Exposition in utero à l'acide 
valproïque et aux autres traitements de l'épilepsie et des troubles bipolaires et risque de malformations 
congénitales majeures (MCM) en France - Synthèse (20/04/2017). And former 2016 reports on the ASNM 
website.  http://ansm.sante.fr/Dossiers/Valproate-et-derives/Valproate-et-derives/(offset)/0.   
Accessed 29 April 2017. 
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Ethical Considerations Concerning the Inclusion of Women with Epilepsy 
in Pregnancy Registries
Summary
Pregnancy registries are essential sources to gain 
medical and therapeutic knowledge in women with ep-
ilepsy who are pregnant or have the desire to give birth. 
The benefit of treatment for the mother has to be bal-
anced with the prenatal and postnatal risk for the child. 
To gain reasonable medical evidence, pregnancy regis-
tries have to include an adequate and representative 
number of pregnant women with epilepsy. They will 
have to observe women during pregnancy and delivery, 
as well as the foetus respectively the child during its 
development. In addition, different health care provid-
ers have to coordinate their efforts, sharing data while 
preserving the mother privacy interests. Given these 
requirements, the multitude of antiepileptic drugs, and 
the poor knowledge concerning the important impli-
cations of the adopted therapy by potential mothers 
with epilepsy, the rate of patient inclusion in pregnancy 
registries is still insufficient to provide reliable recom-
mendations for an appropriate medical management. 
An ethical approach as outlined here aims to overcome 
some of these obstacles.
Epileptologie 2015; 32: 188 – 193
Keywords: Pregnancy, epilepsy, antiepileptic drugs, preg-
nancy registries, ethics
Considérations éthiques en lien avec l’inclusion 
de femmes épileptiques dans des registres de 
grossesse
Les registres de grossesse sont des sources essen-
tielles de connaissances médicales et thérapeutiques 
chez les femmes épileptiques enceintes ou désirant 
donner naissance. Le bénéfice du traitement pour la 
mère doit être mis en balance avec le risque pré- et 
postnatal pour l’enfant. Pour obtenir une preuve médi-
cale raisonnable, les registres de grossesse doivent in-
clure un nombre adapté et représentatif de femmes en-
ceintes souffrant d’épilepsie. Ces femmes devront être 
suivies pendant leur grossesse et leur accouchement, 
et le fœtus, puis l’enfant, dans son développement. De 
plus, différents prestataires de soins de santé devront 
Corine Mouton Dorey
Institute of Biomedical Ethics and History of Medicine
University of Zurich
coordonner leurs efforts et partager des données tout 
en préservant la vie privée de la mère. Face à de telles 
exigences, à la grande variété de médicaments antiépi-
leptiques et au manque de connaissances sur ce qu’im-
plique le traitement adopté par les mères potentielles 
souffrant d’épilepsie, le taux de patientes incluses dans 
les registres est encore insuffisant pour fournir des re-
commandations fiables pour une prise en charge médi-
cale adaptée. Une approche éthique, telle qu’exposée 
ici, vise à surmonter certains de ces obstacles.
Mots clés :  Grossesse, épilepsie, médicaments antiépi-
leptiques, registres de grossesse, éthique
Ethische Überlegungen zum Einschluss von 
Frauen mit Epilepsie in Schwangerschaftsregister
Schwangerschaftsregister sind unverzichtbare 
Quellen zum medizinischen und therapeutischen 
Wissen bei schwangeren Epilepsie-Patientinnen oder 
epilepsiekranken Frauen mit Kinderwunsch, wenn es 
darum geht, den Nutzen einer Behandlung für die Mut-
ter gegen die prä- und postnatalen Risiken für das Kind 
abzuwägen. Für stichhaltige medizinische Evidenz be-
darf es einer ausreichenden Zahl an Schwangeren mit 
Epilepsie in den Schwangerschaftsregistern. Erfasst 
werden müssen Daten zum Schwangerschaftsverlauf 
und zur Geburt bei diesen Frauen sowie zur Entwick-
lung des Fetus bzw. des Kindes. Ferner müssen unter-
schiedliche medizinische Leistungserbringer ihre An-
strengungen koordinieren und entsprechende Daten 
unter gleichzeitiger Wahrung der Datenschutzinteres-
sen der Mutter zur Verfügung stellen. Angesichts dieser 
Anforderungen, der Vielzahl an Antiepileptika und des 
spärlichen Wissens um die bedeutenden Auswirkungen 
der jeweiligen Therapie auf potenzielle epilepsiekranke 
Mütter ist die Zahl der in Schwangerschaftsregister 
eingeschlossenen Patientinnen noch nicht ausreichend 
gross, um zuverlässige Empfehlungen bezüglich des 
angemessenen medizinischen Managements aus-
sprechen zu können. Ein ethischer Ansatz in dem hier 
aufgezeigten Sinne dient dazu, einen Teil dieser Hin-
dernisse zu überwinden.
Schlüsselwörter:  Schwangerschaft, Epilepsie, Antiepi-

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leptika, Schwangerschaftsregister, Ethik
Introduction
Epilepsy and pregnancy could have a combined del-
eterious effect on one another: pregnancy can worsen 
the evolution of the epilepsy, and epilepsy and antie-
pileptic drugs (AED) can complicate the normal course 
of pregnancy and the in-utero foetal development with 
immediate or more long-term complications for the ex-
pected child. Pregnancy registries represent the most 
utilized research method to better understand and 
prevent possible harm to the mother and the foetus. 
The physical risks of participating in these clinical reg-
istries is considered minimal and the possibility to gain 
knowledge about the underlying disease and the safety 
of different AEDs is very important for the foetus and 
child, and for future pregnancies for all women shar-
ing the same conditions. Yet, the inclusion of pregnant 
women in pregnancy registries as well as the necessary 
long-term follow-up is difficult to achieve, and as a re-
sult pregnancy registries may not provide the neces-
sary results to advise and appropriately treat pregnant 
women with epilepsy. To improve this situation, it is 
important to understand the ethical issues governing 
the participation of pregnant women with epilepsy in 
pregnancy registries.
1. Pregnancy and epilepsy: in search of more me-
dical evidence
Epilepsy is a disorder that might lead to a more 
complicated course of pregnancy. Pregnancy can lead 
to an increase in the number of seizures compared to 
the pre-pregnancy period, irrespective of any treat-
ment modifications [1]. Seizures themselves can affect 
the foetus and the delivery [2]. About 3 to 5 births per 
1000 are from women with epilepsy. Additionally there 
are women whose first seizure occurs during pregnan-
cy without a prior diagnosis of epilepsy. There is thus 
a great need to train health care providers to appro-
priately care for these women during their pregnancy 
[3]. For the mother, the foetus and the child, epilepsy 
is indeed a major challenge to be addressed during 
pregnancy as well as during the neonatal and postnatal 
periods. In 2008, a first statement on health outcomes 
of AED use in pregnant women established guidelines 
to address the risk of teratogenicity and major con-
genital malformations as well as minor malformations 
and long-term cognitive disorders. At this time, a lack 
of medical evidence was already pointed out regarding 
the underlying mechanisms leading to pathology and 
the variant findings across different AEDs or combina-
tions of AEDs [4]. A recent systematic review and meta-
analysis confirmed that pregnant women with epilepsy, 
compared to pregnant women without epilepsy, have a 
small but significantly higher risk of complications of 
spontaneous miscarriage, antepartum haemorrhage, 
post-partum haemorrhage, hypertensive disorders, 
preterm induction of labour, increased caesarean sec-
tion, preterm birth and foetal growth restriction [5]. 
The authors show that most of these complications are 
found in women taking antiepileptic drugs. This review 
took into account observational studies published be-
tween 1990 and 2015, with old and new AEDs. Meador, 
commenting on this meta-analysis, has reiterated that 
knowledge about pregnancy outcomes and adverse 
outcomes in neonates and children exposed in utero to 
AEDs is still insufficient [4]. André et al. have also iden-
tified the need for more monitoring data as well as ran-
domized controlled studies on newer AEDs [6].
The main limitation for gathering more medical evi-
dence in order to better manage pregnant women with 
epilepsy lies in the difficulty to include pregnant wom-
en in clinical research. 
2. Pregnant women and clinical research
Pregnant women are legally considered as “vulner-
able persons” for interventional and pharmacologic 
research concerning AED. This classification was made 
not primarily because of the risk of the research for the 
women themselves, but due to the risk for the embryo 
respectively the foetus (after 9 weeks of pregnancy) 
and its future development in the neonatal and child-
hood periods. The interests of the mother and the foe-
tus are obviously closely related, but they could also 
be in opposition when the necessary treatment of the 
mother might be harmful for the foetus. The whole sit-
uation becomes even more complex because regulatory 
organs, such as the FDA, EMEA or Swissmedic don’t re-
quire interventional clinical research in pregnant wom-
en or children at the time of a new drug approval. They 
will ask for complementary monitoring after the drug 
is approved and marketed. The situation resembles an 
off-label prescription of AED in a pregnant woman with 
a moral legitimacy higher than pre-approval interven-
tional research, which could have established the safe-
ty profile of the AED in the first place. Some research-
ers have tried to justify a more invasive approach by 
advocating that the foetus is a patient holding rights 
of a person. Their aim was to help the ethical review 
committee supporting a research that could benefit 
the foetus with limited infringement of the mother’s 
autonomy [7]. In countries like Switzerland, this ap-
proach is difficult to follow, as the foetus is not legally 
considered a person. In the USA, the National Institute 
of Health (NIH) has proposed to encourage the devel-
opment of clinical research in pregnant women and the 
acquisition of medical evidence for their treatment. The 
NIH recommendations included 3 major points: identi-
fying specific areas in which clinical research is press-
ing, supporting ethical committees to accept more 
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widely research in pregnant women, and reclassifying 
pregnant women from “vulnerable patients” to a mere 
scientifically “complex population” [8]. In order to bet-
ter understand the barriers to perinatal research and 
randomized controlled research in pregnant women, 
Brandon et al. have conducted a qualitative research 
with investigators and members of ethical commit-
tees in the field of mental health in pregnant mothers. 
They identified four issues that are equally relevant to 
epilepsy and pregnancy: i) the difficulty of identifying 
a control group with placebo or reference treatment; 
ii) the safety concerns for the mother at risk of under-
treatment, for the foetus concerning congenital and
teratogen risks, for the child concerning its cognitive
development; iii) the demanding process of inclusion
of participants and the conceptual difference between
clinical care and clinical research; iv) the possible re-
striction of the autonomy of pregnant women due to
their possible low level of comprehension, the consid-
eration of the relationship between the father and the
foetus/child, and the risk of breaches in confidentiality
due to the involvement of numerous research stake-
holders [9]. Randomised clinical research with preg-
nant women would be better accepted in the absence
of off-label treatment. Yet, in epilepsy and pregnancy,
the main research concerns just such off-label research
looking for the effects of AEDs on mothers, foetuses
and children. Acquiring strong medical evidence in
pregnancy and epilepsy is for these reasons difficult,
and until today medical research has relied upon obser-
vational studies and clinical registries. These pregnancy
registries can moreover help facilitate the design of
possible future randomised controlled studies.
3. Pregnancy registries
Pregnancy registries have been widely used to learn
about pregnant women with epilepsy treated with 
AEDs. The UK Epilepsy and Pregnancy Register, for ex-
ample, enabled the identification of the increased risk 
of major congenital malformations under a combi-
nation therapy or a therapy with valproate [10]. The 
Florida Medicaid registry showed that these types of 
results could be translated into practice, as the use of 
valproate decreased significantly favouring second-
generation AEDs [11]. Nevertheless, registries have 
their limitations. Their target population is not always 
well defined and the findings may not be generalizable. 
Information on exposure to AED may be only partial or 
inaccurate, outcomes data can be incomplete as spon-
taneous abortions or stillbirths might not be reported. 
Other registries such as the National Swedish Medical 
Birth Registry, or the European registration of congeni-
tal abnormalities and twins (EUROCAT) may provide 
information that could help identify complications due 
to the in-utero exposure of AED, but these registries do 
not provide the basis to assure the best management 
of pregnant women with epilepsy [12].
The Agency for Healthcare Research and Quality 
(AHRQ) published in their user guide for clinical reg-
istries a special chapter on pregnancy registries (pp. 
135-169). This guide identifies the variables commonly
collected and the issues to consider for interpreting the
results of these registries [13]. Stating that pregnancy
registries are different from other clinical registries, the
guide requires that women be enrolled prospectively,
a meaningful control group established, sufficient sta-
tistical power achieved, and that accurate data on drug
exposure be collected. Additionally, to measure repro-
ducible outcomes in pre-and postnatal periods, differ-
ent sources of information from various health care
providers are required.
The AHRQ’s definition of pregnancy registries 
(“Pregnancy registries are prospective observational 
studies specifically designed to collect clinically relevant 
data and provide information for treating or counsel-
ling not only women who are pregnant but also women 
of childbearing potential”) concerns both pregnancy 
registries that collect data on epilepsy treatment, and 
pregnancy exposure registries required for the post-
marketing safety studies of new AEDs. Post-marketing 
registries are not randomised and may harbour limita-
tions when a pharmaceutical company, only interest-
ed in its own product, is funding them. Therefore it is 
important to identify the different types of pregnancy 
registries i.e. national registries, independent academic 
registries or pharmaceutical company registries, and to 
better understand their purpose, modes of enrolment, 
types of measured outcomes or possible control groups 
and duration of follow-up. 
The epilepsy Therapy Development Project Work 
Group on Teratogenicity has reviewed pregnancy reg-
istries and methodological aspects [14]. To avoid bias 
and confounding factors, they recommend that all eli-
gible women be included prospectively and that the 
included women should accept to provide all informa-
tion necessary for profiling the risks of complicated 
pregnancy or foetal problems. Ideally, the participating 
women would contribute to the regular monitoring of 
AED exposure concerning the type of drug, dose, and 
blood levels. In addition, they would be asked to accept 
to be part of the post-partum follow-up questionnaire, 
including measurements of pre-defined possible out-
comes for the neonate and the child. 
These requirements may however be too demand-
ing for women from the control group who will have to 
balance the burdens of the study with a possible con-
tribution to a common good of research. Additionally, 
the findings of early malformations or late cognitive 
disorders will depend upon the length of child observa-
tion, the longer the observational period, the higher the 
possibility to identify these disorders. The assessment 
of these outcomes thus depends heavily on the rate of 
women and children lost to follow-up in the registry. 
To sum up, the inclusion of epileptic women in preg-

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nancy registries requires quite constraining demands 
from the participants in order for the registry to be 
scientifically valid. These conditions may dissuade the 
pregnant women to consent to participate in the preg-
nancy registry and finally make the registry futile. As 
a result, and in order to gain the necessary knowledge 
for the management of pregnant women with epilepsy, 
ethical issues have to be further explored about the de-
cision process to create and run pregnancy registries in 
women with epilepsy. 
4. Ethical considerations for developing pregnan-
cy registries
The aim of clinical registries in pregnancy and epi-
lepsy is not only to gain scientific knowledge and safety 
data on the use of AED, but also to provide counselling 
and support to epileptic women who are pregnant or 
are considering pregnancy. The previous section shows 
that creating and managing pregnancy registries is a 
complex process. The main issues concern the identifi-
cation of the most appropriate population with epilep-
sy to be included in pregnancy registries, the informa-
tion provided to the selected women, and the respon-
sibility of the participating health care providers in the 
management and communication of the results from 
these registries. 
In contrast to the potential heavy burden of par-
ticipating in pregnancy registries, the direct benefits 
for the mothers included in the registry are relatively 
small. They can expect better information and follow-
up care of their epilepsy during this and future preg-
nancies. The foetus being exposed to possible maternal 
seizure and AED will have no direct benefit, with the 
exception of a possible long-term follow up after birth, 
which could detect and possibly mitigate minor malfor-
mations and cognitive disorders. Yet, few studies have 
followed the children beyond 6 years, and it is still un-
certain as to whether negative effects on IQ might be 
reversible [15]. Other pregnant women with the same 
kind of epilepsy as well as their foetus may benefit 
from the findings, if the clinical registries are scientifi-
cally valid and powered statistically, and if the pregnant 
mothers are exposed to the same type and dosage of 
AED. All these requirements for generalizable and use-
ful clinical registries are still burdened with a high level 
of uncertainty in terms of measured outcomes and 
scientific validity. This makes it difficult to include and 
keep women in the registry. 
French et al. have reviewed the ethical issues gov-
erning participation in clinical registries and dissemina-
tion of their findings [16]. As pregnancy registries aim 
to generalize knowledge, their design and conduct de-
pends upon the legal requirements of research on hu-
man subjects, and informed consent from participants 
is necessary. However, there are circumstances in which 
regulatory institutions recognize that AED side effects 
can be reported directly by health care providers in a 
voluntary or even in a mandatory way. The manage-
ment of pregnancy registries has to balance moral obli-
gations towards respecting the autonomy of the moth-
er and her informed consent with the public health 
interest to have safe AEDs. As pregnancy registries do 
not offer the same strength of medical evidence as ran-
domized controlled clinical trials, the public regulatory 
institutions should communicate rather cautiously. 
They usually have to consider a bundle of factors for 
labelling AED in pregnancy, based on the number and 
seriousness of events reported, the evaluation of a pos-
sible causality following the intake of AEDs, and the 
balance of maternal benefit versus foetal risks. There-
fore, the medical and research epilepsy communities 
are responsible for creating the best possible quality 
pregnancy registries, including the appropriate women 
with epilepsy to gain valid scientific information. 
In addition to the well established requirements 
of good clinical practice and legal obligations, Table 1 
proposes an ethical approach to guide the conduct for 
pregnancy registries, which identifies the balance of 
powers between mother, other members of the family, 
healthcare providers and public or private institutions. 
The main values are related to autonomy, privacy, 
trust, common good and justice. Additionally, the con-
cept of agency strengthens the importance of knowl-
edge and information in order for the women to exer-
cise their autonomy and for the health care profession-
als to act in a responsible way. Agency is considered as 
the freedom to achieve whatever the individual, as a 
responsible being, decides to achieve [17].
Education and information are crucial at all levels: i) 
for women with epilepsy in order for them to consent 
to participate in the pregnancy registry and to accept a 
long-term follow-up; ii) for the partner to support the 
mother’s commitment to the registry and the child’s 
medical and psychological follow-up; iii) for the differ-
ent health care providers to share data and coordinate 
the care in a transparent and confidential way; iv) for 
public health administrators publishing guidelines to 
assure the protection of women and foetus even if they 
go against commercial interests. 
Awareness and knowledge of the impact of epilepsy 
and AED on pregnancy have been assessed in women 
with epilepsy. Their knowledge was found to be insuf-
ficient [18]. There is a clear demand for more informa-
tion, especially in women aged less than 35 years [19]. 
A qualitative approach with focus groups identified this 
need for information particularly as most of the wom-
en concerned had an unintended pregnancy [20]. These 
findings emphasize the importance to develop precon-
ception counselling for women with epilepsy and their 
partners, and to foster shared decision-making [21].
Health care professionals are not only account-
able for informing women and their partners, but they 
should also work in a coordinated network to guaran-
tee the confidentiality of the registry data, the informa-

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tion given for the benefit of the mother, and to safe-
guard the scientific value of the registry. The registry 
steering committee should moreover behave with pru-
dence in the interpretation and dissemination of the 
registry results. Furthermore, transparency and trust 
between participants should be maintained during the 
lifespan of the registry, and facilitate the inclusion and 
retention of the highest possible number of mothers 
and children. 
In addition to the necessary defence of the com-
mon good of managing future pregnancies in women 
with epilepsy and gaining knowledge about the safety 
profiles of AEDs, public institutions should respect jus-
tice and support social acceptance of the unpredictable 
future of mothers with epilepsy, their foetus and their 
child. Justice can be seen as the main argument for sup-
porting inclusion of women in the registry, if they expe-
rience the support of the community and feel encour-
aged to reciprocally contribute to pregnancy registries. 
Conclusion
This brief review on epilepsy and pregnancy has 
identified the difficulty of appropriately balancing the 
benefit of the epilepsy treatment for pregnant wom-
en, whilst at the same time protecting the foetus and 
preserving a normal development for the new-born. 
Clinical research is difficult to undertake with pregnant 
women, who will typically be considered as “vulnerable 
subjects”. Pregnancy registries offer a good observa-
tional research alternative, as long as they not only fol-
Table 1:  Ethical considerations for the inclusion of women with epilepsy in pregnancy registries.
Cluster of data to be collected 
during the lifespan of the preg-
nancy registry
Persons con-
cerned in 
first place
Health care providers 
involved
Issues for inclusion Ethical 
concepts
Epilepsy disease and pregnan-
cy: history, former pregnancies, 
comorbidities, evolution during 
pregnancy, complications of 
pregnancy or epilepsy
Mother GP
Neurologist
Obstetrician
Mid-wife
Consent: Mother Information 
Confidentiality
Data sharing
Coordination
Autonomy
Privacy
Trust
Exposure to AED: 
Nature, modification (type or 
dosage), compliance, combina-
tion, other treatment non-AED 
(e.g. folic acid)
Mother GP
Neurologist
Obstetrician
Biologist (laboratories)
Consent: Mother Information 
Coordination
Public health interests
Private (Pharma) interests
Autonomy
Common good
Trustworthiness
Transparency
Conflict of 
interests
Foetus: development, death, 
major malformations, minor 
malformations
(Foetus)
(Mother/
Parents)
Obstetrician
Paediatrician
(Radiologist/images)
Parent Information
Data sharing
Confidentiality
Linkage to birth registries
Dissemination of results 
Compensation of side eﬀects
Agency / ac-
countability
Justice
Child: malformations, cognitive 
disorders, other disorders
Child 
(Parents, 
Family)
GP
Paediatrician
Psychologist
School teacher
Parent Information and consent 
to follow-up
Coordination
Access to data
Dissemination of results 
Compensation of side eﬀects
Autonomy
Agency / ac-
countability
Privacy
Justice
All Mother 
and future 
mothers 
with similar 
conditions
Registry administrator
Steering committee 
(governance)
Confidentiality
Transparency
Scientific validity
Data access
Feedback to health care provi-
ders and regulators
Funding
Conflict of interest
Publication of results
Trustworthiness
Prudence
Accountability
Conflict of 
interests
Justice
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low good clinical practice and legal obligations, but also 
include the appropriate population for a long enough 
period. This paper proposes ethical considerations able 
to guide the inclusion of women with epilepsy in preg-
nancy registries. This approach aims to strengthen the 
respect for patients’ autonomy and privacy, and pro-
motes the common good of future pregnant patients 
and the foetus. In practice, patients’ agency and health-
care professionals’ accountability should be developed 
further. This can be achieved firstly through the educa-
tion of women with epilepsy, secondly through shar-
ing information in a transparent and confidential way 
within a coordinated network of healthcare providers. 
Finally, this will also require just institutions able to re-
act quickly, disseminate findings with prudence and as-
sure social protection in case of deleterious effects of 
antiepileptic treatment for the mother or foetus.
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Lessons learnt  
The three following lessons were learnt: 
Sharing patient data for public interest 
The benefits of sharing patient data are twofold: i) sharing amongst all healthcare providers 
optimizes clinical management of epileptic mothers of childbearing age, and ii) sharing 
patient data for research purposes benefits future mothers. More data is necessary not only for 
valproate, but also for all new chemical entities used against epilepsy. Clinical registries are 
essential sources of patient data, but it is difficult to fund registries to share data comparing 
several antiepileptic drugs as pharmaceutical companies target research funds at their own 
products, avoiding head to head comparisons. This raises the additional issue of 
accountability for public interest. Moreover, mothers of childbearing age and families are 
mobile, and sometimes patients want to escape from the burden of epilepsy or bipolar 
disease, thus making long-term observation a challenge. A national registry should be 
trustfully governed for the long-term with the active participation of patients and families, 
and incorporate follow-up for children. Public intervention is again justified. 
Difficulties translating patient interest into practice  
Ethical considerations should facilitate pregnancy registries, ensuring the application of the 
non-maleficence and precautionary principles, and the respect of human rights for medical 
care and scientific progress. This implies the public health duty to effectively gather and 
disseminate all relevant information. The  “DepakineTM” case exemplifies the failure of 
public agencies regarding scientific findings and the ethical recommendations for collecting 
patient data as suggested in the publication. The absence of appropriate patient datasets 
delayed the speed of reaction of the government and the pharmaceutical company involved. 
This has reinforced the feeling of distrust amongst patients, and led to conflicts between the 
different stakeholders.  
Difficulties protecting patient rights  
The rights of pregnant women are complicated by concerns for the health of their foetus. 
National legislation does not usually recognize the foetus as a right-bearer, but the mothers 
may (and the fathers as well). Policy-makers should protect these women with better 
education, information and support. Healthcare providers are also obligation-bearers towards 
mothers and their families. They should keep their own knowledge up to date, inform patients 
and their families, and share patient data in a confidential, coordinated healthcare network. 
Appropriate governance should support these efforts.  
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6. Conclusion
These two case studies identified justified reasons for public interest, but this public interest 
was not translated into practice and vulnerable populations were worse off. Moreover, public 
health authorities did not appear willing or able to improve the level of implementation. 
Privacy rights were not discussed in the first place, and in the cardiology case patients were 
passive about possible issues with information, consent and governance. In the case of 
pregnant mothers, issues related to the seriousness of drug adverse effects on foetus and 
child, and to the negligence of public agencies were masking privacy issues. In both cases, 
patient rights to have access to appropriate information, to exercise autonomy and to act 
accordingly were disregarded and not adequately documented. Justified reasons for public 
interest could have been hindered because of competing political, economical, and 
commercial interests. As a result, it was difficult to balance public interest and patient rights 
as they were not in a competitive situation, but both were nevertheless undermined.  
Clarification of rights and interests would necessitate adjusting the ethical governance for 
patient data. Healthcare professionals, health administrators and policy-makers are in a 
central position for ascertaining public interest over private ones, for ensuring and enhancing 
patient rights, and for creating and using clinical registries to provide more empirical 
evidence to improve their work. It is therefore worthwhile examining their experience and 
ethical awareness regarding patient data. That is the aim of the next part of this report. 
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PART III. QUALITATIVE APPROACH 
In the introduction, the need to balance expected public interest with a morally acceptable 
overriding of patient rights was acknowledged in order to keep pace with the fast 
technological development of large patient data sets. Nevertheless, the study of the former 
cases indicates that an inappropriate governance of patient data could undermine the quality 
and safety of patients’ treatment, impact the fair evaluation of healthcare policies, and neglect 
patient rights. The attribute “inappropriate” is used broadly, as knowledge about the 
healthcare stakeholders’ awareness of these possible ethical issues with governance is 
lacking. 
I used qualitative research to ascertain how the stakeholders perceived the ethical issues, and 
how these issues could affect their roles and responsibilities regarding patients and their data. 
Qualitative methods are well suited to contextual research, describing the situation as 
participants experience it, testing their understanding of a situation or a phenomenon, and 
analyzing opinions. Although it does not aim at representativeness and generalisability of the 
findings, qualitative research provides an in-depth understanding underlying how people 
think and act according to a given situation or phenomenon. The methodology is codified and 
it requires all steps to be documented. Such an approach facilitates the exploitation of new 
insights into the ethical management of patient data and makes the acquired knowledge 
transferable.  
7. Patient data in the patient’s voice? A qualitative study on Swiss
healthcare stakeholders and patient data
On behalf of my two co-authors, Dr. Holger Baumann who has contributed to the analysis 
and reviewed the paper, and Prof. Nikola Biller-Andorno who has contributed to the study 
design and reviewed the paper, I submitted a formatted version of the following article to the 
peer-reviewed journal BMC Medical Ethics (BioMed Central) on April 21st, 2017. 
The submitted manuscript: 
Patient data in the patient’s voice? 
A qualitative study on Swiss healthcare stakeholders and patient data. 
Corine Mouton Dorey, Holger Baumann, Nikola Biller-Andorno  
ABSTRACT  
Background 
There is a growing interest in aggregating more biomedical and patient data into large health data sets 
for research and public benefits. However, collecting and processing patient data raises new ethical 
issues regarding patient’s rights, social justice and trust in public institutions. The aim of this empirical 
study is to gain an in-depth understanding of the awareness of possible ethical risks and related moral 
obligations among those who are involved in projects using patient data, i.e. healthcare professionals, 
regulators and policy makers. 
Methods 
We used a qualitative design to examine Swiss healthcare stakeholders’ experiences and perceptions 
of ethical challenges with regard to patient data in real-life settings where clinical registries are 
sponsored, created and/or used. A semi-structured interview was carried out with 22 participants (11 
physicians, 7 policy-makers, 4 ethical committee members) between July 2014 and January 2015.  The 
interviews were audio-recorded, transcribed, coded and analysed using a thematic method derived 
from Grounded Theory.  
Results 
All interviewees were concerned as a matter of priority with the needs of legal and operating 
norms for the collection and use of data, whereas less interest was shown in issues regarding patient 
agency, the need for reciprocity, and shared governance in the management and use of clinical 
registries’ patient data. This observed asymmetry highlights a possible tension between public 
and research interests on the one hand, and the recognition of patients’ rights and citizens’ 
involvement on the other. 
Conclusions 
The advocation of further health-related data sharing on the grounds of research and public interests, 
without due regard for the perspective of patients and donors, could run the risk of fostering distrust 
towards healthcare data collections. Ultimately, this could diminish the expected social benefits. 
Interests in patient data should not stand in for the patient’s voice. On a normative level, this study 
thus provides material from which to develop further ethical reflection towards a more integrative 
approach involving patients and citizens in the governance of their health-related big data. 
KEY WORDS 
Agency. Ethics. Healthcare stakeholders. Justice. Patient data. Patient rights. Reciprocity. Clinical 
registries. 
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INTRODUCTION 
Patients’ healthcare data is used by a range of stakeholders, for a variety of different purposes, and this 
picture is rapidly changing. Greater digital integration of large health datasets is advocated for its 
benefits to clinical research and healthcare practice, blurring the distinction between research activities 
and medical care. [1] The expected social benefits are estimated to be considerable, especially with 
genomics and precision medicine aiming at more targeted and safer treatment for patients. 
Consequently, new approaches to informed consent are being examined, to facilitate the collection and 
use of routine patient data into big health data networks. Indeed, it is unrealistic to obtain informed 
consent for secondary uses of patient data, when the purposes of such uses are not known at the time 
of data collection. [2] As a result, patients’ rights to be informed and to give consent before their data 
is shared may not be respected, infringing upon the fundamental human right to privacy. Moreover, 
many patients are unaware of possible conflicts of interests regarding data sharing, including for 
commercial purposes. It seems that existing protective laws and ethical arguments do not fully address 
these new challenges that are developing, especially with regard to possible conflicts between patient 
rights and public interests. [3] 
Traditionally, clinicians have been responsible for protecting patient privacy, with their moral 
obligations stemming from deontological rules and trust agreements. However, nowadays the 
management of patient data involves a more diversified population of health-related stakeholders, 
such as experts in digital technology, genomics, and cost-effectiveness measurements. The healthcare 
system is becoming more business-like, required to continuously improve medical practices and 
learning, whilst remaining economically sustainable, through cost-effective service delivery. [4] 
Besides this, insufficient anticipation of the potential for attacks on patient rights, with the rapid 
development of large patient data sets, could have serious repercussions for patient privacy, as well as 
social group protection and trust in physicians and public institutions. [5] I t  thus seems necessary to 
better understand the ethical awareness of healthcare stakeholders ( HCS) who contribute to the 
establishment of large patient data sets. To this end, we have chosen to investigate empirically HCSs’ 
experiences and ethical consciousness, with regard to patient data, in the setting of clinical registries in 
Switzerland. 
Clinical registries (CRG) are a good proxy for large patient data sets. They use observational methods 
to gather patient data in order to assess medical outcomes and processes at population levels. [6] They 
cover a large healthcare domain, extending from clinical quality improvement, safety monitoring and 
cohort studies, to clinical research and policy evaluation, and they are confronted with similar digital 
changes and challenges as those of the wider field of patient healthcare data. There is growing concern 
for patient rights, as it could be possible to re-identify specific individuals, when CRGs built with de-
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identified or anonymised data are linked, or include genetic information. There is also concern that 
aggregated information could stigmatize and harm some groups of patients and citizens, because of 
their disease, lifestyle or extra healthcare costs. HCSs should therefore be aware of their moral 
obligations when they decide that a clinical registry is necessary and when they decide to contribute to 
it. 
Switzerland is a country with robust privacy rights written in its Constitution “Everyone has the right 
to be protected against the misuse of their personal data”. [7] Healthcare data are considered as 
sensitive personal data. To collect and use them, it is necessary either to have a legal basis, to 
demonstrate a dominating public interest, to have informed consent, or to have anonymous or coded 
data. [8] In comparison to other countries such as the United Kingdom, Australia, Sweden or 
Denmark, CRGs are not extensively developed in Switzerland. [9] However, this is changing. The 
Health2020 report promotes integrated management, cost-savings and better data for the health 
system. [10] Therefore, initiatives in favour of e - health, database linkage and national data sharing 
are facilitating the collection and use of routine patient data, and consequently the development of 
CRGs. However, to date, there is no empirical data on HCSs real-life experiences of CRGs. 
This paper reports a qualitative study designed to investigate Swiss HCSs’ ethical awareness regarding 
the management of patient data in real-life settings where CRG are decided, created, managed and 
used. The main finding is the emergence of a possible tension between public interest and patient 
rights due to the HCS’ asymmetrical awareness of ethical issues. The study helps to understand and 
explain the factors at the root of this tension. It thereby motivates further normative reflections on the 
ethical approach that is taken for building large patient data sets, i.e. an approach that emphasizes a 
fair distribution of benefits and burdens amongst all stakeholders, patients and citizens included.  
METHODS 
A thematic analysis, derived from Grounded Theory, and using semi-structured interviews, was 
selected to explore HCSs’ individual experience and reflections. [11] The cantonal research ethics 
committee declared the study to bear no ethical risk (KEK-StV-Nr. 42/14). Participant information 
sheets were sent in advance by email to all possible interviewees. At the beginning of the interviews, 
consent forms and confidentiality agreements were explained, signed and exchanged.  
In order to have a wide diversity of roles and experiences, a purposive sampling frame selected three 
targeted groups of HCSs:  
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- Group (M) comprises physicians involved in “Making” CRGs. Including two sub-groups,
frontline physicians collecting data (M’) and data centre managers (M’’);
- Group (R) includes people “Reviewing” CRG protocols in research ethical committees;
- Group (A) includes people “Asking” for CRGs i.e. sponsors, regulators and policy-makers who
require, fund or control the creation of CRGs.
The study sample did not include CRG patients, as their identities were anonymised or coded, i.e. not 
accessible. Thus, the abbreviation HCS used for respondents does not include patients. Recruitment 
was based on the information provided by the Swiss Medical Association “FMH” platform for CRGs 
[12], through the first author’s direct contacts and by snowballing. Sample size was determined by 
data saturation, i.e. the point at which additional data fails to generate new information. A range of 15 
to 25 interviews was foreseen, with group M expected to be the largest group, as its members are the 
closest to patients. 
Documents to participants were produced in 3 languages: French, English and German. The 
participant information sheet included a definition of clinical registries based on the U.S. Agency for 
Healthcare Research and Quality (AHRQ) document. At the time of the interview, this definition was 
read and the interviewees were asked to fill in a matrix, based on the AHRQ definition, to identify 
their own CRG experience [see Additional file 1]. 
The interview topic guide was developed with the help of an ad-hoc literature review identifying an 
initial framework of possible ethical issues to be raised by CRG stakeholders [see Additional file 2]. 
The topic guide included three items: 
- Participants’ personal experience of CRG. Assessed with open-ended questions;
- General CRG issues. Interviewees were encouraged to think aloud. Prompt cards were used to
highlight potential ethical issues and blank cards were used to record other emerging issues;
- Possible recommendations for future CRGs.
The topic guide was reviewed by external experts in qualitative research and epidemiology, and tested
with native-speakers of the three languages. An additional file shows an example of the topic guide
used for group M [see Additional file 3]. For groups R and A, the first item was slightly modified, so
as to be more appropriate to these participants’ roles and experiences. To ensure a relaxed and trusting
atmosphere, a methodology of face-to-face interviews, at the interviewees’ location, was chosen.
Interview proceedings were recorded in a qualitative research journal.
Interviews were conducted by one of the authors (CMD), who is trained in qualitative methods. 
Interviews took place between July 2014 and January 2015, and were conducted in English, French 
and German. Thirty candidates were contacted, 22 accepted to participate. Reasons provided by those 
who declined participation included lack of time (n=5) and a lack of experience with clinical registries 
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(n=3 who then provided the name of a more appropriate candidate). Saturation was recognised after 
the first 15 interviews, however the study continued as 4 more interviews had already been planned. 
To confirm saturation, three more interviewees, from fields outside of the initial sampling frame 
(quality management, patient association, clinical ethicist), were selected using a discriminative 
sampling approach and interviewed. The interviews lasted on average 59 minutes (median 60 
minutes).  All interviews were audio-recorded and transcribed verbatim. The transcription was done 
on a continuous basis and data were exported into NVivoTM software for Mac. Coding and 
categorisation processes were gradually updated. First-level codes were regrouped in an iterative 
process between data collection and analysis. Memos were written throughout the research process. 
The first interviews were reviewed using the final coding book. Facilitated by NVivoTM, the thematic 
analysis procedure used successive matrices to cross-tabulate different categories of response. Our 
interpretation followed a mix of deductive (initial framework-informed) and inductive (theory-
generating) approaches, with a continuous comparison method to interpret expected and emergent 
themes. [13] The final analysis followed the OSOP method [14], resulting in a map of key themes. 
This contained explanations of patterns and linkages, analysis of deviant cases, and allowed us to 
generate inputs for an emergent theory. 
The first author coded all the transcripts, developed themes and proposed the final analysis. To finalize 
the coding book, colleagues, acknowledged at the end of the article, independently coded a sample of 
de-identified transcripts in English, French and German. As educational background can influence 
qualitative interpretation, it is important to note that the first author has a medical background and 
further education in bioethics and empirical research. The co-authors, who enriched and validated the 
analysis, have backgrounds in biomedical ethics, philosophy and medicine. 
FINDINGS 
Respondent characteristics 
Table 1 shows the participants’ demographic information. Health domains were diversified. The 
region of Zurich and the public health sector were the most represented. A majority of interviewees 
were male and had a medical background. This gender imbalance was unavoidable.  Most of the 
interviewees crossed more than one box of the definition table, indicating that they had experience in 
more than one type of CRG. A few interviewees (mainly M’) did not find it relevant to differentiate 
between CRGs for research and CRGs for quality improvement, as for them, these different goals 
require the same data, and indeed, the patients involved are the same. 

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Table 1. Characteristics of the interviewees (n=22) 
Male (n, %) 19 (86%) 
Age (median, range) 55 (39-68) 
Years of experience with clinical registries (median, range) 14 (1.5-27) 
Experience working abroad >1 year (n, %) 12 (55%) 
Number of registries currently involved in (median, range) 2 (1-6) 
Current main role regarding CRg (n) 
First line data collectors (M’) 
CRG manager (M’’) 
Initiators/ sponsors (politics, federal administration, patient organisation, quality 
management) 
Reviewers (cantonal ethics committee, clinical ethicist) 
6 
5 
7 
4 
Education background (n)* 
Medical doctor 
PhD science 
Economy 
Law & humanities 
Nurse 
16 
5 
1 
2 
1 
Health care domain (n) 
Main Medical fields 
Anaesthetics 
Cardiology 
Dermatology 
General practice 
Infectious diseases 
Nephrology 
Paediatrics 
Public Health 
Other HC fields 
Data management direction 
Quality management 
Health administration 
Ethics 
Health policy 
1 
1 
1 
1 
1 
1 
1 
2 
2 
1 
3 
4 
3 
First language (n)* 
German 
French 
Italian 
17 
6 
2 
Places of work (n) 
Geneva 
Lausanne 
Fribourg 
Bern 
Zürich 
1 
3 
2 
4 
12 
Sector (n) 
Public 
Private 
19 
3 
* Interviewees could satisfy 2 characteristics. CRG: clinical registries
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Categories and gradual findings 
Five anticipated categories, identified in the initial framework of expected ethical issues, where used 
as prompt cards:  
- patient information
- data ownership
- trust
- moral obligations
- confidentiality
Throughout the interview process, additional issues arose concerning data set linkages, data sharing, 
communication between stakeholders, feedback of results, quality of data, utility of CRG, funding 
issues and legal constraints. Interviewees used blank cards to highlight the additional issues of 
financial needs, data quality and inter-operability Therefore, to encourage reflection on these concerns, 
without leading the interview, two supplementary enabling cards were added after the first 6 
interviews, and were also used as supplementary anticipated categories of analysis: 
- communication-networking
- long-term value
These seven initial categories were used in the coding process, as well as the following emergent 
categories: perceived CRG definition and knowledge, legal aspects, transparency, governance, 
beneficence, similarities with biobank, empathy with patients, and a parking-lot category named 
“other possible ethical issues”, which included elements of card strategy and prioritization. 
Comparing and looking for interactions across these categories, three broader themes have been 
identified for HCSs: behaviour, attitude and strategy. 
Thematic analysis 
Respondent behaviour 
Legal concerns were extensively discussed, despite the absence of specifically legally oriented 
questions in the topic guide. (Table 2) Swiss law confers upon HCSs the right to record and use CRG 
data. It assures that HCSs respect privacy rights, confidentiality, anonymity-coding rules and informed 
consent. In effect, this judicial backbone strengthens professional deontological rules requiring that 
HCSs “first, do no harm” and abide by their professional secrecy duty. 

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Table 2: Healthcare professionals’ behaviour – Legal norms 
Necessity of legal norms: Interviewee comments (A, M’, M’’, R indicate group affiliation) 
For opt-out preferential option 
As a basis for confidentiality 
To better define research 
With guidance for implementation 
Applied with an idea of prudence 
[M’’]. “First of all we had to fight for the legal fundaments, because if you 
don’t have a legal fundament then in cantons some hospitals would simply 
refuse to deliver the data, which would then lower our response rate below the 
international acceptable limit. So, legal, a legal baseline is very 
important…There is a moral obligation to use data, to improve quality of life 
of patients, therefore to have good quality data and completeness. It means 
obligation to have an opt-out...There is a conflict of moral obligation with the 
data protection officer who wants first to protect individual privacy. That is 
why a law will help for [name of the clinical registry] registry.” 
[M’]: “Confidentiality is very important to get that your patient information is 
given and that the patient is not disappointed. Depends on what you do, I 
mean, organ transplant recipients everybody knows they are transplanted so 
there is not that much to hide. With HIV that’s much different. You have more 
concern in the HIV cohort study.” 
[R] [translation] “There is a clear contradiction in the definition of a clinical
trial in the law and in the ruling order. As a result, researchers want to take
advantage of this…we have recurring discussions on this question, whether it
is research or not. And researchers put a lot of energy and intellectual efforts
to argue that in this particular concrete case, it is not research.”
[M’’] “Well I mean, there is the legislation and so on, but maybe there is 
probably not enough guidance in practice, that is known by the people who 
are developing registries and using them.” 
[M’] “That’s an ongoing discussion. Because it’s a pain. …  if you have a 
question that is beyond an individual patient’s treatment, basically it’s 
science. … So my interpretation is that we have to ask for every project for 
specific approval for the specific question, which is what I am doing...but not 
everybody in the cohort study is of my opinion and we have heated discussions 
because it makes a big difference if you have 40 projects running in this 
cohort study which are scientifically looking at the cohort study and all these 
40 need ethical approval or don’t. … you can go through any kind of audit 
and I know if you don’t have ethical permits you are lost. You are dead before 
the game even starts; because for a lawyer, if you have no document, you’re 
dead.” 
Mandatory CRGs for healthcare statistics were presented as a good example of an underlying stable 
structure and stable financial basis. Additional ad-hoc research purposes could thus be managed by 
simply adding other predefined items into the case report forms of the initial registry. Regarding non-
mandatory CRGs, the interviewees were fighting for a legal basis for opt-out consent procedures, 
rather than an insistence upon opt-in consent, to facilitate CRG recruitment. Some HCSs mentioned 
their discretionary power in addressing confidentiality or informed consent issues depending on the 
types of patients included, for instance with HIV patients. 
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Major concerns pertained to the difficult distinction between clinical care and research CRGs. In 
practice, the question raised by respondents was whether they should submit projects that are not 
easily classified to a research ethical committee CRG, as illustrated in the following examples:     
- Research CRGs with anonymous or coded data,
- Quality CRGs delivering generalizable output,
- CRGs including biomarkers and genomics data,
- Secondary uses of CRG collected data for research projects that were still unknown at the time of
patient recruitment.
Confronted by this issue, HCSs behaved in heterogeneous ways. Many viewed the HRA (Human 
Research Act) rules, in particular the obligation for a written informed consent, as too burdensome. 
Some research ethical committee members suspected that investigators deliberately try to avoid HRA 
legal obligations when designing CRGs. Some interviewees were working on new consent procedures, 
or wanted to further clarify the guidelines. In contrast, a few respondents from group M’ said that they 
were systematically applying the HRA when the CRG purpose involved the collection of data not 
directly linked to patient treatment; their motivation was to protect patients, but more importantly to 
protect themselves from legal risk. Whilst physicians had a wider conception of research based on the 
purpose and use of the CRG, lawyers considered CRGs with non-identifiable data as monitoring tools, 
and not as research, stating that they could subsequently correct their approach with a retrospective 
ethical authorization if CRG results were published as research. 
Besides these legal aspects, interviewees’ behaviour focused on the operational management of CRGs, 
their long-term value being dependent on data quality, standardization, completeness, system 
interoperability, and financial conditions. (Table 3) All participants recognized these standards as 
necessary conditions for the benefits of CRGs to be realised. Given the time spent on CRGs by 
healthcare providers, and sometimes patients (longitudinal follow-up), they wanted to ensure that 
CRGs  deliver good quality information, to aid better decision making. Everyone insisted on the 
quality of the whole process of collecting, aggregating, controlling and analysing CRG data as 
especially important, but some interviewees were uncertain about how to ensure the best quality of 
data. The further interviewees were from the data collection process, the stronger their doubts about 
CRG quality and value was. The long-term operation of CRGs posed specific problems. Interviewees 
mentioned a risk of lower quality and reduced rate of patient inclusion each time a clinical team 
changes, and the corresponding need to continuously inform and train investigators. Securing financial 
resources was also highlighted as potentially problematic for the long-term management of CRGs.  
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Table 3: Healthcare professionals’ behaviour – Operational rules 
Good operational management Interviewee comments (A, M’, M’’, R indicate group affiliation) 
Importance of data quality 
Trust in quality 
Good management needs human 
and financial resources 
Issue of definition of quality 
Steering committee to set the rules 
Utility is essential 
[M’, principal investigator]: “The crucial aspect of a registry is what kind of 
data do you put into this registry, and how well is this data controlled, and how 
good is the quality of this data in the end.  This is what really counts… It is 
difficult you know; I'm continuously involved if there are some questions about 
definitions. Definitions always evolve. How do you, what kind of data point do 
you collect?” 
[A]: “My special problems with the evaluation registries as we call them, is that 
the physicians deliver the data to these registries, enough data, good quality data 
and that you have registries that you can use! That was always a problem and it 
is a problem: how to make them mandatory or how you can guarantee that the 
data are full and good. That is always the problem.” 
[R]: [translation] “Money is necessary, for infrastructure and people, but public 
services are always reluctant. …With the National Research Fund, it is 
discouraging, they don’t want to engage themselves in the long term…a better 
coordination should exist between institutions and the National Research Fund, 
with a guarantee at the launch of a project that institutions will take over later.” 
[M’]: [translation] “It is difficult to measure quality in medicine. What is it? Is it 
patient satisfaction? Is it cost-effectiveness? Because when parliamentarians 
speak about quality, it is completely wrong: for them, it is quality – price ratio; 
when they think quality, it is profitability, and for me it is not. Quality has 
nothing to do with money…because if you want true quality, it would be 
expensive.” 
[M’]: “You need some clear rules how will these data and samples be used, you 
know, by whom? And we have actually modelled ourselves a bit along the HIV 
cohort study which has a scientific committee; so, whenever somebody has a 
research question, he has to go there, has to write the proposal, we review the 
proposal and we accept the proposal or not.”  
[M’’]: “If we collect data, we have to organize everything that we can create as 
much information out of this data as possible. So, I think it is, it’s only serious to 
collect data if they can be used for something. If they are just collected and if 
they are not, cannot contribute to improve the system, then it is, I think it is not 
ethical to collect them.” 
Respondents’ operational focus was most commonly related to data quality. Some of them used the 
expression “garbage in, garbage out” to explain how the quality of data production influences the 
quality of CRG output. However, their approach to the concept of quality was more complex when 
CRG outputs were themselves used as quality indicators for comparative healthcare effectiveness. Not 
all physicians agreed with the idea of better quality at lower costs. 
To guarantee CRG long-term value, all interviewees insisted on the necessity of working with a 
steering committee that would set the operational rules of good clinical practice, data access, research 
authorship, thus improving communication and fostering trust between CRG agents. The usefulness of 
CRG data and outputs was an important factor for delivering CRG benefits. Interviewees pointed out 
the risks of collecting the wrong data, or in the wrong way and generating waste (“data cemeteries”). 
The prospect of not using CRG information was considered as worse than that of misusing it. 
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Respondent attitude 
The “attitude” theme revealed HCSs’ thoughts, beliefs and values towards themselves, peers, patients, 
and society, i.e. disclosed something about their moral obligations. A majority of interviewees 
declined to comment on the card on moral obligations, touching and looking at the card, but then 
moving on to comment on another card instead. Some HCSs considered the word “moral” too 
judgemental or inappropriate, and refused the “outing” on moral obligations. Nevertheless, morally-
connoted words like “right” and “wrong” were frequently used when they thought aloud about patient 
information, confidentiality, trust and long-term value. A few HCSs referred to moral obligations as 
the roof governing the whole CRG activity. Interviewees’ attitude varied between the different groups, 
based on their proximity to patients and the existing deontological code for physicians. 
i. Attitude towards themselves and other HCSs (Table 4)
Group A said that moral obligations were implicitly handled in their political engagement when they 
were making laws. They recognized the moral obligation to apply legal norms, and to modify the 
legislation if necessary. Group M was aware of professional duties to inform patients, to respect 
secrecy, to accept peers’ scrutiny and finally to participate in CRGs as in other types of activities that 
would improve healthcare quality for patients. With regard to patient information, their motivation 
was not only deontological, but also utilitarian to maintain a trustful relationship for increasing patient 
participation in the registry and maintaining patients in a cohort. A minority of interviewees 
considered that the addition of federal and local legislations on top of the professional code of 
deontology represented an excessive administrative burden.  
Most of the interviewees recognised that communication with external physicians, experts and 
politicians was difficult. One interviewee associated this communication with the word “preaching” in 
order to illustrate the effort required to convince others that the data are of good quality, 
representative, and provide real-life evidence, i.e. that people could trust the CRG results and apply 
them in their daily work.  The issue of data sharing and networking was regularly mentioned but 
difficult to clarify with interviewees: On the one hand, they showed a willingness to harmonize 
definitions and standardise electronic entries to ensure the quality of the CRG.  On the other hand, 
they appeared reluctant to communicate with information technology specialists, who were considered 
insufficiently capable to understand and subsequently translate medical information into standardized 
items. Furthermore, some respondents recognized that transparency could be perceived as another 
obstacle to data sharing, because physicians may prefer non-transparency. 
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Table 4: Healthcare professionals’ attitude towards themselves and peers 
Attitudes Interviewee comments (A, M’, M’’, R indicate group affiliation) 
Moral obligations inherent to 
political engagement 
Necessity to better inform patients 
Norms can be burdensome 
Issue of transparency and 
communication 
[A] [translation] “They [mandatory hospital CRGs] are mandatory
statistics, therefore it seems relatively obvious as moral obligations to
maintain them.”
[A] “Our role is to propose to the parliament a law, that is useful, the
most useful possible [for CRG].  That’s I think our most noble and our
most important duty.”
[M’’]: “I think the patients are not well informed and I think maybe there 
are some fields, which could be destroyed if there would not be an 
objective information. You know, at the moment, there are a lot of news for 
example showing the data or pictures from persons are provided on the 
internet because they have been taken out of clouds or whatever. And I 
think this increases the fear, and I think it will be very important to inform 
patients on what data are stored, why they are stored and that they cannot 
be identified for example.” 
[M’]: “We don’t need new regulation because as a doctor, as a lawyer, 
you have your professional obligations to keep your clients or patients’ 
data secret. So, if you don’t do that, you can be brought to court 
nowadays, so I don’t see what it changes if the patients must sign 5 such 
forms entering a hospital, on biobank, on whatever registry... it is 
counterproductive. You want to have an informed and empowered patient 
but it’s completely the other effect, you induce with paperwork. Nobody 
can understand the legislation.” 
[M’’] “I am absolutely convinced that physicians do not want to have this 
level of transparency, because everyone in this country who is allowed by 
the patient to load, enter to his file, can see what the other physician did, 
and “untransparency” is a very important thing in the health care 
system.” 
Finally sharing CRG data was not synonymous with linking registries to create bigger data sets. The 
interviewees close to patients insisted on the importance of meaningful information. They sought to 
provide bottom-up inputs to data centre managers and steering committees in order to help make the 
findings understandable and meaningful. For them, “big” was not clinically interpretable and useful 
for their practice.    
ii. Attitude towards patients’ role and agency (Table 5)
All interviewees recognized patient rights to know, to protect privacy and to own their data. However, 
their attitude regarding patient information indicated some discrepancies with this position. No clear 
answer was given to the question of the destiny of data following patient withdrawal. Also, the 
possible risk that patient information could be neglected in the absence of formal consent was 
accepted – for instance, when a data centre treated their data anonymously, patients were not supposed 
to be informed. Despite our research design including the prompt cards “patient information” and 
“trust”, respondents didn’t attach much importance to empathy with patients, patient information or 
patient agency; many interviewees thought that patients did not care about or could not understand 
CRGs. Exceptions to this attitude concerned one participant who belonged to a patient association in 
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the discriminative sampling, as well as most of the treating physicians who – in comparison to other 
HCSs – indicated greater concern for patient information, in the interests of building and maintaining 
a trusting relationship with their patients.   
Table 5: Healthcare professionals’ attitude towards patients 
Perception of patients’ capacity Interviewee comments (A, M’, M’’, R indicate group affiliation) 
Patients want to know 
Patient information is not systematic 
Not much value assigned to patient’s 
capacity to understand  
Patient information is a moral duty 
Patient information is useful to 
maintain trust 
Patients have the capacity to contribute 
actively 
[A] [translation] “Patient information is the most important. Patients
need information in order to be able to consent or refuse. Information
should be in a language they could understand.”
[M’’] “We have asked the physicians and the patients what they
thought about that, and they were saying: well I am not against but I
want to be informed, I want to be informed preferably by my family
physician, by my GP and I want to know what is going on, but I am not
opponent to this type of research, but I would like to know.”
[M’’] “We have a formal agreement [from the federal commission for 
professional secrecy] that the data can be transmitted to us. They are 
anonymous, and the patients don’t know.” 
[M’] [translation] “Well, for me it is important to inform patients …yes 
the patients, even if they usually don’t care about it.”  
[A] [translation] [interviewer’s question about the perception of
patient’s position] “The patient? it is eight million of citizens, and each
of them have their head, their morality, their feelings, their perception
of the reality… There is no patient lambda …If I had to answer your
question, I would say that a patient lambda in Switzerland has no idea
about what you are asking- It is a level of mental abstraction that is
present in less than 1% of the population.”
[M’] “We do not need [an informed consent] because we, basically we 
collect data which is collected anyway, so you could argue the patient 
doesn't really care, but he needs to know what it's done, you know.” 
[M’] “A well informed patient is convinced that he can really trust how 
his data is handled, about security of the data. He will be more willing 
to say yes; I agree that my data will be put into this database.” 
[M’’] “We also plan to have a, in a second line, a patient self-registry, 
so that the patients themselves can register themselves into the registry. 
So, there is two ways to go in. So, either for the doctor, physician, or 
then for the patient himself: I have this rare disease, I want to be part 
of this registry.” 
All interviewees supported respect for patient autonomy, recognising that patients had no obligation to 
provide their data and participate in CRGs.  A few respondents indicated that patients might feel a 
moral obligation of reciprocity to share their data when they have previously benefited from the 
healthcare services (e.g. transplant). Group R contested this idea of patient altruism, as 25% of clinical 
studies were stopped in Switzerland because not enough patients agreed to participate. No respondents 
were ready to accept patient membership in steering, nor they think that patients could act as members 
of a governance body. They never mentioned the possibility or need to empower patients’ agency. 
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Some interviewees remarked that patient associations were weak and that patient participation in a 
steering committee would only be an “alibi”, with no added value. A few respondents stated that 
patients were too “self-centred” to be able to participate. Only one interviewee spoke about the 
possibility of patients registering themselves in a CRG, in the special context of rare diseases. 
iii. Attitude towards society (Table 6)
A few interviewees explained that patients disliked the label “patient” as they were hoping for 
recovery to “normal”. They explained that patients would like to be part of the overall citizen 
community, i.e. the society. Respondents defined CRGs’ societal value as the delivery of public 
benefits and the possibility of improving medical knowledge. They recognized that, depending on 
their purpose, all health stakeholders could benefit from CRGs. Physicians and hospitals would 
improve their work, researchers would identify new patterns, experts would make better informed 
recommendations, public health would justify their decisions and health regulations, and insurers 
might introduce premium rebates. As a result, patients in general would benefit from all of these 
improvements, i.e. patients’ family and future patients. Some interviewees mentioned that patients 
themselves might secure direct benefits as participants of longitudinal cohorts could benefit from 
better medical follow-up, as they are regularly contacted. A few emphasized the value of these 
benefits compared to less specific data collection from diagnosis related groups.  
For most of the respondents, CRG data sharing and the dissemination of this information increases the 
social value of CRGs. The belief in these public benefits justified public funding and governance. 
Group R was particularly supportive of moral obligations concerning transparency, openness and 
comparative effectiveness between HCSs. To this end, it was suggested that physicians need to be 
better trained in information technologies and public health sciences. Group A focused as a matter of 
priority on addressing two major risks: privacy infringement because of excessive transparency, and 
the wastage of data because of data cemeteries and low cost-utility ratio. Waste was more an issue for 
the political right, whereas the political left was ready to take financial risks relating to long-term 
viability. 
Governance was an important issue, but subject to conflicting views. Most interviewees supported 
public governance to serve public interests. For them, CRG resource allocation should remain 
scientifically and academically driven and be free from conflicts of interest, as in the case for projects 
supported by the Swiss National Research Fund.  A few interviewees were in favour of small, non-
bureaucratic governance, independent from institutional, economic or political powers, i.e. public 
authorities would provide financial support, but would not be involved in CRG governance. 
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Table 6: Healthcare professionals’ attitude towards society 
Perception of society benefit & role Interviewee comments (A, M’, M’’, R indicate group affiliation) 
Patients are citizens 
Clinical registries benefit society 
Patients may benefit directly 
Social value is related to meaningful 
use 
Value increases with data sharing 
Value needs better physicians’ 
education  
Value includes financial risk-taking 
Value is related to trust 
Value and governance 
Conflicts in interest 
[A] “The patient is all of us”.
[M’] “Primarily it’s a tool for everybody who has a research question “. 
[M’’]: “It is always known that patients in a registry, they are usually 
better followed than other patients. ...because we have to see them every 
half year [in the cohort].” 
[M’]: “You want to do that in a meaningful way; I mean we don’t do it in a 
sense that the DRG system; all the patients get a DRG kind of diagnosis, 
you know. So, in the end of the year you can bring all these DRG diagnosis 
together.  But they are worth not that much.  Obviously, they are worth 
very much because you are paid according to the DRG so it's important, 
but in terms of what they really say, what the patient has, and as outcome, 
it's, it’s, you can't use it.” 
[R] “Sharing data increases the value of the collected clinical registry. A
good register communicates, publishes results and invites further research
proposals on these data.”
[R] “Physicians should understand the value of what they do when they
use epidemiological data. Most physicians feel the moral obligation to
keep registries for good quality assurance, but they tend not to share them,
not to be transparent. Therefore, comparison is not possible and quality
could not be improved. We should have a better national medical
education and training, including evidence based medicine, epidemiology
and the practice of critical thinking and reflection. Continuous education
as well for medical development.”
[A] [translation] “There is always a risk of error in the long term. I have
some colleagues who told us that investments have to be made only in
research projects that we are sure in advance that they would provide
results. They have a serious problem understanding the word research.”
[A] [translation] “Here, the socialist party will say: we need a beautiful
law that ensures financing, governance, and an interdisciplinary
governance which controls everything…etc. and which costs three times
more. What the right side says is: no, we provide a legal basis and let the
people free, and if they make mistakes, there are enough means to address
them …it is this vision that I called the principle of trust.”
[M’] “The CRGs should have a medical and social value. The Federal 
Office of Public Health is not apt to do it. It could financially support 
CRGs but only professional societies could govern CRG.”  
[A] “Transparency issue is a possible deceptive motivation for a registry.
CRG may be advocated for patient interests, but in fact would be
performed and used for publications and academic careers of the
investigators first of all.”
The definition of “public” was restricted to institutions and public associations or academies. No 
interviewee considered representatives of civil society as potential members of governance 
organisations for CRGs. Nor did they support health data literacy programs to facilitate the 

Submitted Manuscript
 
participation of citizens, even when the question was directly asked. One interviewee said that the 
necessary education should be done in school and not later, because it would not be feasible or 
effective with patients or adult citizens. The role of communities and society was mainly limited to 
funding issues, with cantonal and federal contributions, and sometimes, unusual health contributors 
such as the national lottery. Moreover, lobbying or private funding were seen as risking unfair 
allocation of healthcare resources. 
For group R, governance was not the role of an ethical committee, but it required a common long-term 
political vision including the prioritization of CRG projects, and an ethics of responsibility for each 
physician and patient. 
Respondents’ suggested strategy  
When they came across moral conflicts between norms guiding their behaviour and their attitudes, 
interviewees started to develop practical strategies to support decision-making. Some had already 
aligned their values and actions to guide their medical judgment, but their decisions were not always 
consensual. 
Confronted with the need for meaningful CRGs, HCSs proposed to intervene at different levels: 
- To increase patient participation in CRGs, group M’’ believed in their capacity to influence
policy-makers to promote opt-out forms of consent and new forms of consent, whereas group M’
relied on better patient communication to develop more trustful relationships.
- To increase physicians’ participation, a few suggested using financial strategies either as
incentives (pull strategy) or as penalties (push strategy).
- To improve data quality, all respondents favoured the establishment of steering committees and
transparency rules to improve trust between peers. Many interviewees also called for the
development of interdisciplinary teams and systems to increase interoperability and simplify CRG
process.
Other issues remained more controversial. When in doubt about the distinction between care and 
research, a minority of HCSs implemented a default-strategy of systematic declaration to the research 
ethical committee to protect their own interests. The definition of data ownership was also not 
consensual among the different groups. Physicians favoured the deontological approach of being 
stewards for patient data, whereas policy-makers preferred a split “puzzle” approach to data ownership 
avoiding power concentration. Patients were considered data owners, but only a minority of HCSs 
thought that patients ought to have some kind of compensation rights for the use of their data. 
These strategic initiatives, although not formerly established, indicate how HCSs balance their 
behaviour and attitudes to adapt to their changing professional environment. They provided useful 
empirical observations to develop the final qualitative analysis proposed in the following discussion. 
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DISCUSSION 
Data interpretation and final analysis 
This qualitative research project explored the ethical awareness of HCSs involved in the collection and 
management of patient data in the context of clinical registries. The final analysis revealed that HCSs 
could be more aware of the potential emergence of an ethical tension between patient rights and public 
interests around patient data. This final analysis, resulting from the thematic analysis summarized in 
Figure 1, combined the following three interpretative steps.  
Figure 1: Thematic organisation for in-depth understanding 
i. HCSs concentrate on legal norms, deontological code, operational data management rules and
good clinical practice, in order to ensure the legitimacy and utility of the collection and use of
patient data necessary for the different types of CRGs. Their ethical justification relies on the
principles of non-maleficence, prudence as well as social utility and benefits. In contrast, they give
little consideration for patient rights to be adequately informed, i.e. to be informed even when
consent is not required, to receive feedback, to have the right to ask questions and the right “not to
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know”. HCSs argue that patients have no moral obligations to participate in CRGs, but at the same 
time they try to stimulate participation by calling for opt-out procedures and new forms of 
consent. HCSs’ ethical awareness seems to be more guided by their professional needs 
surrounding the collection and use of patient data than by an interest in the protection of patient’s 
rights and autonomy. From a normative point of view, this utilitarian perspective may impede an 
adequate assessment of the risk of infringing patient rights for the sake of professional and public 
interests. 
Communication between HCSs is problematic and compromises peers’ trustworthiness, because 
they do not support unconditional transparency and scrutiny of their work, and do not show much 
interest in bottom-up inputs. Communication with patients raises a similar issue.  HCSs do not 
assign much value to the patients’ capacity to understand and contribute to governance, and 
therefore do not foster reciprocal trust with patients. These limitations with transparency and trust 
increase the risk that peers are reduced to simple data collectors, and patients to simple data 
sources in the production of a CRG. These difficulties with recognizing patients as fully capable 
of shared decision-making indicates that HCSs’ interests for patient data  c ould overcome the 
consideration of patients as an end themselves. The potential utilitarian bias in favour of public 
interests noted above is therefore insufficiently balanced by a more Kantian deontological 
approach forbidding the treatment of individuals merely as the means to others’ ends. 
iii. HCSs have demonstrated little overall awareness of the role of citizens in the governance of CRG
patient data and the need to develop citizens’ education for such a role. HCSs don’t foresee the
involvement of civil society representatives in governance. They recognise the need for public
funding, but not the possibility that society could contribute to assess the whole range of social
benefits and risks, i.e. balancing privacy against public interests. From a normative perspective,
the process of deliberation and decision-making thus remains unduly expert-centred, favouring
research, economic and political objectives, with a risk of conflicts of interest, hidden agendas and
injustice.
To sum up, a potential tension between public interests and patient rights is related to the HCSs’ 
asymmetrical perception of the ethical issues around patient data. Patients are solicited to give up 
rights to their health-related data, but their participation appears restricted to their role as data donors, 
with little recognition of the possibility of meaningful participation in decision-making. This observed 
lack of reciprocity between HCSs and patients, as well as amongst peers and the rest of society, gives 
rise to different ethically problematic consequences: it carries the risk of weakening trust in the 
patient-physician relationship undermining solidarity and justice at the societal level, and unfairly 
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infringing upon patient rights. The transferability of these findings to other debates regarding the use 
of patient data in the healthcare system needs to be examined. 
General discussion 
The aim of this research was to gain an in-depth understanding of how those involved in the collection 
and use of patient data, healthcare professionals, regulators and policy makers, were aware of related 
ethical issues regarding patient’s rights, social justice and trust in public institutions. Transferable 
research findings can be recapitulated as follows:  First, a utilitarian inclination towards norms and 
guidelines aiming at facilitating the collection and use of patient data appears insufficiently balanced 
by an overly strict, duty-oriented deontological approach to patient rights; second, HCSs did not 
assign much importance to patient rights in terms of patient agency and their ability to share steering 
decisions; third, at the societal level, it follows a pre-eminence of experts’ role in the governance of 
large patient data sets at the expense of consumers’ representation. These findings are all ethically 
problematic in themselves. Furthermore, they are also likely to undermine the expected social benefits 
of data sharing. For these reasons, HCSs should be more aware of the identified tension and further 
ethical guidance is required to address it. 
No other qualitative study to date has explored the subject in Switzerland. However, our findings are 
in line with the current evolution of the Swiss healthcare system. First, the Federal Act for National 
Oncology Registry, approved in March 2016, will ease the production of patient registries with an opt-
out procedure. [15] Second, operational recommendations for health-related registries have been 
published in July 2016 to ensure data protection and data quality, appropriate information and 
management, and cost/utility of CRG data. [16] Finally, a broad informed consent for all secondary 
research usages of samples and related patient data has already been implemented in some public 
hospitals, and is on its way to be implemented nationally. [17] All these events were in discussion at 
the time of the interviews, and it is thus difficult to determine whether the events have influenced the 
interviewees or if the reverse is true. Nevertheless, there has not been a concomitant development of 
ethical considerations, promoting patient agency and consumer participation in the management of 
patient data. This absence fits with the study’s final analysis of a possible tension between patient-
consumer rights and public interests. This observation is reinforced by the organisation of the project 
for a Swiss Health Personalized Network. This national project relies on bioinformatics-based systems 
and sharing of data from health institutions, academic research, and primary care, but does not involve 
patients or donors in its governance. [18] 
Previously published literature confirms that healthcare professionals and administrators give little 
attention to patients’ ability to understand or contribute to governance. The qualitative studies referred 
to in the design stage of our study interview guide were conducted in the UK and North America. [19-
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29] Similar to our findings, healthcare professionals and administrators in these studies were vigilant
about data protection rules, data security, confidentiality, responsibilities for patient data, and they 
strived for simplicity in data processes, transparency, and consensual rules between peers. These 
studies also included focus groups or interviews with patients.  Patients’ opinions showed some 
divergence with other HCSs’ perceptions. Patients accepted the sharing of their data, but wanted to be 
informed and to have the freedom to participate or withdraw. They did not want their data passed to 
third parties, insurance or pharmaceutical companies, without being specifically asked beforehand. 
Patients usually favoured trust and partnership with their treating physicians. In fact, it seems that 
citizens in general, as well as patients in specific, have the capacity to intervene and assess the just 
equilibrium of patient rights and public interest concerning the use of personal health data. In 
Australia, a country with a long history of clinical registries, community and consumer representatives 
already participate in the governance of clinical registries. [30] More recently in the USA, following 
the Obama initiative on precision medicine, community citizens have participated in the registry design 
of the “One million Americans” cohort project. [31] Indeed, Fair Information Practices principles 
(FIPPs) have been developed to set common standards for patient involvement in the governance of 
personal health and genomic data. [32]
Assuming the transferability of our findings to all health-related big data, the tension between legal, 
professional and operating norms on the one side, and respect for patient agency and citizen 
contribution on the other side, could be difficult to resolve in the absence of additional ethical 
guidance. There is a risk that those with the expertise or economic power to effect change might 
favour additional legal and operational norms, to authorize the use of patient data for research and 
public interests. Thus, purported social benefits could justify ever greater usage of patient data, at the 
expense of listening to patient voices. This could lead to an erosion of the necessary reciprocity, 
solidarity and trust in the healthcare system, leading to the following conflict: more data sharing, 
justified on the grounds of social benefit, could foster distrust towards healthcare professionals and the 
public healthcare system in general, thus reducing the expected social benefits. The risk of such a 
counterproductive result provides due grounds for addressing the tension between public interest and 
patient rights, as identified in the qualitative research.     
The World Medical Association (WMA) has also raised concerns about the management of large 
patient data sets and biobanks, some relating to privacy, and others relating to patient autonomy and 
dignity, and to commercial issues. [33] WMA recommends that the collection and usage of patient 
data should require patients to be properly informed, with a clearly defined set of information about 
how their data will be used. Further, WMA recommends that when this is impracticable, there must be 
a governance process that protects patient rights across all future uses of their data. A broad consent 
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agreement should not be unconditional. These recommendations primarily concern physicians, and so 
may not be followed by other HCSs.  
Nevertheless, these ethical reflections regarding large patient data sets could be broadened, to integrate 
patient and citizen concerns. The sphere of freedom and protection for patients could be delimited in 
the first instance beyond which the scope for research and public benefits from patient data could be 
fall under a multidisciplinary governance structure, including representatives from a range of different 
social communities. Such an integrative approach would introduce more reciprocity into HCSs’ ethical 
frameworks, and would enrich top-down ethical considerations of legal and operational norms, 
implicated in the digital transformation of the healthcare system. This integrative approach can already 
be spotted in the literature. Ethical, legal and social implications (ELSI) are regularly examined for 
large data sets of patient data and precision medicine. ELSI focuses on topics of consent, disclosure, 
data sharing, privacy and confidentiality at a population level. [34] As a complement, in its 2015 
report, the Nuffield Council on Bioethics recommended the usage of four essential principles - respect 
for the person, respect for established human rights, participation of those with morally relevant 
interests, and accounting for decisions – that support an integrative ethical approach to biological and 
health data. [35]  
In the wider medical domain, ethical reflections have already been developed in similar situations, 
when a tension has arisen between clinical research for public interest, framed with a utilitarian 
approach, and individual care, based on a deontological frame and patient rights. Beyond the primary 
application of medical information, to achieve good patient care, it is advocated that patients’ values 
and knowledge should also be considered, when their data is used. [36] In the case of governance of 
big biobanks, Brownsword has challenged the dichotomy of participants’ rights vs. public interest with 
regard to informed consent, return of information, and the evaluation of public interest. For him, the 
establishment of the legitimacy of public interest and associated private projects, requires an 
evaluation of the principle of proportionality including consideration for the rights of participants and 
the community. He proposes an enhancing consent, providing a “mini-constitution” that 
simultaneously protects patients from disproportionate claims of public interest, whilst introducing 
greater flexibility for future research. Brownson proposes two layers of consent. Thus, participants 
would: i) provide informed consent for certain specified research uses of the data and samples given to 
the biobank, and ii) provide further consent for a special procedure and its outcome in connection to 
future public interest that was unanticipated at the time of consent. Patients’ rights would further be 
protected with various options for withdrawal or opting out, within the mini-constitution. [37] This 
human rights based approach could be applied to all large patient data sets, to enhance present-day 
ethical approaches with greater patient involvement. Any flexible aspects of patient rights would be 
pre-determined before rules for data sharing are established.  

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It is acknowledged that patients are at the same time both private and public individuals, and thus 
scientific citizens have an increasing role in the management of human genetic and health databases in 
a democratic society. Citizens’ participation would therefore require the development of public 
programs for health digital education, and public spaces for deliberation and citizen consultation. [38] 
The WMA and Nuffield Council on Bioethics have already recognised the roles of patients through 
their recommendations on patient autonomy, dignity, capacity to decide, and shared governance with 
all citizens concerned by health information. Their approach is compatible with an ethics based on 
patient narrative identity, as an alternative to the human rights theory. Grounded in his work on 
narrative identities, Ricœur’s ethics exemplifies the possibility of overcoming the duality of 
utilitarianism vs. deontology for patient data management. [39] In his reflection on medical judgment, 
Ricœur advances the following rules: i) physicians should regard the patient as an individual, ii) each 
individual is indivisible and should not to be fragmented into biological, psychological and social 
parts, and iii) maintaining reciprocity and trust is necessary to ensure that patients don’t become 
dependent on HCSs. Patients can thus be considered as citizens with a rich narrative identity, with 
patient data forming part of this identity. Ricœur identified a tension between health and the wish to 
live well that can parallel the tension between public interest and patients. [40] He recognised the 
threat of “objectifying” the human body following the mixing of the therapeutic project and the 
epistemic project of biomedical research, in other words the tension between considering the patient as 
a person, and the protection of public health. His approach to narrative identity at both the individual 
and collective level offers one way of reconciling, in practice, this tension around the ethical aim of a 
“good life, for and with others, in just institutions”. [41]  
These remarks are meant to open up a constructive normative perspective on the further development 
of an integrative ethical approach to the management of health-related data – an approach that 
addresses the tension between public interests and patient rights and agency that has emerged in this 
empirical study. While it is beyond the scope of this paper to enter into a detailed normative 
development, we think that the ethical approaches presented above, that emphasize the need to involve 
patients and citizens, provide us with a good starting-point for further ethical reflections.  
Limitations and future steps 
The final analysis of this study must be considered with caution, as empirical findings are not directly 
translatable into normative ethics. During the interviews, we could not avoid a gender effect, which 
reflects the actual Swiss situation of fewer women than men in leadership positions. Interviewees were 
also predominantly physicians, as often observed in the healthcare domain. Patients were not 
interviewed, with the exception of a patient organisation representative from the discriminative 
sample. Therefore, the investigation was limited to the perspective of healthcare professionals, 
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regulators and policy makers about patients’ views. As a next step, it would be paramount to 
investigate the patient perspective directly, as well as the evolution of the patient-physician 
relationship when confronted by the arrival of a third, a “digital information” partner. It is not always 
easy to study patients and patient organisations when it comes to subjects such as patient data sets or 
precision medicine, as they can be too focused on specific pathologies. Some authors also mentioned 
that patients might be under the influence of for-profit industrial lobbies. [42] Our findings, showing 
consequences for the whole of society, argue for broad representation from the community in future 
survey or mixed-method empirical investigation.  
This study adds, however, relevant knowledge to the ethical evaluation of practices around large 
patient data sets, and represents useful material from which to develop further normative reflection 
towards a more integrative ethics, in order to involve patients and citizens in the governance of health-
related big data. 
CONCLUSION 
The increased role of large patient data sets in clinical research, medical care, and public health, is 
changing the behaviour and attitude of most HCSs towards patients and patient data management. This 
empirically-based research explores ethical awareness around the production and use of patient data in 
the context of Swiss clinical registries. Although HCSs were aware of the need for legal and 
operational norms to guarantee non-maleficence, prudence and beneficence in the use of patient data, 
they tended to show less interest in the moral risk of infringing upon patients’ rights, in particular 
those related to agency and capacity to share in the governance of their health-related data. The final 
analysis identified a potential tension between patient rights and public interest, which risks 
undermining the expected benefits of large patient data sets. This tension could be addressed with a 
more integrative ethical approach that empowers patient agency and consumer advocacy in 
governance bodies, and gives priority to a core of patient rights before easing the rules to facilitate the 
usage of patient data for research, precision medicine and public health. In short, interests in patient 
data should not stand in for the patient’s voice. 
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Additional file 1. Definition of clinical registries for the purpose of the qualitative study 
Definition of clinical registries after the Agency for Healthcare Research and Quality*  
A clinical registry is an organized system that: 
1. produces healthcare data using observational study methods to collect uniform data (clinical and
other), outcome-focused, from a population of patients defined by a particular disease, condition or exposure,
2. used for one or more predetermined  purposes  i) clinical care (measurement and improvement of the
quality of healthcare services and process,  monitoring of safety and harm, comparison overtime), ii) scientific
research (knowledge/natural history of the disease, effectiveness of a drug, device or intervention in real-life,
off-label uses of therapeutic products, recording of safety and unexpected event), or iii) policy (cost-effectiveness
evaluation, health technology assessment, comparison between institutions or physicians) ,
What makes the specificity of a clinical registry is its purpose according to how their populations are defined, 
for instance: 
• Product registry: assess patients (all or samples of-) exposed to therapeutic products (drugs or devices)
• Health services registry: assess clinical quality and outcomes in patient groups having a common
procedure
• Disease or event registries: assess populations with the same diagnosis
* Glicklich RE, Dreyer NA, eds. Registries for Evaluating Patient Outcomes: A User’s Guide. 2nd ed. (Prepared by Outcome
DEcIDE Center [Outcome Sciences, Inc. d/b/a Outcome] under Contract No. HHSA29020050035I TO3.) AHRQ Publication
No. 10-EHC049. Rockville, MD: Agency for Healthcare Research and Quality. September 2010.
Definition and taxonomy of clinical registries 
Type of clinical registry CRG 
Population definition 
Product registry 
(patients exposed 
to therapeutic 
products: drugs or 
devices) 
Health services 
registry (patients with 
a common procedure: 
looking at clinical 
quality assessment and 
outcomes) 
Disease or event 
registries 
(population with 
the same 
diagnosis) 
Clinical 
care 
Quality measurement & 
improvement 
Monitoring safety and harm 
Comparison overtime 
Scientific 
research 
Disease knowledge & natural 
history 
Effectiveness of a drug, 
device, or intervention in real 
life 
Off-label uses of therapeutic 
products 
Recording safety and 
unexpected events 
Policy 
Cost-effectiveness evaluation 
Health technology assessment 
Comparison between 
institutions or physicians 
Pr
ed
et
er
m
in
ed
 p
ur
po
se
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 Additional file 2. Literature research strategy for the qualitative research 
May 2014 
A. Clinical registries AND B. Ethical Issues AND C. Qualitative Research
OR 
Clinical, patient, disease-
registries  
Medical records  
Electronic health records 
Medical record linkage 
OR 
Informed consent, 
anonymity, confidentiality, 
privacy, data sharing, 
ownership, conflict of 
interest, bioethical issues, 
clinical ethics, ethical 
review, ethics research, 
principle-based ethics, 
Ethics, morality. 
OR 
Interview  
Focus group  
Grounded Theory  
Mixed methods 
Phenomenological analysis 
Thematic analysis 
Narrative analysis 
Discourse analysis 
Pubmed 38 
Web of science 31 
After duplicates removed 39 
After abstract reading 13 
After full-text assessment for eligibility 11 
[Reference number in the manuscript]. Paper’s first author. Journal’s name, year of publication, volume, pages. 
[19]. Stevenson F et al. Family Practice 2013; 30:227–232. [19] 
[20]. Baird W et al. J Med Ethics 2009;35:92–96. 
[21]. Korngut L et al. BMC Medical Research Methodology 2013, 13:135. 
[22]. Baskaran V et al. Informatics for Health and Social Care 2013; 38(3): 196–210. 
[23]. Caine K et al. J Am Med Inform Assoc 2013;20:7–15. 
[24]. Maiorana A et al. Implementation Science 2012, 7:34. 
[25]. Wright A et al. BMC Medical Informatics and Decision Making 2011, 11:36. 
[26]. Walker J et al. J Gen Intern Med  2009, 24(6):727–32. 
[27]. Jenkings K N et al. Informatics in Primary Care 2007;15:93–101. 
[28]. Barrett G et al. BMJ 2006, 332: 1068-72. 
[29]. Robling M R et al. J Med Ethics 2004;30:104–109. 
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Additional file 3: Topic guide example for the group “M” making the clinical registries 
      Place: Date: Code: 
A. EXPERIENCE WITH CLINICAL REGISTRY (IES): Sub-group M
• How would you describe your role for the registry?
• Can you explain what is the main purpose of your CRG?
• When did you last have to solve a problem regarding the registry?
• Can you tell me more about that?
• Is it a typical issue you have to face?
a. If yes:  frequency? Burden? Possible consequences? Suggested solution?
b. If no: what would be a usual /typical issue? Could you explain it further? Possible
burden? Consequences? Suggested solution?
• How close to your idea, are the other people involved in your CRG? If not closed, can you explain to
me why?
• Can you tell me more about the management / governance of the CRG?
• Who do you think benefit the most from this CRG? Why?
B. EXPLORING GENERAL ISSUES
• Some physicians and public health responsible persons say that it is difficult to start or run a clinical
registry. Can you tell me why they may think that?
• Do you share their point of view? Why?
• I have picked up some of the issues they reported about CRG on these cards: …see cards. Can you look
at them, and think aloud…
o What do you think about these different themes?
o What do they mean for you? Why?
o Are they all relevant?
o Could you put them in a sort of order? Or in relation to each other??
o Could you give me an example of a main issue?
o Could you please tell me more about …
o Could you explain why the issue on the last card is not so important for CRG?
• How will you define “relevant”… (In relation to what or to who?)
• Is there one or more issues not addressed by these cards?
• If yes, can you write them on these white cards? …
• How would you arrange the cards now? (Emerging ethical framework)
• What do you think patients would think?
• How do you feel now with these themes for CRG?
C. POSSIBILITY OF EDITING RECOMMENDATIONS (if short with time: bold only)
• How easy or difficult would be to address the main issues you mentioned?
• What would be the best way to do?
• Would you recommend developing guidelines on what you advise to do?
• How easy do you think would it be to implement such a set of recommendations?
• Can you explain me why?
• What will you advise to do about that?
• Would you recommend national ethical guidelines? Why?
• If yes, how do you see the best governance for the implementation and revision of such ethical
guidelines?
D. DEFINITION TABLE (beginning or end of the interview with demographic questions)
Looking at the general definition of CRG given in the information sheet, I have made a table. Could we
please tick all the boxes relevant to your registry. ! table
E. CONCLUSION
• Thank you very much for your collaboration, I hope you enjoyed this interview,
• Looking back at it, is there anything you would like to add…
• Possibility to re-contact him/her by mail or telephone if something appears unclear at the analysis.
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8. Conclusion  
The methodology used was a thematic analysis based on individual semi-structured 
interviews. This approach, derived from Grounded Theory, provides the opportunity to 
reflect on the empirical data at the same time as it is collected and analysed.79 The interview 
questions can be modified during the study, based on the output of an ongoing reflective 
analysis. This process helps generate good material for further normative reflection.  
Interpretation is an important feature in qualitative research. Total impartiality is hardly 
attainable, but cross-validation of study design, data coding and categorizing help limit bias 
and misinterpretation. Fellow members of the Institute of Biomedical Ethics had the 
generosity to perform parallel coding of several extracts of the study.  
 
The study uses the context of clinical registries to explore the experience and ethical 
awareness of physicians, regulators and policy-makers towards the collection and use of 
patient data gathered in large datasets. Patients were not interviewed, and their perspective on 
patient data is drawn from the respondents’ perception. There is, nevertheless, coherence 
between our results and findings in the literature. Health professionals privilege legal and 
operational aspects to achieve useful patient datasets. They respect patients’ rights as required 
by the law, but do not consider patients and lay people capable of understanding health-
related data.  Consequently, they do not acknowledge the opportunity to empower patients’ 
agency or promote governance memberships. Conversely, patients are willing to contribute to 
research as long as their data is not communicated to private sector firms. They therefore 
demand more information, feedback and active participation.  
 
This observed asymmetry would result in a tension between the utilitarian reasons underlying 
public interest, and the patient rights concerning the use and dissemination of their data. 
International and national expert groups have already investigated this ethical issue. Our 
article draws on the positions of the World Medical association and The Nuffield Council on 
Bioethics, which recommend a wide approach to patient rights including the concepts of 
autonomy, dignity, capacity to decide and shared governance. These associations recognize 
the social benefits attached to health-related data. This was also identified in our study.  
 
Trust is an issue in the asymmetry of perspective between patients and other healthcare 
stakeholders. A trustful partnership was advocated by patients and treating physicians. 
                                                      
79 Ritchie, J., Ormston, R. 2014. The applications of qualitative methods to social research. In Qualitative 
Research Practice. A Guide for Social Science Students and Researchers, 2nd ed. Ritchie, J., Lewis, J., 
McNaughton Nicholls, C., Ormston, R. eds. London: Sage Publications Ltd, ch 2. 
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However, this link weakens as the distance between the patient as a data-donor and the health 
professional as a data-user, grows. This observation indicates that consideration of patient 
rights could vary depending on the proximity of healthcare professionals and their different 
goals. The issue of trust was also present between health professionals, leading to the 
question of truth in data, and the desire to strengthen the legal frame. Reasons for public 
interest to collect and use patient data, might thus be distorted by the utilitarian views of 
some groups of health professionals. Similar inconsistency over public interest was also 
observed between on the one hand the promotion of public interest for patient data at the 
expense of a minimum legal consideration for patient rights, and on the other hand the fear 
that patient data would be collected but not used i.e. wasting medical resources, time and 
bothering patients for nothing.  
 
Potential conflicts of interest and overriding of patient rights in the absence of benefit 
indicate some incoherence with the model of balancing between public interest and patient 
rights, and the necessity to develop more appropriate governance for patient data. The 
following issue is to evaluate the contribution of these empirical findings to normative 
reflection. To this end, I have pragmatically and intuitively proposed two reflective paths 
under a priori opposed perspectives: a judicial one based on human rights, and an ethical one 
based on the concept of narrative identities. The first approach reproduces the constitutional 
framework of human rights and the conditions permitting their restriction at the level of 
patient data. The governance includes agreement, as in a contract, between patients and 
professionals on the level of flexibility and options for participation. The second approach to 
governance refutes the opposition between the patient as a capable person and the promotion 
of public health interests. Defining narrative identity at both individual and collective levels 
would reconcile patient rights and public interest around a common ethical aim.  
 
In the next part of my dissertation, I shall develop a normative reflection based on the 
narrative perspective. 
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PART IV. NORMATIVE APPROACH 
The issue of the ethical governance of the production and use of patient data has been raised 
in the context of the former empirical findings covering reasons behind public interest, the 
translation of public interest into practice, and potential improvements in patient rights. The 
situation is complex. Professional stakeholders are multiple, coming from medical, 
biotechnological, informatics, economics or public policy. Patients are also diverse, 
presenting with acute or chronic diseases, or even refusing to be labeled as a patient. Faced 
with this plurality of stakeholders and differing contexts, it is not possible to identify a unique 
ethical issue to be resolved with patient data. As in an orchestra, governance would need to 
consider all players and to adapt to changes in the processing and usage of patient data.  
This metaphor evokes a narrative approach to patient data. My medical practice was based on 
a narrative process that successively involved listening to patients, establishing anamnesis 
and symptoms, performing clinical examination, integrating laboratory results, considering 
diagnostics, finally establishing the therapeutic possibilities with the patient, and following 
up where appropriate. Each patient was unique and illustrated a different story. Even when I 
was responsible for large hospital wards, I nevertheless still managed to understand each 
patient and his/her data individually. This experience led me to envision individual patient 
data as a short story, data from several patients as a novel, and large patient data sets as a 
library. This also means that each patient is, at the same time, a character, a «voice» in his/her 
story, as well as in the collective story of a community, and for future patient stories. 
Preliminary remark 
The notions of narrative ethics, narrative identity, agency and narrative medicine are widely 
used in the literature, but can cover different definitions or concepts. It is thus necessary to 
clarify how Ricœur uses these terminologies. Narrative ethics is usually one of several 
approaches to moral deliberation in clinical ethics. However, Ricœur does not limit narration 
to the reconfiguration of an issue based on psycho-sociological, anthropological, or cultural   
resources. His work has to be understood as philosophical ethics based on a narrative 
approach, and not as another contribution to applied narrative ethics. For him, narration is a 
necessary step towards knowing and understanding oneself and others, and their 
corresponding actions. The characters in action develop their narrative identity, both 
individual and collective, with the two poles of sameness and selfhood. Selfhood confers to 
each character, his/her dimension of agent “capable, acting and suffering”, and accountable 
for his/her actions and life. Moreover, Ricœur uses the concept of agency at a philosophical 
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level, and not in terms of special behaviours, relationships or values as usually acknowledged 
or challenged in biomedical ethics.80 Ricoeurian agency is linked to an “identity being 
capable”, a perspective closer to the concept of human dignity than to a measurable capacity 
to decide or act.  
In addition, narrative medicine is central to both narrative ethics and narrative identity, as it 
focuses on the relationships between a patient and his/her physician,.81 In Ricœur’s work, 
narrative medicine permits the emergence of the patient’s voice and subsequently his/her 
contribution to collective and historical narrations. At the level of applied ethics (named also 
posterior or prudential by Ricœur), narrative medicine is essential to the development of 
reciprocity and trust in the relationship between patient and physician. 
9. Rethinking the ethical approach to health information
management through narration: pertinence of Ricœur’s ‘little
ethics’
I published the article in December 2016, in the peer-reviewed journal Medicine, Health Care 
and Philosophy, 19(4): 531-543.82 
The publication: 
80 Lopez Barreda, R. 2016. Towards a broader understanding of agency in biomedical ethics. Medicine, Health 
Care and Philosophy, 19:475-483.  
81 Charon, R. 2001. Narrative Medicine. A model for empathy, reflection, profession, and trust. The Journal of the 
American Medical Association, 286(15):1897-1902. 
82 doi:10.1007/s11019-016-9713-6 
SCIENTIFIC CONTRIBUTION
Rethinking the ethical approach to health information
management through narration: pertinence of Ricœur’s ‘little
ethics’
Corine Mouton Dorey1
Published online: 20 June 2016
! The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract The increased complexity of health information
management sows the seeds of inequalities between health
care stakeholders involved in the production and use of
health information. Patients may thus be more vulnerable
to use of their data without their consent and breaches in
confidentiality. Health care providers can also be the vic-
tims of a health information system that they do not fully
master. Yet, despite its possible drawbacks, the manage-
ment of health information is indispensable for advancing
science, medical care and public health. Therefore, the
central question addressed by this paper is how to manage
health information ethically? This article argues that Paul
Ricœur’s ‘‘little ethics’’, based on his work on hermeneu-
tics and narrative identity, provides a suitable ethical
framework to this end. This ethical theory has the merit of
helping to harmonise self-esteem and solicitude amongst
patients and healthcare providers, and at the same time
provides an ethics of justice in public health. A matrix,
derived from Ricœur’s ethics, has been developed as a
solution to overcoming possible conflicts between privacy
interests and the common good in the management of
health information.
Keywords Health information management !
Hermeneutics ! Justice ! Narrative identity ! Self-esteem !
Solicitude
Introduction
Health information management (HIM) is defined as
‘‘management of the acquisition, organisation, retrieval,
and dissemination of health information’’ (Medline 2013).
Advances in information technology have opened up new
possibilities for healthcare information to contribute to
clinical care and public health, including links to
biomarkers and genetic databases. Parallel to this progress,
patients and clinicians hope for health benefits without risk
to privacy or intrusive scrutiny. In the healthcare system,
information management most often concerns large patient
databases. The main ethical challenges pertain to patient
informed consent, confidentiality, trust and trustworthiness
(Juengst 2014). The development of genomics has widened
the knowledge gap between the different stakeholders and
increased the complexity of ethical issues regarding the
consent process, data sharing, and return of results to
donors (Tabor et al. 2011). Challenging conflicts in moral
norms have emerged: beneficence versus harm when pro-
viding information, respect for persons’ autonomy versus
their questionable capacity to assimilate information, and a
lack of fairness in the access to support or education for
interpretation of genomics information (Appelbaum et al.
2014).
Moreover, technological progress in health information
tends to focus attention on the information production tools
and the increasing possibilities for data-driven decision-
making for health purposes. New healthcare stakeholders
from the information technology sciences have entered the
medical field with their own health indicators. This issue is
recognised by the World Medical Association as an
important challenge for medical ethics (WMA 2013).
Citizens are also increasingly solicited to contribute
directly to health information, to be involved in the
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decision-making process with their physicians and to
benefit from personalised medicine. This last possibility is
already widely used to leverage the efficacy of transplan-
tations (Dion-Labrie et al. 2010). In the future, health
information systems might ultimately deliver moral rec-
ommendations to healthcare stakeholders. Furthermore, the
way information is generated and used has an impact on
how medical knowledge is shared (Be´ranger and Ravix
2014). Thus, it is essential that all participants in HIM be
involved in the ethical deliberation.
Yet, when patients or healthcare professionals are
exposed to multiple HIM situations, they may be subject to
conflicting moral recommendations. It is still unclear how
to address ethical issues, given the broad spectrum of data
covered by health information management. The standard
biomedical ethical frameworks are usually targeted to a
limited domain: clinical care, research or public health.
The management of health information thus requires an
accommodating normative ethical basis. It is possible to
combine several moral theories in order to cover the
entirety of the HIM field, analogous to the model of
reflective equilibrium defended by Rawls (1971) and
Daniels (1979). But this approach has been criticised, first,
on the grounds that it is difficult to access and put into
practice (Beauchamp 2004) and, second, because in this
model each framework risks losing its distinctiveness and
its specific moral justification (Arras 2007, p. 67). More-
over, combining parts of different ethical frameworks to fit
the entire scope of health information compromises the
coherence of the underlying ethical theory. Therefore, there
is need for a more comprehensive overarching model for
ethical management of health information.
The aim of this research is to answer the question of how
to manage health information ethically? In light of the
expanding fields covered by HIM, a narrative approach
offers an answer to the how by providing a complete pic-
ture, depicting all characters and their interactions over
time. Narration is currently being revisited in its ethical
intention, combining principlism, casuistry and virtue eth-
ics, and positioning itself as a hermeneutic enterprise
(Brody and Clarck 2014). Ricœur’s work on interpretation
is closely related to the narrative aspects of texts, actions
and history (1991). Indeed, for the French philosopher,
narration is crucial for the mediation between action and
moral theory. Based on one’s own narrative identity,
everyone is capable of action aimed at the ‘‘good’’ and
‘‘obligatory’’ (Ricœur 1992). Thus, his ethical theory sur-
passes the binary model of moral rules guided by norma-
tive theories, which has been considered too restrictive
(Takala 2015).
This paper starts by identifying the narrative dimension
of health information management. Narration establishes a
bridge between HIM description and interpretation, which
in turn leads to Ricœur’s view on narrative identity and
ethics. Ricœur’s ‘‘little ethics’’ is then portrayed and
applied in a simplified ethical matrix for HIM. It argues
that Ricœur’s fundamental aim of ‘‘the good life with and
for others in just institutions’’ provides the appropriate
ethical basis for managing health information. The article
does not aim to re-interpret Ricœur’s philosophical ethics.
Its purpose is to show the relevance of the proposed matrix
for the ethical governance of HIM, and to illustrate this
with examples in HIM. Finally, possible objections to this
Ricœur-inspired approach are briefly addressed.
A narrative approach to health information
management
The production and use of health information should not be
reduced to a disembodied collection of data as it engages in
a narrative dynamic involving several healthcare stake-
holders. Healthcare stakeholders (HCS) refer here to all
HIM players, namely patients, donors of biological sam-
ples, physicians and other healthcare professionals, but also
to information experts, health payers and regulators when
they are involved in the management of health information.
This section outlines the value of placing the health
information elements into a narrative mattering map, tak-
ing into account the role of stories.
The mattering map approach to narration
Montello describes the mattering map as a how approach to
moral thinking, which helps focus discernment on what
matters (2014). In analogy to Montello’s model, the HIM
mattering map has voices that tell the story embedded in
HIM, stakeholders as characters, the healthcare domain as
the context, and the purpose and regulations as the plot. The
subsequent resolution of the HIM story identifies the ele-
ments that really matter for patients, their relatives, and
observers. Patients (or donors of biological samples) are the
voices who tell the story. Other stakeholders can contribute
to the tale, but they are not the main narrators. For instance,
the physician’s voice can be the one that informs patients and
collects data. He also shares patients’ data with other users,
and may analyse and interpret the results. Regarding HIM,
narration is never about a single voice, and characters reveal
their sense of social and self-agency through narrative
(Anderson 1997). As in an orchestra, actions and characters
are related by correlation and not by causality. Indeed,
Montello uses the metaphor of music to explain that the
resolution of the plot corresponds to the recovery of ‘‘con-
sonance’’, as opposed to ‘‘dissonance’’ (2014, p. S5).
The patient’s voice has long been valued in narrative
medicine. As it is not just a matter of subjectivity,
532 C. Mouton Dorey
123

objectivity or accuracy, narration reveals something
important and authentic about the patient and supports the
development of patient’s agency and physician’s under-
standing (Shapiro 2011). Frank explains the importance of
patients’ narrative identity and empowerment for medical
decolonisation, i.e. physicians no longer monopolising
patients’ stories for their own benefit (1997, pp. 11–14).
The value of the narrative is not so much about establishing
the absolute truth, but more about emphasising the value of
the trust that should govern the patient-physician relation-
ship. This also applies to the relationships between all
participants in health information management.
Examples of mattering maps in HIM
The mattering map helps identify different forms of nar-
ration in the field of HIM and reveals ethical dilemmas as
dissonances, as illustrated in the following examples.
Firstly, some well-known issues compromising the
benefit of HIM continue to persist. They notably include
the problem of missing voices of patients eligible, but not
included in cohorts. Missing voices originate from char-
acters that are more than the mere numerical proportion of
non-participants. Larger data set sizes may reduce the
influence of misreported data, but cannot make up for what
is not included and recorded. Missing voices could regroup
those who are not compliant to treatment and could, for
instance in tuberculosis or HIV infections, be those who
represent a threat of contaminating other citizens or pro-
moting drug resistance. Their identification in the HIM
mattering map is not only important to ensure valid data,
but also to detect dissonances as a failure of the trust
agreement between these patients and their physicians, or a
lack of transparency and trustworthiness between HIM
characters, or a deception in the construction of the com-
mon good because of biased scientific publications.
Secondly, the mattering map can reveal dissonant HIM
due to the secondary use of data, i.e. when patient/donor
information is provided to third parties in the absence of
patient/donor consent, or even without physicians’ knowl-
edge. Potential breaches in confidentiality and mistrust in
the management of health information require better
guidelines governing access to health databases. This is
especially pertinent with biobanks. Initially based on
human material archived for clinical or research purposes,
biobanks have evolved towards large-scale genetic
research, including the joint analysis of phenotypic and
clinical data from patient cohorts (Wain et al. 2015).
Voices and characters are better identified with the addition
of data on phenotypes and medical contexts. This combi-
nation supports innovative research and more personalised
diagnosis and treatment for patients. Thus, new HIM
mattering maps are emerging in genomics. For instance,
the return of incidental findings to donors follows various
plots, depending on the findings and the type of informed
consent. Considering the family members of the donor,
Lenk and Frommeld have analysed different models, in
which, through the description of actors, roles and contexts,
the narrative components are revealed (2015).
Thirdly, in the context of personalised medicine, the
HIM mattering map has to consider the emergence of
predictive components of increasing precision, which
contribute to more specific diagnostic tests, refined disease
classification and individualised treatments (Jameson and
Longo 2015). As a result, HIM faces an ethical dilemma
between an abstract promise of truth carried in the emer-
gent information, and a concrete decision to be reached on
the communication and use of this information. The
patient’s voice might fade behind the intrusion of these
new medical scientific findings or, quite the reverse,
enforce the patient’s participation in the medical decision.
Each individual could be the heroine/hero in her/his own
health story. This is already noticeable in medical screen-
ing, with the publication of amazing survival stories fol-
lowing early cancer detection. There are also negative
stories of overdiagnosis that challenge the validity of
screening advantages (Moynihan et al. 2014). These con-
flicting stories around the issue of screening exemplify
another risk of narrative dissonance in HIM, e.g. the
accuracy of the decision when there is insufficient evidence
of the predictive value of new biomarkers.
Fourthly, dataset linkages, multiple uses of data in large
medical databases, as well as the increasing availability of
individual health data from the internet or mobile devices,
have contributed to the development of big data in health.
Big data represents the process that uses and reuses health
and research data with the help of sophisticated digital
processing and algorithms; the objective is to identify new
health patterns based on data mining methods, which open
new perspectives for future medical research and are thus
different from traditional hypothesis testing methods
(Nuffield Council 2015, pp. 15–16). The mattering map
recognises these patterns as new types of plots in HIM,
disconnected from inceptive single voices and challenging
the roles and responsibilities of traditional characters.
Indeed, data mining can be performed by information
experts without the intervention of physicians or the need
for close relationships with patients/donors. The applica-
tion of big data algorithms is dramatically increasing
complexity in HIM narration. On the one hand, big data
supports the detection of unexpected or rare patterns that
hypothesis-testing research ignores. On the other hand, the
correlation of findings with disease or prognosis may be
unclear. This evolving but still uncertain medical context
requires revisiting ethical views on individual consent,
privacy, public health interests, information property,
Rethinking the ethical approach to health information management through narration: pertinence… 533
123

altruism and commercial development (Vayena et al.
2012).
Finally, advances in data size and analytic methods in
HIM could be seen as a resurgence of scientific positivism,
adding new narrative paths in the research for truth, and
challenging the moral references for medical and bioethical
judgement. Depending on the queries, numerous different
plots could be revealed, which not only enhance scientific
research, but also carry new patterns in moral thinking for
HIM itself.
These HIM examples are not stand-alone and can be
combined into a wider mattering map. The plurality of
sources and connections constantly enlarges the HIM
domain. Nevertheless, big is not always better for the
management of health information (Toh and Platt 2013).
Therefore, a narrative approach would mitigate the eager-
ness of data-driven medical judgement, and stimulate
reflection in order to better interpret, i.e. discern and
understand the type of precision, truth, and voices that
matter in the management of heath information.
The passage by interpretation and the link
with Ricœur’s philosophy
The narrative approach opens up different perspectives of
interpretation permitting an understanding of the patient,
the message embedded in the health information and the
behaviour of those using the information. The model of text
interpretation can be applied to HIM following the quan-
titative (data processing) and qualitative (information
management) aspects. This duality mimics the distinction
between the locutionary part (the sentences) and the illo-
cutionary part (how sentences are expressed) of a text, both
of which meanings need to be analysed (Ricœur 1973). The
theory of text and the theory of action have been developed
separately in philosophy, and both theories can lead to a
dichotomy between an explanation of structure and an
understanding of motivation. Ricœur refutes this dichot-
omy because there is a continuous interference of human
action in the course of events and vice versa, and this holds
for text and action as well (1991). As a result, everything
that can be understood from human action and history can
be interpreted as a text.
This hermeneutical approach to action as a text is relevant
for both historical and fictional narrative. At the intersection
of these two key classes of narrative there stands human
identity, which has to be understood as a narrative identity.
Ricœur calls narrative identity the assignment of a specific
identity to an individual (or a community) who is the subject
of an action and who tells the story (1988). He differentiates
two poles in the narrative identity: sameness and selfhood
(1992, pp. 115–125). Sameness is about the question ‘‘what I
am’’, the usual identity conception of being the same person,
different compared to others and permanent throughout life
and its course of events. Sameness concerns natural traits,
physical, biological, and genetic characteristics. Selfhood is
about ‘‘who I am’’, the very specific self, who is reflecting,
non-permanent, adaptable, and capable of determining its
own life. Selfhood implies an intimate relationship to oth-
erness, and comprises the idea of faithfulness to the self ‘‘en
devenir’’ (i.e. in the process of developing). Selfhood has an
ethical dimension that evokes the agency freedom advocated
by Sen (1985). Furthermore, the so-defined narrative identity
can be applied to the individual as well as to the community,
and these identities can be combined to build a common
story.
The management of health information finds an echo in
Ricœur’s account of narrative identity. The construction of
the plot brings to life the actions of the characters. Ricœur
considers that this transposition from actions to characters
establishes the characters’ narrative identities in their two
dimensions of sameness and selfhood (1992, pp. 140–143).
Indeed, when patients/donors provide data, they share their
narrative identity as sameness, adding their voice to the
other same. Their narrative identity as selfhood makes
them capable of deciding whether or not to participate, to
give up rights to some personal sameness, to interact with
the other stakeholders and institutions in a responsible way,
to receive feedback information and to adapt accordingly.
Each patient is also part of a community and contributes to
the common narrative identity. Interpretation of the nar-
rative HIM supports both the self-comprehension of a
given participant and the comprehension of others in the
medical and social community. Consequently, private and
community goods are intimately interconnected, and it is
possible to overcome the classical ethical dilemma between
privacy rights and common good.
Furthermore, the interpretation of narrative HIM falls
within the dimension of temporality (Ricœur 1984,
pp. 52–87). The plot includes a succession of events with
the possibility of unexpected events or patterns, depicting
the narrative time. The concept of narrative time is par-
ticularly important with new types of HIM since
biomarkers or population patterns can be delivered at a
time when their value and possible medical use are not yet
understood. As it combines individual and community
aspects, as well as temporality, Ricœur’s concept of nar-
rative identity supports a more comprehensive model for
interpreting HIM narration, compared to the relatively
narrow model of narrative medicine for specified clinical
settings as developed by Charon (2001). This enriched
model helps progress from interpretation to comprehension
of HIM and establishes a first ethical perspective.
Ricœur further defends the passage from narrative
identity to ethics. He identifies different roles for
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characters, with the possibility to be both subject and actor
in a story. Thus, the patient is a human being acting and
suffering, and this attests the correlation between narrative
and ethics (1992, pp. 145–164). In the narrative HIM,
actions are evaluated: patients and healthcare providers are
actors, who can be approved or admonished, and their
individual narrative identity is exposed to the regard of
others. The narrative identity transforms a passive char-
acter into an active one, capable of deciding and acting
accordingly. Specifically, it confers self-determination and
accountability to the role. Therefore the narrative theory
serves as mediation between the theory of action and the
theory of ethics. Moreover, Ricœur’s ethical theory
develops the promise of sharing between the two narrative
identities, personal and collective. Such a promise of
sharing is essential for the ethical governance of HIM. This
paper will thus further explore the ethical vision proposed
by Ricœur.
Overview of Ricœur’s ‘‘little ethics’’
Ricœur first proposed his ‘‘little ethics’’ in the book
‘‘Oneself as Another’’ (1992). He then completed his eth-
ical work in further lectures and in two books on ‘‘The
Just’’ (2000, 2007). He differentiated between the terms
ethics and morality. Ethics is about what is considered to
be good (teleological, Aristotelian perspective), and
morality is about what imposes itself as obligatory (deon-
tological, Kantian perspective). He proposes a new archi-
tecture for ethics which explores ‘‘the capacities and
incapacities that make a human being a capable, acting and
suffering, being’’ (2007, p. 2). The concept of agency
conveys this capability to act and to be accountable for
one’s own actions. Agency expresses itself through the
narrative individual and collective identities (2000, p. 3).
Thus, ethics is not about the identity of things, data or a
disembodied healthcare information system, but about
moral agents (in our topic, healthcare stakeholders). This
analysis supports the idea that the right metaphor for the
healthcare information system is not a business or ware-
house model, but rather a human organisation. Indeed,
Ricœur’s work is about participative and communicative
human organisation, with the concept of ‘‘The Just’’
influencing all human actions.
Ricœur’s ethical philosophy rests upon the following
three propositions: ‘‘(1) the primacy of ethics over moral-
ity, (2) the necessity for the ethical aim to pass through the
sieve of the norm, and (3) the legitimacy of recourse by the
norm to the aim whenever the norm leads to impasses in
practice’’ (1992, p. 170). This article describes the three
steps consecutively.
The primacy of ethics over morality
Ricœur names ‘‘anterior ethics’’ the ethical aim of the
‘‘good life, with and for others, in just institutions’’. Within
this anterior ethics, he distinguishes three ethical values
that are linked, but do not overlap: self-worth, reciprocal
trust, and participative justice.
Self-worth
The teleological philosophy of the good life (sense of life in
its entirety, not only biologic or fragmented) includes the
notion of good virtuous actions, such as standards of
excellence for physicians, as well as the good life towards
which all these actions are directed. When they interpret
their actions, the agents develop a self-interpretation which
becomes self-esteem at the ethical level (1992,
pp. 172–179). Self-esteem corresponds to the good applied
to actions.
Reciprocal trust
Solicitude, as described by the good with and for others is
the ethical phase about reciprocity, sharing and living
together. Solicitude is based on the exchange between
giving and receiving. Although this exchange in a friend-
ship relationship is hypothetically equal, most often a
dissymmetry appears because the initiative for the
exchange comes either from the self or from the other.
Based on an ethical response of benevolent spontaneity
(e.g. the patient) or spontaneous compassion (e.g. the
clinician), solicitude aims to establish equality in dissym-
metrical conditions, the self becomes another among oth-
ers. This element of similitude implies trust and belief in
one’s own worthiness.
Participative justice
The sense of justice is the third phase of this anterior ethics.
When a relationship encompasses many citizens from a
community or nation, the notion of life concerns the
institutions. Institutions are defined by the structure of
living together bound by common customs and not by
constraining rules. The ethical aim introduces the dimen-
sion of justice as proportional equality for each. Ricœur
identifies two faces of the just, one teleological towards the
good and one legal towards the judicial system and the law
of constraints. His anterior ethics focuses on the teleolog-
ical face and concerns the sense of justice, which combines
both aspects of sharing: ‘‘being part of’’ and ‘‘receiving a
share of’’. This dual view precludes opposition between the
individual and the society. The unjust is synonymous with
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unequal, taking too many of the advantages or not enough
of the burdens. This sense of justice extends equality to the
entire humanity.
The normative or deontological level
The second proposition analyses the moral level (i.e. the
norms), which corresponds at the ethical level to self-es-
teem, solicitude and sense of justice. The formalism of the
norms represents the obligations, which ensure a just dis-
tance between HCS in all plots. Ricœur believes that the
passage through the norm enriches the anterior ethics (1992,
p. 203). Autonomy, respect for others and legitimacy of
distributive justice are the dominant deontological values.
Autonomy
At the deontological level, self-respect corresponds to the
ethical aim of self-esteem. Ricœur refers to deontological
Kantian morality and the corresponding principle of
autonomy because the same subject has both powers of
giving orders, and of obeying or disobeying. Maxims are
submitted to the rule of universalisation and associated
with the idea of duty. Self-esteem, which does not pass the
test of universalisation, is ‘‘self-love’’, a penchant for evil
that affects the freedom to act and the capacity for being
autonomous.
Respect for others
Solicitude corresponds at the moral level to respect for
others and to the second Kantian imperative of persons as an
end in themselves. There is a need to (re)establish
reciprocity in front of the initial dissymmetry between
agents and subjects, due to the exercise of power of one will
over another will. The answer of moral norms is a ‘‘no’’, a
prohibition of all the forms of evil, violence, and humilia-
tion, whereas, at the ethical level, solicitude was affirmative
in compensating the dissymmetry in self-esteems.
Legitimacy of distributive justice
Finally, at the deontological level, Ricœur considers a
strictly procedural justice, as developed by John Rawls in
opposition to Utilitarianism (1971). The legal face of the
just is separated from the good, and rests upon the tradition
of the social contract, a founding fiction that is anti-teleo-
logical. Ricœur, however, challenges the procedural justice
of Rawls since the justification of equality and inequalities
has no recourse to anterior ethics. For him, the fiction of the
social contract is compensation for the forgotten ethical
foundation of ‘‘the desire to live well with and for others in
just institutions’’ (1992, p. 239).
‘‘Posterior’’ or applied ethics
Applied ethics follows the third proposition and represents
the other face of ethics, i.e. wise recourse to the ethical aim
when norms face conflict in practical situations. Ricœur
develops practical wisdom in order to deliberate justly at the
three previous levels of the institutional environment, the
plurality of persons and the universal self (1992, p. 240).
Sharing in practice highlights the recourse to values of
equity, confidentiality and the ability to judge wisely.
Institutional environment and equity
The rule of justice includes an element of ambiguity
because of the diversity of the primary goods to be dis-
tributed. The fairest rules of justice face the issue of arbi-
trage between different goods that delimit different spheres
of justice. The indeterminacy in political power may open
the door to domination, totalitarianism and exploitation.
Following Aristotle, Ricœur appeals to equity as practical
wisdom in order to correct possible conflicts in the appli-
cation of the rules of justice.
Plurality of persons and confidentiality
With regard to respect for others and the second Kantian
imperative, conflicts can arise in the application of the
universal law and the need to arbitrate between the mul-
tiple duties that pass the test of universalisation. The dis-
symmetry in interpersonal relations has the potential for
conflicts, with a risk of arbitrariness when the idea of
protection replaces the idea of respect. This distinction is
complex in novel situations, such as biomedicine, where
progress and technology also include an imperative of
responsibility towards the future generation. Ricœur
appeals to a ‘‘critical’’ solicitude as the form of practical
wisdom in the situation of conflicting interpersonal duties.
Universal self and the ability to judge wisely
Finally, the principle of autonomy as self-legislation is
subject to moral conflicts in situations in which moral
judgement has to arbitrate between universal rules of
morality and contextual moral values. Ricœur opts for a
critical argumentative ethics and refers to Rawlsian
reflective equilibrium. In posterior applied ethics, practical
wisdom implies a real discussion with mutual recognition
and openness to truth or to meanings that are foreign to the
self. It is recognition that structures the ethics from self-
esteem to solicitude and to justice, i.e. applied ethics is
developing backwards from the idea of justice to respect
for others and finally respect for oneself as another (1992,
pp. 273–274, 280–281).
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A simplified matrix for health information
management based on Ricœur’s ethics
Ricœur applied his ‘‘little ethics’’ to the medical domain by
developing three levels of moral judgement: ‘‘prudential’’
with practical wisdom in posterior applied ethics, ‘‘deon-
tological’’ at the normative level, and ‘‘reflexive’’ at the
level of anterior ethics (Ricœur 2007, pp. 198–212). In the
situation of medical practice, Ricœur’s starting point for
consideration is posterior ethics. He regards the relation-
ship between suffering patients and physicians as the basis
for ethical significance in bioethics (Ricœur 2007, p. 198).
Ricœur further explores the dimensions of prudential
judgement by comparison with judicial judgement, which
involves a greater number of protagonists (2007,
pp. 213–222). He recognises that the concrete act of
medical decision-making involves a growing number of
protagonists coming from the medical sciences or public
health. New issues are raised such as ‘‘colonisation’’ of the
medical act by rapidly advancing biologic and genetic
knowledge (p. 215), or ‘‘fairness’’ in relation to medical
costs at a population level (pp. 216–217).
This paper has used a similar approach to build an
ethical matrix in the field of health information manage-
ment (Table 1). The proposed ethical matrix includes the
three levels of judgement from Ricœur’s ‘‘little ethics’’ as
columns: anterior ethics (or reflexive), moral norms (or
deontological) and posterior applied ethics (or prudential).
The design of the matrix integrates the second dimension
of the ethical aim of the ‘‘good life, with and for others, in
just institutions’’ aligned with the three steps of ethical
considerations for stakeholders: self, others, and society.
The matrix connects HIM with Ricœur’s ethics using a
Ricœurian path of reflection. Ricœur supports a reflective
process in medical judgement, for instance when he
questions the link between ‘‘the request for health and the
wish to live well’’ (2007, p. 212). An analogous parallel for
HIM would question the evidence of a positive relationship
between profuse health information and improved well-
being. For descriptive purposes, this paper progresses
through the matrix line by line. As in Ricœur’s medical
judgement, the HIM context of the patient-physician
interaction is used as a basis for reflection, which can then
be extrapolated to alternative HIM situations.
Self
The self-esteem developed with the aim of ‘‘the good life’’
expresses itself as the moral norm of self-respect and
autonomy. Patients choose freely to participate in HIM and
give up rights to their personal data. However, the practical
situation is dissymmetrical, the physician having more
knowledge, information and position power than the
patient. Patient agency needs to be empowered, and the
patient-physician alliance will develop agency, providing
that there is trust on both sides. This means, in particular,
that the patient trusts and follows the physician’s advice,
and that the physician trusts the patient’s voice and tries to
fill the gap of the patient’s ignorance. Physicians are also
increasingly accepting scrutiny of their personal work by
the other participants involved in the management of health
information.
In the posterior applied ethics column, HIM relies on the
patient-physician pact based on trust, similar to other
medical situations based on ‘‘agreement regarding trust’’
(Ricœur 2007, pp. 199–200). In the absence of the corre-
sponding moral norms of self-respect and autonomy
(deontological column), this trust pact is weakened, with
the practical risk that patient participation in decisions
regarding HIM would be neglected, and as a result the
patient would feel humiliated or unable to overcome pas-
sivity. Thus, suffering patients are vulnerable to the
physicians’ abuse of power or failure to fulfil their
expectations regarding management of their personal
health information. In the anterior ethics column, the
patient is considered as indivisible regarding clinical, bio-
logical, psychological, and social identities. This narrative
unity stresses in turn the importance of patient agency and
the roles of physicians who face the singularity of each
patient in practice. The physicians’ appropriate training
and experience should help to overcome the dissymmetry
of knowledge between them and the patients, as well as
other HIM agents. More generally, health providers should
be accountable for empowering patient agency and, as a
result, the trust agreement would be maintained for ethical
management of health information.
Others
The anterior ethical aim of solicitude as ‘‘a good life with
and for others’’ expresses itself as the moral obligations of
respect for others and benevolence, which in turn support
the posterior applied values of confidentiality, patient
autonomy, applications of the professional code and
respect for patient rights. Practical wisdom encourages a
collective narrative in the management of health informa-
tion including trustworthiness between all healthcare
stakeholders. The norms of reciprocity and benevolence
protect those who are passive and vulnerable because of
lower capacities, and justify equal consideration of others
as another self.
The fragility of this medical contract comes from the
difficulty of differentiating between the HIM for clinical
care and the HIM for healthcare research, with research
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requiring more stringent norms. Ricœur identifies this issue
when he points out that ‘‘the human body is both a personal
being and the observable object of scientific investigation
as a part of nature’’ (2007, p. 206). Therefore, individuals
can be observed as an object, and the corresponding
measurements can be used independently of the donor,
with the risk of misuse of health information and harmful
exploitation. Following Ricœur’s approach to solicitude
and benevolence for and with others, practical wisdom for
judgement in HIM should follow ‘‘the three rules of
medical secrecy, the patient’s right to the truth, and
informed consent’’ (2007, p. 211).
Society
Solicitude is necessary for sharing data between HCS, but
not always sufficient. A society with just institutions will
provide equitable access to and use of health information
results, as this participation is the foundation of a common
morality. The theme of justice is represented in the first
column of the matrix and culminates in the line ‘‘society’’
with the establishment of a just distance in the relationship
with all other human beings. The concept of justice in
society then evolves horizontally across the three columns
from sense of justice, to social justice based on legislation
Table 1 Ethical matrix for health information management (HIM), derived from Paul Ricœur’s work (1992, 2000, 2007)
HIM healthcare
stakeholders (HCS)
Anterior ethics (teleological,
Aristotle)
Moral norms (deontological, Kant) Posterior, applied ethics (to HIM)
Self Aim at the good life:
Good as actions:
Virtues
Deliberation on means to reach them
Vocation
Standards of excellence
Good as self-esteem:
Narrative unity of life, narrative
identity
Self-esteem different from esteem of
myself
Self-respect:
Goodwill
Universalisation of the moral law
Autonomy as moral selfhood, practical
reason, free choice
Issues:
Passivity within autonomy
Acts not imputable to agent
Perversion: self-love
Misuse of free choice, inclination
towards evil
Patient–physician pact based on:
Trust agreement (on each side)
Agency empowerment
Levelling out dissymmetry of
knowledge and respect
Building alliance to decide and
act
Fragility of the pact:
Patient preferring dependency
Clinician humiliating patient
Others For and with others:
Solicitude (concern for others):
As a vital extension of self-esteem
Friendship and reciprocity
Equal good to others as another self
Sharing
Living together
Benevolent spontaneity
Opposed to suffering
Respect for others:
Golden rule
Norm of reciprocity, benevolence
Dissymmetry between active and passive
roles
Issues:
Torture, violence, humiliation as
destruction of others’ self-respect
Exploitation
Betrayal
Medical contract (mandate):
Confidentiality, professional
secrecy
Sharing truth, collective
narrative
Patient information and consent
Professional codes, patient rights
Trustworthiness between HCS
Fragility of the contract:
Boundary between clinical care
and research
Society In just institutions:
Living together:
Participation in the life of institutions
Common mores
No split between governing and
governed
Plurality: anonymous but
irreplaceable
Action in concert but some are
forgotten
Justice:
Justice as virtue, desire for just and
good actions and things
Equality: distributing as sharing and
repairing
Principles of Justice:
Public health laws:
Legal authority
Legitimation
Justice:
Equality: distributive justice
Social contract
Issues:
Arbitrage between legal authority and
common good morality
Ignorance of teleological foundation
Common good partnership:
Public healthcare agency
Communication, dissemination,
transparency
Solidarity, equity, access to care
Concerns for missing/neglected
patients
Fragility of common good
partnership:
No obligation to be healthy
No obligation to cure
Unreasonable expectations
Lack or excess of prudence
Hurdles to sharing
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and procedure, to justice as equity in the face of practical
problems.
A broader view than the patient–physician pact and the
three prudential rules in medical judgement is required for
HIM at the society level. More precise biomedical infor-
mation from scientific experts changes the paradigm of
medical decision-making towards a more technical
approach (Ricœur 2007, pp. 214–215). Furthermore, pop-
ulation statistics and economics shift the decision-making
process from the suffering individual to the protection and
sustainability of public health according to norms of dis-
tributive justice (pp. 216–217). Justice is thus relevant at
the three levels of judgement, i.e. all HCS have to be part
of the governance of HIM and organise their co-existence;
the legal norms should protect patient privacy and legiti-
mate public health actions; applied ethics should ensure
equity with a just sharing of burdens and a just dissemi-
nation and interpretation of health information.
Application of the ethical matrix reflection path
to HIM examples
The examples described with mattering maps in ‘‘A nar-
rative approach to health information management’’ sec-
tion are analysed using the ethical matrix derived from
Ricœur’s ethics. The points of weakness that were identi-
fied in the Introduction (first paragraph) serve to identify
the ethical issues to be reflected upon. The examples are
discussed as separate cases for didactic reasons.
Trust and trustworthiness: missing patients
and validity of HIM
In clinical practice, a bottom-up participation to common
good would minimise the number of missing patients in
research databases (society). Communication, trust and
trustworthiness between all HCS would be encouraged,
including the possibility of combining social support in the
community network (others). The steering committees for
HIM should consider field knowledge and include repre-
sentatives of first-line data-collectors, patients and social
communities. Drafts of publications should be shared and
discussed prior to publication.
Informed consent, respect for persons’ autonomy
versus their questionable capacity to assimilate
information: HIM and secondary uses of data
Concerning access to health information by third parties,
applying the trust agreement and the medical contract as
described in the matrix would solve the ethical issue of
patients suffering and feeling betrayed following
inappropriate use of their data and consequent infringement
of their privacy. In practice, first-line physicians ought to
be informed by third parties about all aspects and possible
future developments of healthcare information to which
they are contributing (others). While building trust with
patients in the iterative process of consultations, the
physician should also help patients reach an adequate level
of comprehension and provide appropriate information
concerning the current and future management of their
healthcare data. As their level of HIM literacy improves,
patients can aim for a status of associate, sharing decisions
on the management of their health data and information
with healthcare professionals (self).
Consent process, data sharing: issue of broad
consent
As for biobanks, some hospitals have introduced broad
consent covering the future use of patients’ coded or de-
identified health information. This means that patients are
not fully informed at the time of consent since nobody can
know all the future uses. The consent might be legally
right, depending on the specific country of legislation
context. However, Ricœur’s ethical architecture supports
the primacy of ethics over legislation, meaning that just
institutions are not only institutions ruled by law, but are
participative institutions, with shared values for just and
good actions. In practical situations of conflicting judge-
ments on consent process and data sharing, the matrix
refers to the anterior ethics arbitrage based on solicitude
and the sense of justice as sharing and participation.
Therefore, a broad consent should require ethical reflection
involving all HCS before its possible acceptation. The
World Medical Association has also advocated the primacy
of ethics over law and does not favour unconditional broad
consent (WMA 2003, 2015).
Beneficence versus harm when providing
information: personalised healthcare
In the genomics example on the return of incidental find-
ings to patients or their family, no model for information
and consent has been considered as ethically optimal.
Appelbaum et al. have recommended a better education for
donors. They also consider researchers to be account-
able for providing this service and reducing the potential
harms related to health genomics information (2014).
New medical sciences applied to personalised medicine
are provoking the emergence of new biomedical patterns of
sameness, disrupting a patient’s/donor’s self-interpretation.
Narrative identity as selfhood needs to clarify one’s self-
understanding continuously. Furthermore, incidental find-
ings in genomics, or screening results for early disease
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detection, confirm that the narrative time is important: new
findings could emerge unexpectedly in the patient/donor–
physician/researcher relationship.
In the matrix, the applied ethics column supports
Appelbaum’s proposition, i.e. the empowerment of
donor/patient agency, as well as the researchers’/physi-
cians’ responsibility for levelling out the dissymmetry of
knowledge regarding genetic testing (self). As a result,
shared decision-making is possible. The matrix challenges
the usual ethical approach, in which researchers or physi-
cians are left alone to obtain meaningful informed consent
from donors or patients. The teleological aim combining
justice and living together drives the legitimacy of the
moral decisions for HIM in genetic testing and medical
screening, and helps to match the research tempo with the
common good (society). Moving upwards in the anterior
ethics column, the sense of justice will lead to benevolent
sharing with others and protecting the self-esteem of the
most vulnerable. This ethical deliberation results in
recognition of the specific narrative identity of each par-
ticipant, who thus becomes capable of acting and deciding
on genomics testing or medical screening. Furthermore,
based on Ricœur’s ‘‘circular’’ concept of narrative identity
and temporality (1988, pp. 241–249), the matrix proceeds
in a Ricœurian path of reflection and puts critical argu-
mentative ethics on a long-term footing. This permits a
settlement between the two different times of abstract
findings and concrete decision-making. In practice, the
ethical matrix supports the disclosure of incidental findings
under conditions of benevolent reciprocity and time. It thus
opens a reflection path for human governance of data-dri-
ven health management in personalised medicine.
Fairness in HIM: objectification of individuals
versus new scientific advances with big data
The primacy of ethics over legislation holds for the man-
agement of health information with big data. Big data
escapes the traditional narrative of medical practice, clin-
ical research and the patient/donor–physician/researcher
relationships. The ‘‘three rules of medical secrecy, the
patient’s right to the truth, and informed consent’’, as well
as the concept of individual indivisibility are challenged.
Moreover, the high speed of big data development requires
continuous normative adaptation to legitimise their use.
In the matrix, the ethical reflection path for big data
relies on the concept of justice developed in the three col-
umns of applied posterior ethics, moral norms and anterior
ethics. The sense of justice is the key element as it supports
sharing, i.e. making available the sources, algorithms and
results of big data, as well as repairing when findings have
harmed people. The corresponding principles of social
justice and the equitable dissemination of knowledge will
favour a bottom-up ‘‘democratic’’ participation around the
governance of big data. Therefore, citizen education and
participation would protect patients and health providers
from uncontrolled fears leading to an unreasonable princi-
ple of precaution, as well as from potential hidden coercion
of public health or absence of prudence in the use or
commercialization of big data. Such a democratic man-
agement of health big data could enhance the ethical
reflection of HCS, increasing their self-esteem and agency,
and reduce the risk of medical or public arbitrariness.
Finally, this paper has mentioned, at the end of ‘‘A nar-
rative approach to health information management’’ section,
the possibility that moral queries in big data could unveil
innovative normative patterns in moral thinking for health
information management. This could challenge the current
normative principles of justice. The matrix helps to analyse
the issue since procedural justice does not pre-empt the eth-
ical construct for HIM. The process of deliberation starts at
the level of posterior ethics with openness and prudence in the
founding of common good. Then, normative development
proceeds by adjustment using anterior ethics, gradually
revising public health legitimacy and distributive justice.
Moreover, the matrix sets limits in the face of a possibly
misleading moral guidance of big data, with the anterior
ethics column establishing a clear ethical aim. For instance,
the matrix differentiates between esteem ofmyself (self-love)
and self-esteem, and would limit excessive health demands.
In summary
The matrix derived from Ricœur’s ‘‘little ethics’’ is an
appropriate ethical framework for application to the man-
agement of health information because it emphasises
patient agency, trust agreement between HCS, and justice
as equal and equitable participation to the common good.
Ricœur’s ethics takes into account the contributions of
other ethical approaches, such as the Kantian and Rawlsian
theories, but ensures the primacy of anterior ethics over
moral and legal norms. The recourse to anterior teleolog-
ical ethics allows the possible moral conflicts to be over-
come and leads to wise and shared decision-making in the
management of health information in medical practice,
research and public health. This model of continuous eth-
ical reflection could be transferable to other technology-
transformed healthcare activities.
Brief critical appraisal of Ricœur’s ethical
approach
As a result of the widely held view that he was a
philosopher of great complexity, Ricœur is rarely referred
to in biomedical ethics (Potvin 2010). His extensive work
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is built up architecturally in successive books comprising a
continuous in-depth reflection which looks for coherence
between ancient and recent philosophical theories. There-
fore, there is a risk of favouring only part of his work, or of
disregarding it as a whole. In this paper, the focus has been
placed on Ricœur’s ‘‘little ethics’’, and some objections to
this ethical approach need to be briefly addressed.
First, reference to the good life might convey the
impression that Ricœur’s ethics is simply about virtues and
care ethics. Care takes into consideration patients’ voices
and desires, but usually conflicts with a depersonalised
public health orientation. Although his approach has some
points in common with care ethics, Ricœur does not reduce
justice to friendship and equal consideration for others (Van
Stichel 2014). He justifies the teleological aspect of justice
by a passage through the norms of distributive justice and
the political social contract. His ethical approach favours the
concept of common good, rejection of injustice, and solic-
itude/love within the philosophical domain.
Second, the possible reproach of the is/ought fallacy
could be raised. The narrative approach of HIM can be
considered as a descriptive one (‘‘is’’) and therefore as not
having to lead directly to prescription and moral norms
(‘‘ought’’). Ricœur’s ethics avoids any direct connection
between description and prescription when he introduces
the passage by interpretation (1992, pp. 169–170). This
approach is supported by his philosophical work on
hermeneutics. Furthermore, there is no such thing as a pure
‘‘is’’, and empirical data are not only facts, but also include
experiences, cultural and normative elements (Dunn and
Ives 2009). This holds for HIM, with normative influences
having an impact on HIM design and purpose.
Third, the choice of a teleological philosophy as anterior
ethics may be challenged. Anterior ethics is ‘‘de facto’’
teleological. It is difficult to find alternatives. Ricœur
indicates that Mill, but also Kant referred to some teleo-
logical goodwill, albeit in a soft way. Recent ethical
frameworks for healthcare have introduced economic
wellbeing as an ethical theory basis, justified by the need to
have sustainable healthcare (Faden et al. 2013). The value
is then the sustainability of something considered valuable,
and refers to teleological equality as sharing with those in
the future. In this example, economic wellbeing cannot
pass the test of anterior ethics directly. It belongs to the
moral norms.
A fourth objection could be that this overarching ethical
framework is too complex and theoretical. Yet, far from
being too theoretical, this ethical oversight can already be
detected in the management of health information in
practical fields, such as rare diseases, where patient agency,
patient information and consent, physician accountability
and the distinction between care and research are exten-
sively developed (Duchange et al. 2014). Furthermore, this
paper has demonstrated that the ethical matrix adapted
from Ricœur’s ‘‘little ethics’’ supports a deliberation pro-
cess that can address practical issues in emergent narratives
of HIM, such as those raised by personalised healthcare.
Conclusion
The ethical management of health information concerns all
healthcare stakeholders, healthcare professionals, as well
as patients. This paper has suggested that a narrative
approach to HIM is able to connect individual and col-
lective narrative identities. Moreover, this narrative
approach has similarities with Ricœur’s dual concept of
narrative identity as sameness and selfhood. Using inter-
pretation as mediation between narration and prescription,
Ricœur shows the importance of moral agency, and that the
capacities of acting and suffering belong to an ethical
order. Ricœur’s ‘‘little ethics’’ inspires a useful ethical
framework for the management of health information,
helping to prevent the tendency to reduce patients to mere
data, and healthcare providers to mere data gatherers, in
addition to contributing to solving moral conflicts in the
healthcare information context. The ethical matrix pro-
posed in this paper combines the dimensions of self, others
and society with the dimensions of anterior ethics, moral
norms and applied ethics. The dominant values of agency,
trust and justice help to guide practical wisdom in
managing health information.
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10. Conclusion
Narrative identity makes ethical sense of patient data 
I drew upon Montello’s metaphor of opera and her concept of the mattering map indicating 
what matters and to whom.83 Therefore, consistently considering a patient narrative identity 
replaces a too Manichean view with a normal or pathologic patient status. However, Montello 
considers narrative ethics as the domain of literature and not normative. This position 
supports the difficulty of inferring prescriptive “ought” statements from descriptive “is” 
statements. The is-ought fallacy is regularly advocated in bioethics and prevents a direct 
passage from empirical facts to values. Nevertheless, on this matter a Manichean position 
between facts and values is also open to criticism. Based on a hermeneutical approach, 
Ricœur challenges this naturalistic fallacy. He uses the passage by interpretation to expose a 
concept of narrative identity including a responsible self, capable of thinking and acting 
according to values. Furthermore, he develops this narrative identity at an individual and 
collective level, and also in a historical perspective. Applied to patient data, Ricœur’s 
position echoes back to my experience and intuition about a patient’s data being part of 
his/her own story and voice, as well as contributing to a wider community. Referring back to 
the ethical governance of patient data, the coherence of narrative identity in the different 
integrated stories necessitates a common and meaningful direction. This common aim is 
ethics for Ricœur, and he formulates the ethical aim of «The good life, with and for others, in 
just institutions». 
The governance of patient data would then target a common ethical aim for stakeholders as a 
priority over the operational production of patient data. This ethical aim guiding narrative 
identity at individual and collective levels would reconcile public interest and patient rights in 
the management of health information. Actually, consideration of narrative identity as in  
Ricœur’s ‘little ethics’ has helped open up the ethical reflection on patient data. Far from 
being building blocks to construct a data warehouse, patient data instead appear as an 
indivisible component of the individual and collective narrative identity. This approach 
reconciles privacy and public interests, as each individual is potentially both a data donor and 
a person capable of involvement in data governance and return of information. Pursuing the 
orchestra metaphor, justice can be viewed as the musical arrangement creating a common 
harmony. Based on Ricœur’s philosophy, individual rights as well as the reasons underlying 
public interest, should all be driven by the common “direction” of the ethical aim.  
83 Montello, M. 2014. Narrative ethics: The role of stories in bioethics, special report. Hastings Center Special 
Report, 44(1):S2–S6. 
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With respect to the production and use of patient data, this normative frame does not support 
the competing approach of patient rights and public interest. Neither does it acknowledge the 
divide between an ethics of care, ontologically focused on responsibility and relationships 
between people, and an ethics of justice focused on autonomy and individualism. Ricœur’s 
concept of solicitude has been widely used in the ethics of care and too often restricted to a 
compassionate perspective or a sense of justice reduced to equal consideration for others. 
Ricœur has extended the concept of justice, with the idea of The Just also being applied to 
vertical approaches of legal authority, social contract and distributive justice.  
 
This normative reflection facilitates a reframing of the ethical governance for patient data. I 
shall explain it in the following part V.  
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PART V. CONCLUSION 
In this dissertation, I have defined patient data as the production and use of health-related 
data coming from healthcare and biomedical research settings, including their re-use and 
linkage within large patient data sets. I have identified that the underlying reasons for the 
public interest in patient data are numerous and contextual – research, clinics, public health, 
economics. Furthermore, their justification involves different theories of justice, including the 
recourse to reflective equilibrium where viable. I have considered that patient rights are based 
on human rights and human dignity, that patient privacy rights are linked to healthcare 
professionals’ duty of confidentiality, and that rights to be informed and to self-manage 
consent or withdrawal are linked to respect for autonomy. Furthermore, I have used a concept 
of autonomy broader than mere autonomous choice.  
This spectrum of definitions of public interest and patient rights made moral assessment of 
the degree of acceptability of overriding patient rights a challenging one. It was therefore 
necessary to clarify governance of patient data. I thus posed and addressed the question of 
How to appraise the issues raised from the tension between patient rights and public interest 
in the management of large patient data sets? With respect to the how question, my research 
involved different narrative approaches to patient data: narrative identity with Ricœur’s 
philosophy, interpretation of interviews in the qualitative research, and case studies.  
The case studies indicated that in the two practical situations of healthcare policies 
evaluation, and of the public health duty to protect vulnerable populations, public interest and 
patient rights did not appear to compete between them and both were weakened. 
Consequently, it was difficult to find and implement rapid and effective solutions or 
reparations. Large patient data sets were not appropriately developed and used.  
The qualitative research showed that healthcare professionals were aware of legal and 
operating norms to collect and use patient data. However, it could be at the expense of 
patients’ autonomy that they tend to limit themselves to a legal consideration of informed 
consent. There was a risk of tension between utilitarian advocated reasons of public interest 
in patient data on the one hand, and insufficient consideration of patient rights as autonomy, 
dignity and the capacity to share governance on the other.  
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From these two empirical approaches, I found that the management of patient data was not 
optimal when based on competition between public interest and patient rights. I found it 
dissonant. In narration, researchers are usually implicated in the process of interpretation and 
comprehension because of their underlying culture and belief. I was myself influenced by the 
belief that management of patient data should be good, and performed fairly with patients and 
citizens. Two authors in particular have supported this belief. David Wootton, acknowledging 
the importance of numerical data, nevertheless pointed out that: “The chief obstacle was that 
doctors were satisfied with their existing therapies; the barriers to progress were 
psychological and cultural not intellectual.”84 Regarding the concept of Modern Health, 
Jonathan Mann argued that medicine should not compete with public health, nor ethics with 
human rights.85 He acknowledged a move towards more justice and more people taking 
responsibility for themselves, their communities and the future of the world, as there was: 
“more to modern health than new scientific discoveries, or development of new technologies, 
or emerging or re-emerging diseases, or changes in patterns of morbidity and mortality 
around the world.” These two positions supported the necessity to bridge science and 
philosophy with wisdom in the management of patient data. 
 
I then used narration to build a mattering map describing the management of patient data. 
Interpreting what matters permitted a better understanding of the roles and responsibilities of 
all stakeholders as agents. Agency expressed their specific narrative identity. I then 
developed the concept of Ricœur’s narrative identity as a transition to ethics. Ricœur’s 
approach provided an overarching framework able to make sense of the whole mattering 
map, a common ethical aim ensuring an appropriate, consensual governance of patient data. 
 
I presented the three levels of medical judgement developed by Ricœur for applied ethics in 
the medical domain. I used a similar epistemological approach to judgement for patient data 
governance. I subsequently proposed a simplified Ricœur-inspired matrix which develops the 
three levels of judgement for the management of patient data, teleological (ethical aim), 
deontological (legal and moral norms) and prudential (applied ethics) at the level of each 
individual, his/her community and society as a whole. This matrix provides a new framework 
able to dispel doubt and difficulties identified in the previous competing framework for 
patient data management.  
                                                      
84 Wootton, D. 2006. Bad Medicine. Doctors Doing Harm Since Hippocrates. Oxford: Oxford University Press. 
Paperback edition 2007, p. 284. 
85 Mann, J.M. 1997. Medicine and Public Health, Ethics and Human Rights. Hastings Center Report, 27(3):6-13. 
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11. Reframing the ethical issue  
I acknowledge as a premise that there are potential benefits of large patient data sets to better 
cure and care for people. It is nevertheless necessary to understand the ethical management of 
this patient data and to suggest improvements where necessary. Based on the normative 
approach, I developed a new framework for an ethical governance of patient data. I shall now 
provide arguments and test it using the former empirical examples. 
 
The argument is based on narrative identity and selfhood as an ethical dimension of the self. 
Concerning the production and use of patient data, patients and healthcare providers are 
actors, who can be praised or admonished. Their individual narrative identity confers self-
determination and accountability to the role, and supports mediation between the theory of 
action and the theory of ethics. The patient’s voice can be identified as a narrative unity, 
preventing the tendency to reduce patients to mere data donors and, by analogy, healthcare 
providers to mere data gatherers. Moreover, following Ricœur’s philosophy advocating a 
shared development of the two narrative identities, personal and collective, it is possible to 
justify the expression of patient rights at both individual and public levels.  
 
Referring back to Figure 1, the issue of the competing obligations of facilitating public 
interest and partially trading off patient rights, needs to be reframed as follows: 
 
- Patient rights encompass a wider perimeter than the one defined by a principle of 
autonomy restricted to autonomous choice and informed consent. It is about self-esteem 
as virtue, and solicitude as sharing. Faced with the patient’s voice as a narrative unity, 
other stakeholders are developing standards of excellence and benevolent sharing. At the 
deontological level, this ethical approach to rights is justified by respect for the norms of 
principled autonomy, free choice and beneficence. At the prudential level, practical 
wisdom helps translate moral norms into reciprocal trust between patients and physicians, 
respect for confidentiality and professional codes, and accountability for patient’s agency 
empowerment. 
 
- Reasons for public interest rely at the teleological level on the sense of justice and the 
participation of those governing and those governed in the life of institutions. At the 
deontological level, public interest is legitimised by the norms of distributive justice and 
social contract. Practical wisdom at the prudential level can then translate these rules into 
equity for accessing patient data, solidarity, transparency, dissemination of information, 
and prudence in sharing data and returning information. 
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Figure 2 illustrates this new framework which shifts from an approach of competing 
obligations (Figure 1) to a “Ricœurian” ethics aiming at the good life, for and with others in 
just institutions.  
 
 Figure 2: New Framework 
 
 
  
The consensus on common good for patient data management is based on a governance 
process with deliberation starting at the prudential level. In the case of conflicts of norms 
(such as issues with data access, too much or inadequate caution in the dissemination of 
information or when dealing with commercial interests, patients preferring passivity rather 
than agency, or health providers’ attitudes that humiliate patients and peers), pluralist 
governance will adjust the normative development using anterior teleological ethical 
reflection to gradually revise patient rights as well as public interest legitimacy and 
distributive justice.     
12. Application to clinical registries 
Based on this revisited ethical guidance, it is possible to re-assess the previous empirical 
findings in the management of patient data in clinical registries. 
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Swiss stakeholders’ roles and responsibilities for patient data. 
The thematic analysis drew upon traditional principles in bioethics as developed in the 
textbook of Beauchamp and Childress. Reasons for public interest were based on non-
maleficence, beneficence, and respect for legal norms, and justified mainly by utilitarianism. 
Patient rights were limited to a respect for autonomy as self-governance towards consent. 
Therefore, it is not surprising that the respondents’ strategy was to alleviate the burden of the 
informed consent. By contrast, the patients’ perspective reported in the literature and by some 
respondents (e.g. patient association representative) has indicated that patients were expecting 
more information on the use of their health-related data and better opportunities to interact 
and share governance. This asymmetry in the perspective between patients and professionals 
risks creating tension and distrust between lay people and healthcare providers or 
representatives of public institutions.  
 
A Ricœurian approach would be able to pre-empt this risk of tension and distrust. A tension 
resulting from conflicting norms of facilitating an increased use of patient data against 
patients’ autonomy could be beneficially resolved without a competing strategy. Recourse to 
the teleological level of ethics would mitigate the utilitarian justification by opening up the 
reflection to other theories of justice and widening the concept of autonomy (see part I). The 
advantages would be as follows:  
- Fewer conflicts of interest with potential private collaboration,  
- Increased legitimacy of data collection by social contract,  
- Patient rights extended to an autonomy conceived as agency, with the possibility of 
contributing to the governance of large patient data sets,  
- Healthcare professionals’ accountability for patients’ empowerment and standards of 
excellence in the management of patient data.  
 
As a result, transparency, sharing and trust would be strengthened between all players and 
within society as a whole.  
 
The relevance of this new ethical framework for patient data was already apparent with some 
respondents in the qualitative study, as the closer the healthcare providers were to patients, 
the more they acknowledged the importance of informing patients and relying on trust in the 
patient-physician relationships. Moreover, a majority of respondents emphasised the need for 
quality and good data management. Utility was frequently advocated to justify this position, 
but this behaviour could also result from a professional ethos of accountability for excellence 
in medical and data management practice. Implementing the new framework ensures an 
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appropriate governance at the prudential level (applied ethics), i.e. pluralist, deliberative, 
informed and wise. 
 
In the section discussion of the qualitative research submitted manuscript, an ethical approach 
based on Ricœur’s philosophy has already been presented. An alternative reflective path was 
also suggested based on a judicial approach with the concept of the mini-constitutions of 
Brownsword. This approach can be revisited with the Ricœur-inspired new framework.  
Governance would be the place of deliberation for determining the level of flexibility for 
consent and withdrawal rights. Deliberation at this prudential level will be guided at the 
deontological level by a legal approach based on human rights. The potential separation 
between the two paths, Brownswordian and Ricœurian, starts at this level. For Ricœur, the 
concept of agency finds its justification in the concept of narrative identity with selfhood 
being self-esteem at a teleological approach. There is a priori no such teleological approach 
in Brownsword’s rights perspective, although human rights are linked to human dignity. The 
universal declaration of human rights refers to the concept of “inherent human dignity”. It is 
difficult to define the meaning of inherent. Depending on its interpretation from a human 
status, a duty, a right, or a principle to a more transcendental justice position,86 Brownsword’s 
position will separate from or join with Ricœur’s approach.  
Clinical registries and evaluation of public health policy 
Conflicts of legitimacy between data from public administration and clinical registries have 
to be resolved at a political level. The recourse to patient rights based on narrative identity at 
individual, collective and historical levels would facilitate a democratic deliberation. We 
have reported in the qualitative research the divide between liberal and socialist perspectives 
in the Swiss parliament. The issue of the insufficient translation into practice of the study 
findings can be explained by the absence of a political will or its inefficiency in the absence 
of a common ethical aim.  
 
The new framework could improve the ethical guidance under a pluralist governance and 
deliberation on a common aim for the registry. Whatever their purpose, clinical registries can 
provide benefits through better knowledge of diseases, quality improvements in health 
services, evaluation of treatments and assessment of the appropriateness of public policy. As 
they have perpetual difficulties to include sufficient participant numbers, involving patients 
and civil society could improve recruitment and confer value to the registries. The recourse to 
                                                      
86 Düwel, M. 2014. Human dignity : concepts, discussions, philosophical perspectives. In The Cambridge 
Handbook of Human Dignity, Interdisciplinary Perspectives. Cambridge: Cambridge University Press, pp. 23-49. 
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a common ethical aim inspired by Ricœur (and subsequently developing excellence in 
clinical practice, avoiding patient humiliation, empowering their capability to participate and 
sharing data for an agreed registry purpose) would resolve most of the issues of data sharing, 
patients’ passivity and a low rate of inclusion.  
Pregnancy registries and antiepileptic treatment  
The application of the new framework is equally valid to this case study, in order to: i) 
alleviate the absence of pluralist governance; ii) improve the collection of data and data 
sharing; iii) facilitate communication, transparency and accountability between the different 
healthcare providers; iv) educate and inform pregnant women and their families. I will further 
develop the issue of political accountability to disseminate appropriate and timely 
information, and also the necessity to have a long-term follow-up of the families.  
 
At the end of volume 3 of Time and Narrative, Ricœur developed an in-depth philosophical 
reflection on the aporia of the unrepresentability of time in narration, and consequently 
introduced in his argument the theme of intentionality.87 The case study shows the lack of 
congruence between narration and temporalities, the epileptic women in turn being of 
childbearing age, in the pregnancy period, potentially suffering from a miscarriage or 
becoming the mother of a disabled child. The time representations differ, for example linear 
when waiting for the delivery, or suspended “not-narrative” following a miscarriage. In the 
absence of the political intention to act and protect women and their children, a scandal like 
the one with valproate will reoccur and again harm women, children and their families. 
 
Indeed, the new framework is not just an aid to help think and perform ethically in medical 
situations. Its ethical impact extends throughout the legal, social and political domains. Faced 
with new technology, commercial or social pressures, there is a need to better educate people, 
to adapt the academic and professional curriculum of healthcare professionals, to develop 
effective communication and conditions for data sharing, and finally to have the political will 
or intentionality to act. The new framework of narrative identity unity as patient rights, and of 
justice as the reason for public interest, promotes the capability to judge and act. 
 
The next chapter will offer some food for thought in order to implement the new framework. 
                                                      
87 Ricœur, P. 1988. Time and Narratives Vol. 3 (trans: McLaughlin, K. and Pellauer, D.). Chicago and London: 
The University of Chicago Press, pp. 351-352, 374-392. Originally published as Temps et Récit vol. 3, 1985. Paris: 
Editions du Seuil. 
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13. Implementation strategy 
Bioethics is required to provide positions or recommendations in different medical and 
biomedical situations. It is always hard to move from an ethical framework to guidelines and 
practical measures, and this issue also applies to the ethical governance of patient data, and 
large patient data sets. It has already been noted that the translation of research findings was 
often insufficient in practice. Faced with this challenge, I propose combining the two 
principles of imputability and intentionality. I have already explained the necessity of 
intentionality and political will in the previous example. The concept of narrative identity and 
agency makes each stakeholder a capable being, able to think and to act, and thus to be 
accountable for his/her actions. Ricœur names imputability as this accountability for his/her 
own action.88 The association of intentionality and imputability would thus support the 
implementation of the new ethical framework by the different stakeholders and institutional 
organisations. 
 
I will consider the general case of the ethical management of patient data in a modern 
digitalised healthcare system, and thereafter a list of specific applications in the Swiss 
context. 
 
It is widely acknowledged that digitalisation is changing society and also the healthcare 
system. Numerous projects and digital investments are being undertaken to integrate, 
standardise and use patient data with security and confidentiality. ELSI groups are working to 
secure the ethical treatment of the data. Most of the patient data collected in a well-defined 
and controlled way originates from the patient-physician relationship. At the other end of the 
spectrum, the use and re-use of this data fall within the domain of algorithms and data mining 
sciences.89 I consider that these two phases are the essential places for the implementation of 
the new framework for patient data, ensuring the conditions for an ethical, pluralist 
governance of patient data. 
Patient data in the patient-physician relationship 
From an academic perspective, implementation will seek to obtain empirical information on 
what is meant by autonomy, agency and trust for patients, and how they could overcome 
ignorance or passivity. Similarly, empirical data will be required on reciprocity, 
                                                      
88 Ricœur, P. 2007. Reflections on The Just (trans: Pellauer, D.). Chicago and London: The University of Chicago 
Press, p. 2. Originally published as Le Juste 2. 2001. Paris: Editions Esprit. 
89 Obermeyer, Z., Emanuel, E.J. 2016. Predicting the future — Big data, machine learning, and clinical medicine. 
New England Journal of Medicine, 375:1216-1219.  
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accountability, and the patient’s empowerment for the physicians and clinical teams 
interacting with the patient. Data would be collected in focus groups of patients, clinicians 
and mixes of both. (Figure 3). The process is bottom-up, pragmatic, promoting better 
relationships between patients, healthcare professionals and the community, and as a result 
building trust. It is not about testing top-down social-psychological tools of patient activation.  
Education programmes around patient data could then be designed, tested, proposed and 
assessed in the settings of citizen schools, undergraduate medical education at the university 
and further education for healthcare providers. Promoting imputability is the driving factor at 
this patient-physician level. 
 
Figure 3: Enhancing stakeholders’ ethical awareness and accountability 
 
In part I, the possibility to develop patient positive claims to have full, transparent 
information on their data destiny, as well as the possibility to intervene have been mentioned 
as a new concept of data ownership in order to fight the potential feeling of data despoliation. 
Imputability is corollary to these possible developments. 
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Algorithms and use of data  
Similarly, it will be necessary to obtain empirical data on governance and decision-making 
systems of the projects requiring use of patient data. Academics should thus participate in the 
consultation process and pluralist governance of these projects in order to evaluate and 
facilitate fair access to data and algorithms, as well as the conditions of data dissemination. 
Governments should promote the involvement of think-tanks or other forms of research 
groups able to support ethical deliberation on patient data projects. Influencing Intentionality 
is the driving factor at this practical governance level. 
 
I have noticed that in most conferences on big data, personalised medicine or genomics, 
organisers and speakers focus on the expert technical and legal aspects of systems, shared 
data networks, data standardisation, data security. The proposed new framework 
counterbalances these limited approaches by considering that people and governance should 
first concentrate on the common good and related coherent projects. The systems would be 
subsequently adjusted to projects. I have called this approach “integrative” (manuscript in 
preparation). 
14. Proposed examples of actions for implementation  
The following projects would integrate the results of the strategy above. 
Projects promoting imputability  
! Add a lecture on patient data to the bioethics course in the student medical curriculum 
! Design a school programme on health-related data for teenagers  
! Organise an ethics café with community citizens on the issue of patient data 
! Design and propose conference materials for patient associations 
 
Projects targeting intentionality 
! The Swiss Federal Act on Electronic Patient Files (RS 816.1), defines the community as 
the organisational unit of health professionals and their institutions (art. 2, para. d). I 
propose including representatives of the civil society and patient associations. 
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! With regard to the Swiss national consultation on a proposed general consent for the 
secondary used of patient data and samples, I propose the following amendments:  
- do not allow the transfer of patient data to the pharmaceuticals industry without 
formal informed consent,  
- explain better the difference between research biobank and therapeutic biobank, 
- provide more detailed information to avoid the problem of therapeutic 
misconception,  
- explain better the coding process for genetic data and the conditions for the return of 
information,  
- introduce a governance separate from the ethical research committee able to assess in 
the name of patients their rights and the relevance of the research for future projects,  
- organise a website and patient material to update patients on projects and findings 
from biobank and related data sets. 
 
! Create a think-tank working on the ethical issues of private-public partnerships around 
patient data.  
Patient data is increasingly sought by pharmaceuticals and biotechnology companies for 
developing targeted treatments, especially in the domain of genomics medicine.90 Private 
companies and public institutions have the stewardship or ownership of extensive data 
sets. All this health-related data could be regrouped in a common library. Library 
governance and maintenance would need to be organised with a just distribution of 
burden and benefit. Similarly, data access and data outcomes, including patents and 
commercial exploitation, would require regulation. Patients and citizens should be 
integrated into the process as it concerns their data, and the healthcare system they want, 
finance and use. The task of the think-tank would be to consider all the ethical, legal and 
scientific aspects, and help all stakeholders to understand each other and collaborate. 
Conclusion 
As commercial organisations are offering ever more health tests and products for preventing 
disease and/or maintaining or recovering a healthy status, they also have the potential to 
distort private-public partnerships. I assumed at the beginning of my dissertation that 
healthcare digitalisation and modern management of large patient data sets would bring social 
benefits. The quantity of data and the emergence of possible new health/disease correlations 
                                                      
90 Rockhold F, Nisen P, Freeman A. 2016. Data sharing at a crossroads. New England Journal of Medicine 
375(12):1115-7. 
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could a contrario be factors leading to excessive medicalisation and overdiagnosis.91 The risk 
is that the morally good use of large patient data sets for the purpose of safer, precise 
medicine and targeted treatment could lead to inappropriate treatment (morally wrong).92 
Some healthcare stakeholders have already identified the risk of too much medicine. The 
“information paradox” would result in a situation where the patient’s voice could disappear 
behind patient data. The patient’s voice is about “who I am” and not only “what I am”. This 
can evoke the modern claim “not in my name” that could also concern patients, as physicians 
may reserve the right to speak in the name of their patients.93 In Ricœur’s concept of narrative 
identity “Who I am” is about selfhood. On a legal side, listening to “who I am” could 
correspond to the non-compromisable human conditions to be respected in all projects using 
and sharing patient data. 94  Professor Kieran Sweeney, reporting a patient’s journey, 
concludes:  
 
What I have always feared in illness was anonymity, being packaged, losing control, 
not being able to say “this is who I am.”95 
 
 
 
 
*   *   *
                                                      
91 Hofmann, B. 2016. Medicalization and overdiagnosis: different but alike. Medicine, Health Care and 
Philosophy, 19:253-264. 
92 Mouton Dorey, C. 2016. Conference proceedings. Preventing Overdiagnosis 2016 Barcelonna. 
www.preventingoverdiagnosis.net/2016Presentations/Corine_Mouton_Dorey.pdf. Accessed 20 May 2017. 
93 Biller-Andorno, N. 2016. Overdiagnosis in the name of the patient – breaking the vicious circle. Key note 
lecture at the international conference Preventing Overdiagnosis 2016 Barcelona (see note 90). 
94 Brownsword,R. 2016. Oral presentation on Data Commons and Data Ownership, at the symposium on Digital 
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